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Subclinical thyroid disease (SCTD) is defined as serum free
T4 and free T3 levels within their respective reference
ranges in the presence of abnormal serum TSH levels. SCTD
is being diagnosed more frequently in clinical practice in
young and middle-aged people as well as in the elderly.
However, the clinical significance of subclinical thyroid
dysfunction is much debated. Subclinical hyper- and hypo-
thyroidism can have repercussions on the cardiovascular
system and bone, as well as on other organs and systems.
However, the treatment and management of SCTD and pop-
ulation screening are controversial despite the potential
risk of progression to overt disease, and there is no con-
sensus on the thyroid hormone and thyrotropin cutoff val-
ues at which treatment should be contemplated. Opinions
differ regarding tissue effects, symptoms, signs, and car-
diovascular risk. Here, we critically review the data on the
prevalence and progression of SCTD, its tissue effects, and
its prognostic implications. We also examine the mecha-
nisms underlying tissue alterations in SCTD and the effects
of replacement therapy on progression and tissue parame-
ters. Lastly, we address the issue of the need to treat slight
thyroid hormone deficiency or excess in relation to the pa-
tient’s age. (Endocrine Reviews 29: 76–131, 2008)
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I. Introduction
AS OUR ABILITY to detect ever more subtle degrees ofthyroid dysfunction has improved with highly sen-
sitive and specific assays, the concept of subclinical thyroid
disease (SCTD) has emerged over the past several decades.
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Although it is recognized that patients with SCTDmay have
subtle symptoms of thyroid dysfunction, the definition is
purely a biochemical one: SCTD is defined as serum free T4
(FT4) and total or free T3 (FT3) levels within their respective
reference ranges in the presence of abnormal serum TSH
levels. Serum TSH is undetectable or low in subclinical hy-
perthyroidism (SHyper), and it is increased in subclinical
hypothyroidism (SHypo) (1–4). As screening for thyroid dis-
ease becomes more common, SCTD is being diagnosedmore
frequently in clinical practice in young and middle-aged
people as well as in the elderly. However, population screen-
ing and treatment of these conditions are controversial de-
spite the high prevalence of SCTD and the potential pro-
gression to overt disease (5–7), because the risks of SCTD are
uncertain and the benefits of treatment unproven. Opinions
are quite divergent regarding the tissue effects, clinical
symptoms and signs, and the cardiovascular risks of mild
thyroid hormone excess or deficiency (5, 6, 8, 9).
At present, there is no consensus about the TSH concen-
tration at which treatment should be contemplated (5, 6),
except for elderly individuals with serum TSH values less
than 0.1 mIU/liter (6). Moreover, because the definition of
SCTD is based on abnormal TSH levels, the normal TSH
range must be established, and it is proving to be a difficult
task to define the upper limit of normal (10, 11). To com-
pound the issue further, it has been difficult to correlate
possible adverse effects at the tissue level with a TSH cut-off
point, because of the individual set-point of the hypotha-
lamic pituitary-thyroid axis (12).
Here we review clinical and epidemiological data to de-
termine the: 1) prevalence andprogression of SCTD; 2) global
clinical risk (cardiovascular, bone, muscle, lipid, and hemo-
static profile, etc.) associated with SCTD and its prognostic
implications; 3) risks of untreated SCTD in relation to the
patient’s age; 4) benefits of correcting SCTD; 5) optimal treat-
ment; and 6) benefits of a screening program. Lastly, an
algorithm for the practical evaluation and treatment of SCTD
examined from a global viewpoint is provided.
II. Methods
A. Identification of sources
We searched personal files, MEDLINE articles, and refer-
ences of relevant articles and textbooks published from 1970
through April 2007 in the English language (including trans-
lated articles). For MEDLINE, we used the search terms:
thyrotropin (TSH), l-thyroxine, replacement therapy, thy-
roid cancer, thyroid autonomy, TSH suppression, preva-
lence, progression, cardiovascular risk, heart, bone, osteo-
porosis, muscle, quality of life, symptoms, cognitive
function, pregnancy, infertility, elderly, children, and the
keywords hyperthyroidism, hypothyroidism, SCTD, sub-
clinical hyperthyroidism (exogenous and endogenous), and
subclinical hypothyroidism.
B. Methods of evaluation to assess study quality
The two authors agreed on the inclusion/exclusion status
of the studies reviewed after assessing the quality of studies.
Although this review is not a meta-analysis, we critically
assessed the literature and tried to identify high-quality stud-
ies. The TSH range at baseline evaluation was recorded to
determine the degree of thyroid hormone deficiency or ex-
cess that was considered in each study. In the evaluation of
treatment for SCTD, wherever possible, preference was
given to randomized controlled trials and longitudinal stud-
ies; however, very few reports had these characteristics.
Therefore, we included other types of clinical trials. More-
over, we examined whether the control group was appro-
priate, whether euthyroidism was completely obtained after
treatment of SCTD, and whether over- or undertreatment
was avoided. Furthermore, we evaluated whether the meth-
ods used to evaluate the effects of SCTD at tissue level were
correct. Lastly, we evaluated whether a correct statistical
analysis was applied in the studies. Previously published
review articles evaluating the effects of SCTD are discussed.
III. Normal Thyrotropin-Stimulating Hormone Range
Because SCTD is only detected as a TSH abnormality, the
definition of the TSH reference range is critical (13, 14). Over
the last three decades, the upper reference limit for TSH has
declined from about 10 mIU/liter with the first-generation
TSH RIAs to about 4.0–4.5 mIU/liter with subsequent TSH
assays and the use of thyroid antibody tests to prescreen
subjects. The normal TSH range has long been debated (10,
11, 13–15). This issue also impacts on the TSH target level for
replacement thyroid hormone therapy in patients with hy-
pothyroidism, the treatment of patients with mild thyroid
hormone deficiency, and screening to detect SCTD.
TSH in the circulation is heterogeneous with respect to
both glycosylation and biological activity. Assays vary
widely because current TSH immunometric assays involve
the use ofmonoclonal antibodies that differ in specificity and
may measure different TSH isoforms. Thus, the variation in
the reference intervals obtained with different methods re-
flects differences in epitope recognition of different TSH
isoforms. These differences make it difficult to establish a
universal upper TSH reference limit. Lymphocytic infiltra-
tion of the thyroid gland is present in up to 40% of healthy
women. Moreover, the National Health and Nutritional Ex-
amination Survey (NHANES) III survey, which used a com-
petitive immunoassay procedure, reported an antithyro-
globulin antibody (TgAb) prevalence of 10% and detectable
thyroid peroxidase (TPO) levels in 12% of the general pop-
ulation (16). Furthermore, a hypoechoic ultrasound pattern
or an irregular echo pattern may precede antithyroid per-
oxidase antibody (TPOAb) positivity in autoimmune thyroid
disease, and TPO may not be detected in more than 20% of
individuals with ultrasound evidence of thyroid autoimmu-
nity (TA) (17, 18). For this reason, it is recommended that the
serum TSH reference interval be established using blood
sampled in themorning from fasting euthyroid subjects who
have no family history of thyroid disease, are not taking
medication, have no visible or palpable goiter or pathological
thyroid ultrasonography findings, and are not positive for
TPOAb or TgAb (19). For example, in theNHANES III study,
in subjects without reported thyroid disease, TPOAb fre-
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quency increased as TSH levels increased in the study pop-
ulation (being 5.5% at TSH 0.4–1.0 mIU/liter, 30.6% at TSH
3.5–4.0 mIU/liter, and 80–90% in subjects with a TSH con-
centration over 10 mIU/liter (20). Further evidence of a re-
lationship between TPOAb and serum TSH comes from a
Norwegian study (21). In this health survey, all inhabitants
20 yr and older (n  94,009) in Nord-Trøndelag were eval-
uated by a questionnaire and blood samples. In individuals
without a history of thyroid disease, themedian and the 2.5th
and 97.5th percentiles for TSHwere 1.80 and 0.49–5.70mIU/
liter for females and 1.50 and 0.56–4.60 mIU/liter for males.
However, when individuals with positive TPOAb were ex-
cluded, the 97.5th percentiles dropped to 3.60 and 3.40 mIU/
liter for females and males, respectively. Moreover, the per-
cent of TPO-positive subjects was lowest in the TSH range
between 0.2 and 1.9mIU/liter and increasedwith both lower
and higher levels of TSH (21).
In the NHANES III study, a separate population of 13,344
subjects without a history of thyroid disease, goiter, preg-
nancy, or biochemical hypo- or hyperthyroidism; not taking
thyroid medication, androgens, or estrogens; and free of
anti-TPO and TgAb (the so-called “reference population”)
was examined separately from the entire cohort of 17,353
persons. In this groupwithout thyroid disease or risk factors,
the median TSH level was 1.39 mIU/liter and the 2.5th and
97.5th percentiles were 0.45 and 4.12 mIU/liter, respectively
(16). However, TSH values did not have a Gaussian distri-
bution, and about 9% of the subjects in this reference pop-
ulation had TSH levels above 2.5 mIU/liter. Although it may
be conjectured that this “upper tail” was observed because
the group included people with occult TA and negative
anti-TPO antibodies, other recent data argue against this
explanation.
Evidence against occult autoimmunity being responsible
for the “tail” in the TSH distribution comes from a recent
German study that established reference intervals for TSH
based on National Academy of Clinical Biochemistry criteria
as well as sonographic confirmation of a normal thyroid
gland (19). Of the 870 apparently healthy persons investi-
gated, only 453 were included in the study; 47.9% of healthy
blood donors did not meet all criteria for normal thyroid
function and morphology by sonography. In this reference
group, the lower limit of reference range for TSH increased
from 0.3 to 0.4 mIU/liter, and the upper reference limit
decreased from 4.1 to 3.7 mIU/liter compared with the
NHANES III study. However, serum TSH levels were not
Gaussian in this study either, which suggests that the upper
tailmay be a biological phenomenon, possibly related to TSH
receptor gene polymorphisms or TSH microheterogeneity.
Of course, occult thyroid disease that cannot be detected by
antibody testing and thyroid sonography can never be com-
pletely ruled out. Moreover, iodine intake may affect the
reference interval for thyroid function tests. The differences
between the German and U.S. data could be related to the
higher incidence of Hashimoto disease in the United States
or because of higher iodine intake or increased thyroidal
autonomy in the possibly mildly iodine-deficient German
population. Despite iodine supplementation programs, io-
dine deficiency persists in some European countries. In a
cross-sectional epidemiological survey in a previously io-
dine-deficient area (western Pomerania, northeast Ger-
many), the reference interval for serum TSH was 0.25–2.12
mIU/liter, and the reference intervals for serum TSH and
free thyroid hormones were narrower and moved to the left
when compared with the NHANES study (22). In an iodine-
deficient village of southern Italy, the entire resident popu-
lation underwent thyroid function tests, thyroid ultrasound
examination, and measurement of urinary iodine concentra-
tion (23). The mean serum TSH concentration in the adult
population was 1.4  1.1 mIU/liter in goitrous subjects and
2.0  2.4 mIU/liter in nongoitrous subjects (23).
Evidence in support of a narrower normal TSH range
comes from the Whickham survey (24). This 20-yr follow-up
study of hypothyroidism in 1700 subjects demonstrated a
higher prevalence of progression to overt disease in patients
with TSH levels above 2mIU/liter. However, the riskwas far
higher in those subjects who had positive antithyroid anti-
bodies at baseline.
Conflicting results have been reported about the association
between TSH at the upper limit of the considered normal range
and cardiovascular risk factors (25–38). Subjects with high-nor-
mal serum TSH (2.0–4.0 mIU/liter) and positive thyroid au-
toantibodies had higher mean serum cholesterol levels than
those with TSH values in the lower half of the normal range
(0.40–1.99mIU/liter) (25).Moreover, administrationofT4 to the
subjects with high-normal serum TSH was accompanied by a
significant lowering of cholesterol and low-density lipoprotein
cholesterol (LDL-C), but only in antibody-positive subjects (25).
In the fifth Tromso study (a cross-sectional epidemiological
study of 5143 subjects), there was a significant, positive corre-
lation between serum TSH levels and serum total cholesterol
(TC) and LDL-C levels in men and women (26). However, this
did not reach statistical significance in women after adjusting
for age and bodymass index (BMI). In an interventional study,
which included subjects with SHypo receiving T4 supplemen-
tation for 1 yr (32 subjects given placebo and 32 subjects given
T4), serum TC and LDL-C levels were significantly reduced
after T4 therapy in subjects with SHypo, including those who
at the end of the study had serum TSH levels between 0.2 and
2.0 mIU/liter (26).
The association between TSH within the reference range
and serum lipid concentrationwas evaluated in a large cross-
sectional population-based study of 30,656 individuals with-
out known thyroid disease (27). Total serum cholesterol,
LDL-C, non-high-density lipoprotein cholesterol (HDL-C),
and triglycerides increased consistently with increasing TSH
(P for trend 0.001), whereas HDL-C decreased consistently
(P for trend  0.001). The association with serum lipids was
linear across the entire reference range, with no indication of
any threshold effect. Moreover, the associations with tri
glycerides and HDL-C were stronger among overweight
than among normal-weight individuals (27).
Studies evaluating whether thyroid function within the
euthyroid TSH range can affect blood pressure have pro-
duced conflicting results (28–33). The relation between thy-
roid function and bloodpressurewas assessed in 284 subjects
(68% hypertensive) who consumed high- and low-sodium
diets. The serum FT4 index was lower (P  0.0001) and the
TSH concentration higher (P  0.046) in hypertensive than
in normotensive subjects, irrespective of other baseline char-
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acteristics, and the FT4 index independently predicted salt
sensitivity of blood pressure (28). Similarly, a population-
based study showed that small differences in serum TSH
(within and above the reference range) were associated with
significant differences in diastolic blood pressure (29). The
relation between serum TSH and blood pressure was also
assessed in the recent Tromso study, a population-based
health survey, which included 5872 subjects not using blood
pressure or T4 medication (30). In this study, there was a
modest but significant positive correlation between serum
TSH within the normal range (0.2–4.0 mIU/liter) and both
systolic and diastolic blood pressure (30).
However, in a cross-sectional study of 2033 individuals in
the Busselton thyroid study, mean systolic blood pressure,
diastolic blood pressure and the prevalence of hypertension
did not differ between subjects with SHypo and euthyroid
subjects, nor did they differ between subjects with serum
TSH concentrations in the upper reference range (2.0–4.0
mIU/liter) and those with TSH concentration in the lower
reference range (0.4–2.0 mIU/liter) (31). On the other hand,
a linear and positive association between TSH and systolic
and diastolic blood pressure was found in a recent cross-
sectional, population-based study on 30,728 individuals
without previously known thyroid disease (32). Comparing
TSH of 3.0–3.5 mIU/liter (upper part of the reference) with
TSH of 0.50–0.99 mIU/liter (lower part of the reference), the
odds ratio (OR) for hypertension was 1.98 [95% confidence
interval (CI), 1.56 to 2.53] in men, and 1.23 (95% CI, 1.04 to
1.46) in women (32). In addition, a measure of endothelial
function, flow-mediated endothelium-dependent vasodila-
tation of the brachial artery, was lower in healthy individuals
with a serum TSH concentration between 2.0 and 4.0 mIU/
liter than in those with TSH values between 0.4 and 2.0
mIU/liter (33).
Conflicting results have also been reported about the as-
sociation between thyroid function and the BMI in individ-
uals with TSH and FT4 within normal range (34–37). A
cross-sectional population study examined the association
between the category of serum TSH or serum thyroid hor-
mones and BMI or obesity (34). There was a positive asso-
ciation between obesity (BMI  30 kg/m2) and serum TSH
levels (P 0.001).Moreover, therewas a negative association
between BMI and serum FT4 (P  0.001) and no association
between BMI and serum FT3 levels. The difference in BMI
between the groups with the highest and lowest serum TSH
levels was 1.9 kg/m2, which corresponds to a difference in
body weight of 5.5 kg among women. The results of this
study suggest that even slightly elevated serum TSH levels
are important in determining body weight in the population
(34). Among 87 obese women (BMI 30 kg/m2), serum TSH
concentrations were positively associated with increasing
BMI, but there was no relationship between serum FT4 and
BMI (35). Furthermore, in 6164 subjects living in Tromso,
TSH concentrations were positively associated with BMI in
women and men who did not smoke (36). However, in 401
euthyroid subjects there was no association between thyroid
status within the normal range and BMI and no difference in
BMI when subjects were stratified according to serum TSH
or FT4 (37). Lastly, there was no difference in serum TSH or
FT4 between lean and obese euthyroid subjects (37).
There are no prospective long-term studies to suggest
increased risks of cardiovascular morbidity or mortality in
patients with TSH levels at the upper limit of the considered
normal range. A recent community-based study carried out
in Busselton, Western Australia, examined whether serum
TSH in the upper reference range (2.0–4.0 mIU/liter) was
associated with cardiovascular end-points (38). The preva-
lence of coronary heart disease was not higher in subjects
with a serum TSH level in the upper normal range (2.0
mIU/liter) than in euthyroid controls (0.4–2.0 mIU/liter).
Similarly, it did not differ between subjects with and those
without thyroid antibodies (38).
In summary, the strongest epidemiological evidence for
lowering the TSH normal range is the higher rate of anti-
thyroid autoimmunity in subjects with TSH between 3 and
4.5 mIU/liter and the higher rate of progression to overt
thyroid disease in this subgroup. Arguments in favor of
lowering the upper limit of the TSHnormal range are the cost
of monitoring patients with thyroid autoantibodies and a
TSH concentration between 3.0 and 4.5 mIU/liter, the risk of
progression to overt disease, and the potential morbidity in
subjects lost to follow-up.
Arguments against lowering the upper limit of normal
include the fact that mild elevations in serum TSH are some-
times reversible (39), the expense of therapy without proven
benefit, and the possibility of overtreatment leading to iat-
rogenic hyperthyroidism. In fact, links between TSH at the
upper limit of normal range and some important cardiovas-
cular risk factors are either conflicting or inconclusive (25–
38). Moreover, the evidence in support of lowering the upper
limit of the TSH normal range should be weighed against the
health and economic impact that a reduced TSH rangewould
have (11). About 10% of the 25,862 individuals screened in
the Colorado study had mild thyroid failure, namely a TSH
level above the laboratory upper limit of 5.1 mIU/liter (40).
About 74% of those subjects had TSH levels between 5.0 and
10.0 mIU/liter. Given these figures, about 13 million people
in the United States may have undiagnosed SHypo. A de-
crease in the upper limit of the TSH reference range from 5
to 3 mIU/liter would result in an increase of more than 3.0-
to 5.0-fold in the percentage of patients classified as having
mild thyroid disease (41).
A more convincing demonstration of the positive impact
on patient outcome in identifying and treating persons with
TSH levels in the upper normal range is necessary before
lowering the upper limit of normal for serum TSH. In ad-
dition, it must be recognized that a normal range upper or
lower limit, based on a reference population, does not of
necessity mean that any person who falls outside that limit
requires treatment or has an illness. In the meantime, careful
follow-up should be considered for asymptomatic patients
with serum TSH levels between 3 and 4.5 mIU/liter, espe-
cially if they have positive anti-TPO antibodies.
IV. Set-Point of the Hypothalamic-Pituitary-Thyroid
Axis and Individual TSH Range
The finding that individuals have a set-point of the hy-
pothalamic-pituitary-thyroid axis was a breakthrough in our
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understanding of SCTD (12). The relationship between se-
rum FT4 and TSH in an individual can be considered to
establish the individual’s hypothalamic-pituitary-thyroid
axis “set-point.” Andersen et al. (12) measured serum TSH
concentrations eachmonth in 16 healthymale volunteers and
found that the width of individual 95%CI of TSH values was
approximately half that of the whole group. Consequently,
it is theoretically possible that a test result may be abnormal
for an individual but still be within the laboratory reference
limit.
Interindividual differences in the hypothalamic-pituitary-
thyroid axis set-point are genetically determined (42, 43).
Moreover, genetic variants have been found to affect both
blood pressure and serum TSH levels (44). Consequently,
interindividual differences in the hypothalamic pituitary-
thyroid axis set-point might explain the different symptoms,
signs, and peripheral thyroid hormone effects in subjects
with exactly the same hormonal pattern. Furthermore, the
biological activity of thyroid hormone, in terms of T3 avail-
ability, is regulated by type 1, 2, and 3 iodothyronine deio-
dinases (D1, D2, and D3) (45). The efficiency of conversion
of T4 to T3 by D2 increases as the serum T4 decreases (45).
Consequently, in the presence of a low level of T4 or in case
of a hypothyroid state, D2 is increased and can generate a
significant quantity of plasma T3. Moreover, polymorphisms
in genes involved in thyroid hormonemetabolismmay affect
thyroid hormone bioactivity (46). Deiodinases are tissue spe-
cifically regulated, and this may have consequences for the
peripheral effects of thyroid hormone and for set points of
endocrine feedback regulation (47).
In conclusion, a serum TSH level within the normal range,
even if it is below 2.5 mIU/liter, may not be as sensitive a
parameter of thyroid dysfunction for individual subjects as
had previously been thought. Therefore, it is important to
evaluate and integrate the laboratory results in relation to the
clinical assessment, e.g., the patient’s symptoms, physiolog-
ical status (e.g., age, pregnancy, etc.), and underlying health
status (other comorbidities and drug intake).
V. Subclinical Hypothyroidism
A. Subclinical hypothyroidism and minimally increased
TSH
SHypo represents a condition of mild to moderate thyroid
failure characterized by normal serum levels of thyroid hor-
moneswithmildly elevated serumTSH concentrations (1–2).
A panel of experts recently divided patients with SHypo into
two categories: patients with mildly increased serum TSH
levels (4.5–10 mIU/liter), and patients with more severely
increased serum TSH levels (10 mIU/liter) (6). We shall
examine the progression of the disease, the adverse effects,
and treatment using these definitions of thyroid hormone
deficiency.
B. Etiology of subclinical hypothyroidism
The etiology of SHypo is the same as the etiology of overt
hypothyroidism (1, 2)(Table 1). It is most often caused by
chronic lymphocytic thyroiditis (goitrous Hashimoto’s thy-
roiditis and atrophic thyroiditis), an autoimmune disorder of
the thyroid gland that is the most common cause of de-
creased thyroid hormone production in patients with ac-
quired mild, subclinical, or overt hypothyroidism (2, 48–50).
Other causes of primary hypothyroidism may result from
therapies that destroy thyroid tissue such as radioactive io-
dine treatment or external radiation therapy. Mild and overt
hypothyroidism are common after external radiotherapy of
the head and neck area and develops gradually within the
first year with a risk that appears to be dose-dependent (51).
It is frequent after external radiation therapy in patients with
Hodgkin’s lymphoma, leukemia, aplastic anemia, brain tu-
mors, or bone marrow transplantation. Chemotherapy also
may induce hypothyroidism in patientswith lymphoma (52).
Women with breast cancer may have an increased risk of
autoimmune thyroid disease after adjuvant chemotherapy
and tamoxifen (53, 54). Transient or persistent increases in
serum TSH may occur after subacute, postpartum, or pain-
less thyroiditis and after partial thyroidectomy.
Several drugs may induce subclinical or overt hypothy-
roidism particularly in patients with underlying autoim-
mune thyroiditis (iodine-containing compounds, lithium
carbonate, cytokines, and interferon) (2, 51). Amiodarone, a
benzofuranic-derivative, iodine-rich drug used to treat
tachyarrhythmias, can inhibit thyroid hormone production.
The chronically high iodine intake induced by amiodarone
administration may increase the prevalence of chronic au-
toimmune thyroiditis in genetically susceptible individuals
or may precipitate hypothyroidism in patients with autoim-
mune thyroiditis. Iodine-induced subclinical or overt hypo-
thyroidism may develop in patients treated with amioda-
rone, particularly in areas of high iodine intake (55). Excess
dietary iodine, medication, topical antiseptics, and iodine-
contrast agents used for diagnostic procedures may induce
mild or transient hypothyroidism. Lithium carbonate, which
is prescribed for the treatment of manic-depressive disor-
ders, may impair thyroid hormone synthesis and release and
TABLE 1. Causes of subclinical hypothyroidism
Chronic autoimmune thyroiditis (risk factors: family history of
autoimmune thyroid disease, personal or family history of
associated autoimmune disorders, Down syndrome, Turner’s
syndrome)
Persistent TSH increase in subacute thyroiditis, postpartum
thyroiditis, painless thyroiditis
Thyroid injury: partial thyroidectomy or other neck surgery,
radioactive iodine therapy, external radiotherapy of the head
and neck
Drugs impairing thyroid function: iodine and iodine-containing
medications (amiodarone, radiographic contrast agents), lithium
carbonate, cytokines (especially interferon ), aminoglutetimide,
ethionamide, sulfonamides, and sulfonylureas
Inadequate replacement therapy for overt hypothyroidism
inadequate dosage, noncompliance, drug interactions (iron,
calcium carbonate, cholestyramine, dietary soy, fiber, etc.),
increased T4 clearance (phenytoin, carbamazepine,
phenobarbital, etc.), malabsorption
Thyroid infiltration (amyloidosis, sarcoidosis, hemochromatosis,
Riedel’s thyroiditis, cystinosis, AIDS, primary thyroid
lymphoma)
Central hypothyroidism with impaired TSH bioactivity
Toxic substances, industrial and environmental agents
TSH receptor gene mutations; G gene mutations
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may be associated with the development of goiter (40–60%
of cases) and mild or moderate hypothyroidism (56–58).
Patientswho develop persistent hypothyroidismduring lith-
ium treatment are more likely to have underlying chronic
Hashimoto thyroiditis.
Interferon-, used for the treatment of hepatitis or certain
tumors, alone or in combination with IL-2, may induce thy-
roid dysfunction due to the activation or enhancement of the
autoimmune process (51, 59). Risk factors associatedwith the
possible development of hypothyroidism include female sex,
longer duration of interferon- treatment, presence of
chronic hepatitis C virus, older age, and preexisting presence
of anti-TPO antibodies. The prevalence of interferon--as-
sociated hypothyroidism in patients with chronic hepatitis C
virus is reported to be between 7 and 39%, and the presence
TPO antibodies may be an important risk factor (51) that
predicts persistent hypothyroidism at the end of interferon-
treatment. TA and dysfunction frequently occur in multiple
sclerosis patients during interferon- therapy, particularly
within the first year of treatment; thyroid dysfunction is
generally subclinical and transient in over half of the
cases (60).
Hypothyroidismmay develop during treatment with ami-
noglutethimide, ethionamide, sulfonamides, and sulfonyl-
ureas, which interfere with thyroid hormone synthesis (51).
Persistent primary hypothyroidism and transient, mild TSH
elevation are frequent complications of sunitinib therapy, an
oral tyrosine kinase inhibitor recently approved for the treat-
ment of gastrointestinal stromal tumors and renal cell car-
cinoma (61). Toxic injury to the thyroid gland was reported
after exposure to various pesticides, herbicides, industrial
chemicals, and naturally occurring environmental chemicals
(51). Infiltrative disease (Riedel’s thyroiditis, amyloidosis,
hemochromatosis, and cystinosis) or infectious disorders of
the thyroid gland (Pneumocystis carini infection and Kaposi’s
sarcoma in patientswithAIDS)may induce thyroid hormone
deficiency; however these diseases rarely cause hypothy-
roidism (51).
The postpartumperiod is associatedwith an increased risk
of developing subclinical or overt hypothyroidism. Simi-
larly, subjects with a family history of autoimmune thyroid
disorders, autoimmune endocrine diseases, and nonendo-
crine autoimmune disorders (vitiligo, pernicious anemia, ce-
liac disease, atrophic gastritis,multiple sclerosis, etc.) have an
increased risk of hypothyroidism (62–64). Autoimmune thy-
roiditis can be associated with other endocrine deficiency
syndromes: polyendocrine failure syndrome type 1, which
includes hypoparathyroidism, adrenal insufficiency, and
chronic mucocutaneous candidiasis; and polyendocrine fail-
ure type 2, which includes adrenal insufficiency, type 1 di-
abetes mellitus, and primary ovarian failure.
SHypo is frequently observed in patients with overt hy-
pothyroidism receiving inadequate replacement therapy due
to poor compliance, drug interactions, or inadequate mon-
itoring of therapy. In fact, between 17.6 and 30% of patients
with overt thyroid failure were reported to have SHypo due
to inadequate thyroid hormone supplementation (40, 65).
Germline loss-of-function mutations in one or both alleles
of the TSH-receptor gene can cause SHypo (66, 67). TSH was
slightly (6.6–14.9 mIU/liter) to moderately (24–46 mIU/
liter) increased in these patients and was associated with
normal free thyroid hormone concentrations, normal thyroid
size, and normal biochemical parameters of TA (67). Re-
cently, a low prevalence of TSH receptor mutations was
reported in a large series of subjects with sporadic and fa-
milial nonautoimmune SHypo (68). However, TSH receptor
mutations should be considered in subjects with a familial
TSH increase associatedwith normal thyroid ultrasound and
without markers of TA.
C. Differential diagnosis of serum TSH elevation
Only persistent or progressive SHypo should be consid-
ered an early stage of thyroid disease. It may be difficult to
distinguish between transient disturbances of thyroid gland
function and mild thyroid failure (Table 2). Transient hypo-
thyroidism, followed by a euthyroid state, may be due to
thyroiditis caused by viral infection (subacute thyroiditis) or
autoimmunity (postpartum, painless, or silent thyroiditis). In
the early phase of the disease, a mild TSH increase with
absent or mild symptoms of hypothyroidism may make it
difficult to distinguish who will recover from those destined
to be permanently hypothyroid. Moreover, evidence from a
long-term follow-up of patients with subacute thyroiditis
suggests that viral infection can precipitate an autoimmune
thyroid disease in susceptible individuals, thereby resulting
in the development of permanent hypothyroidism (51). A
diagnosis of persistent SHypo can be verified by reevaluating
TSH concentration after 6 or 12 months. This will ensure that
only persistent or progressive disease is treated, andwill also
rule out the possibility that abnormal values were due to a
laboratory error. A high thyroid autoantibody titer associ-
ated with an increased persistent serum TSH concentration
may be useful to identify individuals with autoimmune thy-
roid disease who are at increased risk of developing perma-
nent hypothyroidism.
It is important to identify transient TSH elevations caused
by drugs that interfere with the central neurodopaminergic
pathway, such as metoclopramide and phenothiazines (69,
70). A transient increase in TSH is common in hospitalized
patients during the recovery phase of euthyroid sick syn-
drome (71). TSH concentrations may be falsely increased in
some assays because of the presence of heterophilic anti-
bodies against mouse proteins (72). Patients with untreated
adrenal insufficiency may have high serum TSH concentra-
tions (73). Rare causes of slightly highTSHconcentrations are
TSH-secreting pituitary adenomas or isolated pituitary re-
sistance to thyroid hormone (74), however in this case the
TABLE 2. Serum TSH increase not associated with persistent
SHypo
Transient SHypo following subacute, painless, or postpartum
thyroiditis
After withdrawal of thyroid hormone therapy in euthyroid patients
Laboratory analytical problem (assay variability, heterophilic
antibodies)
Impaired renal function
Recovery phase of euthyroid sick syndrome
Untreated adrenal insufficiency
TSH-secreting pituitary adenoma
Isolated pituitary resistance to thyroid hormone
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increased TSH is associated with elevated serum T4 and T3
levels.
Central hypothyroidism can present with mild TSH ele-
vation (5–10 mIU/liter) in approximately 25% of cases that
may represent bioinactive TSH (2). The association of low
serum thyroid hormone levels with normal or slightly high
serumTSHhas often been observed in patientswith pituitary
or hypothalamic disorders.
D. Prevalence of subclinical hypothyroidism
The prevalence of SHypo has been reported to be between
4 and 10% of adult population samples (16, 40, 65, 75–79).
Two large population-based screening studies have pro-
vided important epidemiological data about SHypo: the
Whickham Survey (75), and NHANES III (16). A third im-
portant large study, the Colorado Thyroid Prevalence Study
(40), was not truly population-based. In the Whickham Sur-
vey (2779 subjects), SHypo, defined by serum TSH levels
above 6mIU/liter,was identified in 7.5%of females and 2.8%
of males (75). TSH levels did not vary with age in males but
increased markedly in females after the age of 45 yr. Serum
TSH concentration was not age-related in women without
antithyroid antibodies.
The sample examined in NHANES III (16,353 people
aged  12 yr) represented the geographic and ethnic dis-
tribution of the U.S. population (16). SHypo was found in
4.3% of this population (normal TSH range, 0.39–4.6 mIU/
liter). TPOAb were significantly associated with thyroid
failure, were more prevalent in women than in men, in-
creased with age, and were more prevalent in whites than
in blacks.
In the Colorado study (over 25,000 state residents attend-
ing a series of statewide health fairs), 9.5% of all subjects had
an elevated serum TSH concentration (normal range, 0.3–5.1
mIU/liter), and 89% of these were not on thyroid hormone
therapy (40). Seventy-five percent of these individuals had
serum TSH levels in the 5–10 mIU/liter range. In each age
decade, a higher percentage of women than men had an
elevated serum TSH concentration; the difference was sig-
nificant after age 34 yr (P 0.01). In the ninth decade of life,
the prevalence of elevated TSH was as high as 15–20%.
The prevalence of mild thyroid dysfunction was higher
in older populations in all epidemiological surveys con-
ducted so far (16, 40, 65, 75–80). Elevated values of serum
TSH (6 mIU/liter) were found in 6.73% of subjects in a
healthy urban population over the age of 55 yr in which
a highly sensitive serum TSH assay was used to screen 968
subjects (79). Using a very sensitive assay, Parle et al. (76)
measured serum TSH concentrations in 1210 patients aged
over 60 yr registered with a single general practice. High
TSH values occurred more frequently in females (11.6%)
than in males (2.9%), and antithyroid antibodies were
identified in 60% of patients with high TSH concentrations
(76). In a study of 370 patients (287 women, 83 men)
between 60 and 97 yr of age, after excluding patients with
a history of thyroid disease, 14.6% of the women and 15.4%
of the men had SHypo (78).
SHypo is more frequent in areas of iodine sufficiency, i.e.,
4.2% in iodine-deficient areas compared with 23.9% in areas
of abundant iodine intake (80). This finding was confirmed
by a high prevalence of SHypo in Iceland (18%) andHungary
(24%), which have a high iodine intake (81). Similarly, the
incidence rate of overt hypothyroidism was lower than that
of hyperthyroidism in an area with moderately low iodine
intake (82). Iodine supplementation of a population may
increase the incidence of thyroid hormone deficiency (83, 84).
In conclusion, SHypo represents a common disorder. The
wide range (4–10%) of its prevalencemight be due to the TSH
cutoff used to define SHypo and differences in age, gender,
and dietary iodine intake in the populations studied.
E. Natural history of subclinical hypothyroidism
In the 20-yr follow-up of the Whickham cohort, an in-
creased serum TSH level was predictive of progression to
overt hypothyroidism (24). Old age, female sex, and TPO
antibodies were also associated with an increased risk of
progression to overt hypothyroidism. The annual rate of
progression to overt hypothyroidism was 4.3% in women
with both raised serum TSH and antithyroid antibodies, 3%
if only serum TSH was raised, and 2% if only antithyroid
antibodies were present. A serum TSH level above 2 mIU/
liter was associated with an increased probability of overt
hypothyroidism (24). Thyroid autoantibodies were found to
have prognostic relevance in other studies carried out in
elderly subjects (76, 85–90). Rosenthal et al. (89) reported that
one third of geriatric patients developed overt hypothyroid-
ism during 4 yr of follow-up. Among these, overt hypothy-
roidism developed in all subjects with initial TSH levels
above 20 mIU/liter, and 80% of those with high-titer thyroid
antimicrosomal antibodies (regardless of initial TSH level)
became overtly hypothyroid (89).
Several possible prognostic factors for overt hypothy-
roidismwere analyzed in a prospective study of 82 women
with increased TSH concentrations due to autoimmune
thyroiditis, radioiodine treatment, or thyroidectomy, over
a mean observation period of 9.2 yr with annual follow-up
(90). After 10 yr, 28% of the women had developed overt
hypothyroidism, and 68% remained in the subclinical
stage. TSH value became normal in 4% (all from the group
with TSH between 4–6 mIU/liter). According to the initial
serum TSH concentrations (TSH 4–6, 6–12, and 12
mIU/liter), Kaplan-Meier estimates of the incidence of
overt hypothyroidism were 0, 42.8, and 76.9%, respec-
tively, after 10 yr (P 0.0001). In the entire population, the
risk of hypothyroidism was higher in patients with TSH
levels above 6 mIU/liter and positive antimicrosomal an-
tibodies (90).
In another prospective study, serum TSH was the most
powerful predictor of the outcome of spontaneous SHypo
in 107 subjects over the age of 55 yr with SHypo and no
history of thyroid disease (91). Twenty-eight patients
(26.8%) developed overt hypothyroidism, and 40 (37.4%)
normalized their TSH values. The incidence rate of overt
hypothyroidismwas 9.91 cases per 100 patient-years in the
whole population, and 1.76, 19.67, and 73.47 cases per 100
patient-years in subjects with initial TSH values between
5.0–9.9, 10.0 –14.9, and 15.0–19.9 mIU/liter, respectively.
A stepwise multivariate Cox regression analysis showed
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that the only significant factor for progression to overt
hypothyroidism was serum TSH concentration (P 
0.0001). The same authors analyzed the time course of
normalization of TSH levels in 40 patients (32 women,
mean age 62.8  8.2 yr) with spontaneous SHypo (TSH 
5 mIU/liter and normal FT4) during a mean (sd) obser-
vation period of 38.3 17.0 months (range, 12–72 months)
(39). The rate of normalization was greater in patients who
had lesser degrees of serum TSH elevations and negative
antithyroid antibody titers. Thus, the rate of normalization
was 52% for those with serum TSH values between 5.0 and
9.9 mIU/liter and only 13% for those with TSH values
between 10 and 14.9 mIU/liter. Fifteen patients (37.5%)
normalized their TSH levels during the first year of fol-
low-up and 27 (67.5%) during the first 2 yr. Ten patients
(25%) had decreased TSH values at the fourth or fifth years
of follow-up. However, the final spontaneous TSH nor-
malization was in the range of 3 to 5 mIU/liter. Most
subjects (65%) ended with TSH values higher than 3 mIU/
liter, and 12 patients (30%) had values above 4.12 mIU/
liter; only a minority of patients (10%) showed a reversion
to TSH less than 2 mIU/liter (39). Finally, in another study,
11 of 21 octogenarians with SHypo and a TSH value
greater than 4.7 mIU/liter had normal thyroid function
after 3 yr (92).
A high risk of disease progression was observed in preg-
nant women with asymptomatic autoimmune thyroiditis
(93). Women with autoimmune thyroiditis had basal TSH
values significantly higher, albeit still normal, in the first
trimester (1.6 vs. 0.9 mIU/liter; P  0.001) than did women
with healthy pregnancies used as controls. Despite a 60%
average reduction in TPOAb titers during gestation, serum
TSH remained higher in women with autoimmune thyroid-
itis than in controls throughout gestation: at delivery, 40% of
cases had serum TSH levels above 3 mIU/liter, and 16% had
serum TSH levels above 4 mIU/liter. A TRH test carried out
in the days after parturition showed an exaggerated response
in 50% of the cases.
The risk of progression from subclinical to overt hypo-
thyroidism is less common in children and adolescents,
and the recovery of thyroid function is more frequent. In
18 children and adolescents with autoimmune thyroiditis
and elevated TSH, seven patients were euthyroid, 10 con-
tinued to have SHypo, and one became hypothyroid after
a follow-up period of 5.8 yr (94). In another study, about
25% of adolescents affected by goitrous thyroiditis had
spontaneous resolution of the disease over 20 yr, and
about 33% developed overt hypothyroidism (95).
In conclusion, progression from mild to overt hypothy-
roidism may be related to the cause of thyroid hormone
deficiency, the basal TSH value, and the patient’s age.
Moreover, SHypo may be a persistent or transient disease
(96). Transient expression of TSH-receptor blocking anti-
bodies may explain the recovery of thyroid function in
some cases (2). On this basis, it may be reasonable to
reevaluate patients with previously diagnosed SHypo to
assess whether it is persistent. This may be accomplished
by progressive reduction in l-T4 dosage followed by serial
TSH testing.
F. Symptoms, quality of life, and cognitive function in
subclinical hypothyroidism
The decision to treat patients with SHypo is often based on
the assessment of the clinical symptoms and signs of mild
disease. A number of validated instruments are available to
evaluate the presence or absence of various symptoms and
signs of thyroid hormone deficiency (which are less sensitive
in mild disease than in overt disease) or to evaluate mood,
cognition, or quality of life. Moreover, the clinical picture of
hypothyroidism has changed in recent years because of an
earlier diagnosis. Formerly, the classical clinical picture of
hypothyroidism focused on severe, long-standing disease.
Thus, old clinical scoring systems may not identify symp-
toms and signs of very early disease, even if present. To
complicate the issue further, nonspecific symptoms that oc-
cur in hypothyroidism are present commonly in persons
with normal thyroid function or TA (97–99). Another obscure
issue is the possible link between depression and impaired
thyroid function (100, 101). This association is further com-
plicated by evidence that autoimmune thyroiditis is more
frequent in depressed patients than in healthy euthyroid
individuals (20 vs. 5%) (102)
The groups of Billewicz (103) and Seshadri (104) have
developed symptom scores to investigate the value of symp-
toms in discriminating overt hypothyroidism from euthy-
roidism, and these systems have also been applied to inves-
tigate the potential clinical significance of SHypo. In the
Colorado study, a questionnaire that included 17 thyroid
symptoms revealed a clear correlation between the type of
symptom (dry skin, poor memory, slow thinking, muscle
weakness, fatigue, muscle cramp, cold intolerance, puffy
eyes, constipation, and hoarseness), the number of symp-
toms, and elevated TSH (40, 105). A small increase in total
symptoms was observed with progressive deterioration of
thyroid function. In fact, whereas euthyroid subjects re-
ported a mean of 12.1% of all listed symptoms, overtly hy-
pothyroid subjects had 16.6% of these symptoms (P  0.05
vs. euthyroid group), and subjectswithmild hypothyroidism
had 13.8% (P 0.05 vs. euthyroid group). Moreover, report-
ing more symptoms, in particular recently “changed symp-
toms” increased the likelihood of disease.
Using a new clinical score constituted by 14 symptoms and
signs of hypothyroidism to assess the severity of thyroid
failure, Zulewski et al. (106) found a good correlation be-
tween this score, FT4, and TSH in patients with SHypo.
However, thyroid status was not predicted from clinical
signs and symptoms in a retrospective study conducted in a
primary care geriatrics clinic (107). There was no significant
relationship between TSH levels and the total number of
hypothyroid symptoms experienced by all patients (P 
0.99), and logistic regression analyses showed that clinical
signs and symptoms were poor predictors of SHypo in these
elderly patients (107).
A community-based cross-sectional study was recently
performed on a total of 1423 non-healthcare-seekingwomen,
aged 18–75 yr randomly recruited. Short-Form 36 (SF-36)
and the Psychological General Well-being Index (PGWI)
were used to evaluate health-related quality of life in subjects
with SHypo defined as serum TSH above 4.0 mIU/liter. In
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this study, SHypo was not associated with lower well-being
or impaired health-related quality of life (108).
The presence of symptoms in patients with SHypo was
evaluated in two studies. In a study by Cooper et al. (109),
patients with SHypo had a higher prevalence of hypothyroid
symptoms than age- and sex-matched euthyroid controls.
However, in a study by Kong et al. (110) of women with
SHypo, the most common hypothyroid symptoms were fa-
tigue (83%) and weight gain (80%). At presentation, 20
women (50%) had elevated anxiety scores, and 22 (56%) had
elevated scores on the General Health Questionnaire (110).
Results obtained with anxiety scores and cognitive defi-
ciency scores in SHypo subjects are controversial (77, 92,
111–117). Impaired memory function has been reported in
SHypo in small numbers of patients (111, 113), but more
recent larger studies have not corroborated this observation
(77, 92, 112, 114–117). For example, an interview survey of
825Medicare subjects in NewMexico (mean age, 74.1 yr) did
not reveal any differences in the age-adjusted frequency of
self-reported symptoms, cognitive tests, or depression be-
tween subjects with elevated serum TSH (from 4.7 to 10
mIU/liter) and those with normal TSH concentrations (77).
Also, in a prospective observational population study of 559
individuals monitored from ages 85 through 89 yr, plasma
TSH levels and FT4 were not associated with disability in
daily life, depressive symptoms, or cognitive function (92).
The relation between neuropsychological function and
SHypo (defined as serumTSHbetween 3.5 and 10mIU/liter)
was recently studied in 89 subjects with SHypo older than 29
yr and 154 control subjects recruited from a general health
survey (115). No significant differences in cognitive function
or hypothyroid symptoms were observed between patients
and controls, whereas patients scored better than controls on
the General Health Questionnaire (GHQ-30) for emotional
function. In a survey carried out in Pomerania, which in-
cluded 3790 participants with known thyroid disease, 27
subjects with SHypo did not differ from controls in their
mental and physical complaints (116). However, autoim-
mune thyroiditis in 47 patients was associated with negative
effects on health also in euthyroid subjects (116). A recent
cross-sectional study of 5865 patients at least 65 yr of agewith
known thyroid disease (168 with SHypo defined by TSH 
5.5 mIU/liter) was carried out in primary care practices in
England to assess the association with cognitive function,
depression, and anxiety. This study provides good evidence
that SCTD is not associated with depression, anxiety, or
cognition (117). In contrast, in a recent study, functional
magnetic resonance imaging (MRI) was used to evaluate
brain function in overt and SHypo patients in comparison
with euthyroid subjects (118). This study suggested that
working memory (but not other memory functions) is im-
paired by SHypo, and impairment is more severe in overt
hypothyroidism (118).
In conclusion, the presence of symptoms in patients with
SHypo remains controversial. It is difficult to distinguish
euthyroid subjects from patients with SHypo using clinical
symptoms. Moreover, many symptoms are nonspecific. In
our opinion, symptoms of hypothyroidism are probably re-
lated to disease severity, disease duration, and individual
sensitivity to thyroid hormone deficiency, which in turn de-
pend on the sensitivity of the peripheral target organs. Age
may also affect the identification of symptoms of hypothy-
roidism. The typical findings of hypothyroidism are less
common in the elderly and, when present, are often attrib-
uted to chronic illnesses, drugs, depression, or age (119, 120).
Similarly, clinical signs and symptoms are poor predictors of
SHypo in the elderly; this may explain why the diagnosis of
SHypo, like overt disease, may be delayed in elderly patients
(Fig. 1). Symptoms and signs can also be minimal or non-
specific in young and middle-aged patients with SHypo.
Furthermore, patients with SHypo identified by population
screening may be more likely to be asymptomatic than those
identified in clinical trials. In fact, patients with persistent
SHypo orwith a poor quality of life aremore likely to present
to a physician for thyroid function testing. The presence of
specific symptoms may suggest thyroid hormone deficiency
andmay serve to identify patientswhoneed thyroid function
tests and to select SHypo patients who can benefit from
replacement therapy. Patients who report more symptoms
and more recently developed symptoms may be more likely
to have overt thyroid hormone deficiency (105).
G. Cardiovascular risk in subclinical hypothyroidism
The cardiovascular system is a major target of thyroid
hormone action (121, 122). Therefore, evaluation of the car-
diovascular effects of thyroid hormone deficiency has shed
light on the clinical significance of SHypo (121–122). Changes
in cardiac hemodynamics depend on the severity of thyroid
hormone deficiency, but the most frequent changes in hy-
pothyroid patients are increased systemic vascular resistance
(SVR), diastolic dysfunction, reduced systolic function, and
decreased cardiac preload (121–123). All these abnormalities
regress with l-T4 replacement therapy. Hypertension, hy-
perlipidemia, diabetes, and cigarette smoking are major in-
dependent risk factors for cardiovascular disease (124). An
increased risk for atherosclerosis is supported by autopsy
and epidemiological studies in patients with thyroid hor-
mone deficiency and may be in part explained by the hy-
percholesterolemia and marked increase in LDL typical of
this condition (125, 126). Moreover, diastolic hypertension
due to increased SVR, increased arterial stiffness and endo-
thelial dysfunction, altered coagulability, and increased lev-
els of C-reactive protein (CRP) may further contribute to the
increased cardiovascular risk associated with overt hypo-
thyroidism and possibly SHypo (123, 126). In this review, the
cardiovascular risk in patients with SHypo will be assessed
FIG. 1. Hypothetical relationship between age and effect of SHypo on
symptoms, mood, and cognition. Published data suggest that the
possible effects are age related.
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by evaluating cardiovascular morphology and function and
potential risk factors for atherosclerosis.
1. Cardiac function in SHypo. The impact of SHypo on the
cardiovascular system has been evaluated by looking at di-
astolic function, systolic function, and exercise performance
(127, 128). Left ventricular diastolic function was evaluated
in seven studies by Doppler echocardiography and radio-
nuclide ventriculography at rest and during exercise, in
young andmiddle-aged patients with Hashimoto thyroiditis
and mild but persistent TSH increases compared with eu-
thyroid controls (129–135) (Table 3). Subclinically hypothy-
roid patients had a more prolonged isovolumetric relaxation
time and an impaired time-to-peak filling rate (which are
parameters of altered left ventricular diastolic function) than
controls (129–135). As shown in Fig. 2, overt hypothyroidism
can affect left ventricular diastolic function (136–139) by
causing decreased expression of sarcoplasmic reticulum cal-
cium ATPase (121, 123, 136). This leads to reduced calcium
reuptake into the sarcoplasmic reticulum during diastole,
resulting in impaired diastolic relaxation. A similar mecha-
nism could impair diastolic function in patients with SHypo
(129–135). This cardiac findingmay be an important negative
prognostic factor, because isolated left ventricular diastolic
dysfunction has been associated with increased morbidity
and mortality in the general population (140). Moreover,
impaired left ventricular diastolic function at rest may be an
important cause of exercise intolerance and may lead to
diastolic heart failure in the elderly (141).
Conflicting results have been reported about systolic func-
tion at rest, evaluated by systolic time intervals, in patientswith
SHypo (Table 4) (131–135, 142–145). Cardiac systolic function
was normal in patients with SHypo in three studies in which
Weissler’s method (simultaneous recording electrocardiogra-
phy, carotid tracing, and phonocardiogram)was used to assess
systolic function (142, 143, 145). However, impaired at-rest left
ventricular function, as defined by an increased preejection
period (PEP)/left ventricular ejection time (LVET) ratio, was
reported in five studies using the more sensitive echocardio-
graphic technique in SHypo patients compared with control
subjects (131–135). Only Tseng et al. (144) did not find a sig-
nificant variation in PEP and PEP/LVET by means of concur-
rent aortic andmitral valve echocardiography.The systolic time
interval alterations reported in SHypo patients resemble those
found in patients with overt disease (138, 146), although they
areof a lessermagnitude. Impaired left ventricular systolic (147)
and diastolic (130) function on effort were also documented by
Doppler echocardiography and cardiopulmonary exercise test-
ing in SHypo patients in comparison with euthyroid controls.
The finding of impaired systolic and diastolic function
during exercise might have clinical implications in SHypo
patients similar to those that occur in overt disease. In fact,
reduced exercise tolerance and dyspnea on effort are the
most frequent cardiovascular symptoms in overt hypothy-
roidism (136, 147). Unfortunately, symptoms possibly re-
lated to altered cardiac function have not been investigated
systematically in patientswith SHypo. Conflicting results are
reported in three studies in which physical performance was
investigated in SHypo patients (98, 117, 148). In one cross-
sectional study, the reference scores on all eight SF-36 scales
were significantly reduced in people with SHypo compared
with a large UK population, and the most significantly im-
paired aspects of health status were vitality and role limi-
tations due to physical problems (148).
More sophisticated techniques have recently been used to
assess systolic and diastolic function and myocardial texture
in patients with SHypo. Cardiac MRI (CMR), which gives
high resolution, three-dimensional reconstructions, is at
present the most accurate procedure with which to evaluate
cardiac volumes and function. Indeed, it resolved conflicting
data about systolic function in mild SHypo (149). Thirty
women with SHypo (TSH range, 8.7 3.7 mIU/liter) due to
Hashimoto thyroiditis and 20 matched control subjects were
evaluated by MRI in comparison with normal subjects. Car-
diac volumes and systolic performance were significantly
altered in the SHypo patients. In particular, the preload (end-
TABLE 3. Left ventricular diastolic function in patients with SHypo in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients Age (yr) TSH (mIU/liter) Cardiac findings Cardiac methods
Biondi, 1999 (129) 26 36  12 8.6  4.8 1 A, 2 E/A, 1 IRT Doppler echo
Di Bello, 2000 (131) 16 32  12 5.3  1.9 1 A, 7 E/A, 1 IRT Doppler echo
Monzani, 2001 (133) 20 33  12 5.4  2.4 7 E/A, 1 A, 1 IRT Doppler echo
Vitale, 2002 (132) 20 38  12 10.6  4.05 7 E/A, 1 IRT Doppler echo
Brenta, 2003 (130) 10 50  8.7 11.0  4.2 1 TPFR Radionuclide ventriculography
Yazici, 2004 (134) 45 40  7.9 8.41  2.1 1 A, 1 IRT, 2 E/A Doppler echo
Aghini-Lombardi, 2006 (135) 24 35  6.2 5.3  1.1 1 A, 1 IRT, 2 E/A Doppler echo
Values represent mean  SD. IRT, Isovolumic relaxation time; TPFR, time-to-peak filling rate; E/A, early-to-late transmitral peak flow
velocity ratio.
P values for SHypo vs. control subjects: IRT, Biondi and Yazici, P  0.001; Di Bello, P  0.04; Monzani, P  0.03; Vitale, P  0.005;
Aghini-Lombardi, P  0.01. E/A, Biondi and Yazici, P  0.001; Monzani, P  0.01; Vitale, P  0.005; Aghini-Lombardi, P  0.02. A, Biondi,
P  0.05; Yazici, P  0.01; Di Bello, P  0.01; Monzani, P  0.01; Aghini-Lombardi, P  0.01. TPFR, P  0.001.
Altered intracellular 
calcium handling
Slowed myocardial relaxation and 
impaired LV diastolic filling
Reduced peripheral action 
of thyroid hormone
Overt and Subclinical Hypothyroidism
Impaired LV 
diastolic filling
Increased left ventricular 
mass
Long-term Overt and Subclinical
Hyperthyroidism
FIG. 2. Mechanism of diastolic dysfunction in overt and subclinical
hypothyroidism, and in long-term overt and subclinical hyperthy-
roidism.
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diastolic volume) was significantly decreased and the after-
load (SVR) was significantly increased, thereby leading to
impaired cardiac performance (149).
Tissue Doppler imaging is an emerging noninvasive ul-
trasound tool that makes it possible to measure velocities at
any point of the ventricular wall during the cardiac cycle. It
is minimally affected by alterations in afterload and changes
in heart rate (150). Tissue Doppler imaging revealed changes
in myocardial time intervals in several segments in 20
healthy women with SHypo (TSH, 10.5  4.05 mIU/liter)
(132). Myocardial time intervals, evaluated as precontraction
time, the precontraction time/myocardial contraction time
ratio, and myocardial relaxation time, were prolonged at the
level of both the posterior septum and the mitral annulus in
patients with autoimmune SHypo in comparison with con-
trols (132). These alterations were similar to those identified
in patients with overt hypothyroidism (138).
Finally, ultrasonic myocardial textural analysis was used
in two studies to characterize myocardial tissue in patients
with SHypo (131, 133). The cyclic variation index, which is
a percentage of systolic/diastolic change in mean gray levels
of the interventricular septum and the left ventricular pos-
terior wall, was lower in patients than in normal subjects.
These findings are indicative of alterations in myocardial
composition, which may represent early myocardial struc-
tural changes in mild thyroid deficiency.
In conclusion, the most consistent cardiac abnormality
reported in patients with SHypo is impaired left ventricular
diastolic function, which is characterized by slowed myo-
cardial relaxation and impaired ventricular filling (129–135).
Results concerning systolic function at rest are not consistent
(131–135, 142–145); however impaired systolic function has
been identified with new, more sensitive techniques (Dopp-
ler echocardiography and CMR) (131–135, 149). Only two
studies have assessed systolic function and diastolic function
during exercise and documented impaired cardiac perfor-
mance on effort (130, 147). All the cardiovascular alterations
that have been reported in patients with SHypo are similar
to those observed in overt hypothyroidism. This suggests
that there is a continuum in the cardiac changes that occur
throughmild, subclinical disease into overt hypothyroidism.
2. Vascular system and SHypo. T3 directly affects the vascular
smooth-muscle cells that promote relaxation. It also de-
creases SVR by increasing tissue thermogenesis and meta-
bolic activity (151–154). Overt hypothyroidismmay be a risk
factor for hypertension, and reversible diastolic hypertension
has been reported in 20–40% of patients with overt disease
(121, 123, 151–154). An increased risk of hypertension has
also been reported in some studies of patients with SHypo
(155, 156). As in overt disease, three factors can contribute to
systemic hypertension in SHypo: increased peripheral vas-
cular resistance, increased arterial stiffness, and endothelial
dysfunction. An increase in SVR and in mean arterial pres-
sure was reported in some studies of normotensive patients
with SHypo compared with euthyroid subjects (129, 157) but
not in all (133, 135). Recently, a significant increase in SVR
was reported using CMR in 30 patients with SHypo (TSH,
8.7  3.7 mIU/liter) compared with 20 euthyroid controls
(149). These data suggest that mild thyroid hormone defi-
ciency might also affect vascular tone (123).
Increased central arterial stiffness appears to be an im-
portant risk factor for cardiovascular disease. Changes in
arterial wall elasticity may occur before and during the early
stages of atherosclerosis andmay have detrimental effects on
left ventricular function and coronary perfusion. Increased
arterial stiffness may contribute to the development of hy-
pertension and has been reported to be an independent risk
factor for cardiovascular morbidity and mortality (158, 159).
Increased arterial stiffness can be identified from an in-
creased augmentation of central aortic pressure and central
arterial stiffness in untreated patients with overt hypothy-
roidism comparedwith age-, sex-, andBMI-matched controls
(160, 161). Pulse wave analysis has also revealed increased
arterial stiffness in patients with SHypo (156). Increased ar-
terial stiffness has also been identified from increased aug-
mentation gradient, augmentation index, and corrected aug-
mentation index in patients with SHypo compared with
controls (162). Pulse wave velocity is a direct parameter of
arterial stiffness and a marker of cardiovascular risk (163,
164). The brachial-ankle pulse wave velocity is a parameter
of arterial stiffening and is a good independent predictor for
coronary artery disease. It has been used to investigate the
risk of ischemic heart disease in overt hypothyroidism and
SHypo. Both groups of subjects tended to have increased
arterial wall stiffness (160, 161). Diastolic blood pressure and
brachial-ankle pulse wave velocity were significantly in-
creased in patients with SHypo (TSH, 6.9  0.82 mIU/liter)
compared with normal subjects (156, 165). Moreover, central
TABLE 4. Left ventricular systolic function in patients with SHypo in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients TSH (mIU/liter) Cardiac findings Cardiac methods
Bough, 1978 (142) 10 8.1  50 7PEP,7PEP/ET Weissler’s method
Foldes, 1987 (143) 17 10.3  6.34 7PEP,7PEP/ET Weissler’s method
Tseng, 1987 (144) 22 10.7  10.3 7PEP,7PEP/ET Concurrent aortic and mitral valve echo
Staub, 1992 (145) 35 6
14 6–12 7PEP,7PEP/ET Weissler’s method
20 12
Di Bello, 2000 (131) 16 5.3  1.9 1PEP,1PEP/ET Doppler echo
Vitale, 2002 (132) 20 10.5  4.05 1PEP,1PEP/ET Doppler echo
Monzani, 2001 (133) 20 5.4  2.4 1PEP,1PEP/ET Doppler echo
Yazici, 2004 (134) 45 8.4  2.1 7PEP,1PEP/ET Doppler echo
Aghini-Lombardi, 2006 (135) 24 5.3  1.1 1PEP,1PEP/ET Doppler echo
Values represent mean  SD. ET, Ejection time; PEP, preejection period.
P values for SHypo vs. control subjects: PEP, Di Bello, P  0.03; Vitale, P  0.05; Monzani, P  0.02; Aghini-Lombardi, P  0.05. PEP/ET,
Di Bello, P  0.01; Vitale, P  0.05; Monzani, P  0.03; Yazici, P  0.05; Aghini-Lombardi, P  0.02.
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and peripheral pulse wave velocities were significantly
higher in SHypo patients than in normal subjects (156, 165).
The vascular endothelium is a regulator of vascular
smooth-muscle cell function and helps to maintain ho-
meostasis and blood fluidity. Nitric oxide in the endothelium
diffuses to the vascular smooth muscle and induces relax-
ation. Similar to what is observed in hypothyroidism, SHypo
has been found to be associatedwith endothelial dysfunction
(33, 166). High-resolution ultrasound imaging of the brachial
artery showed that, compared with a control group, flow-
mediated endothelium-dependent vasodilatation was sig-
nificantly impaired in hypothyroid subjects with TSH levels
between 4.01 and 10mIU/liter, and greater than 10mIU/liter
(33). Taddei et al. (166) used the perfused forearm technique
to measure the forearm blood flow response to intrabrachial
acetylcholine, which is an endothelium-dependent vasodi-
lator, at baseline and during infusion of the NO inhibitor,
NG-monomethyl-L-arginine, in SHypo patients (TSH, 7.68
3.21 mIU/liter) before and after l-T4 therapy (166). The va-
sodilating effect of acetylcholinewas significantly reduced in
patients vs. healthy subjects and was not affected by NG-
monomethyl-L-arginine. Endothelial dysfunctionwas attrib-
uted to the reducedNO availability. Recent data suggest that
low-grade chronic inflammation could be responsible for
endothelial dysfunction and impaired NO availability by a
cyclooxygenase (COX-2)-dependent pathway, increasing ox-
idative stress in patients with SHypo due to Hashimoto’s
thyroiditis (167).
Carotid artery intima-media thickness (CIMT) can be a
useful parameter in the early diagnosis of atherosclerosis and
coronary heart disease. Increased CIMT has been docu-
mented in SHypo (168, 169). Patients with SHypo had higher
TC, LDL-C, and apolipoprotein (Apo) B levels and higher
mean intima-media thickness (IMT) values compared with
age- and sex-matched controls. Moreover, mean IMT was
positively related to age, TSH, and LDL-C (168).
Myocardial functional reserve, assessed by iv dobutamine,
did not differ between subjects with SHypo and controls and
remained unaltered after treatment (162). There were no
differences in resting global, regional left ventricular func-
tion, or regional myocardial velocities during maximal do-
butamine stress between SHypo patients and controls, or in
patients treated with replacement therapy compared with
baseline values (162). However, in a recent study, coronary
flow reserve was lower in subclinical and overt hypothy-
roidism than in euthyroid subjects (170).
In conclusion, on the basis of the data available, SHypo
could impair vascular function by inducing an increase in
SVR and arterial stiffness and by altering endothelial func-
tion, thereby potentially increasing the risk of atherosclerosis
and coronary artery disease.
3. SHypo and lipid profile. The relationship between SHypo
and serum lipids remains controversial (126, 171). In several
cross-sectional studies, SHypo was found to be associated
with a variable and somewhat inconsistent increase in TC
and in LDL-C (40, 77, 172–176), higher plasma oxidized
LDL-C levels (177), and inconsistent changes in serum levels
of HDL-C (145, 155, 168, 172, 173, 175, 178–190). Not unex-
pectedly, the lipid pattern is more abnormal in SHypo in-
dividuals with serumTSH greater than 10mIU/liter (77, 145,
173, 178, 181–183), and it is also more deranged in those who
smoke (177, 183, 191). Moreover, in a group of healthy eu-
thyroid subjects, Bakker et al. (191) found a strong, positive
relationship between TSH and LDL-C in insulin-resistant
subjects, but not in insulin-sensitive subjects.
The association between SHypo and serum TC and LDL-C
has been investigated in several large population-based stud-
ies. In the Whickham Survey, SHypo was not related to
hyperlipidemia (174). In the NHANES III, mean cholesterol
levels and rates of elevated cholesterol levels were higher in
people with SHypo (TSH, 6.7–14.9 mIU/liter) than in eu-
thyroid controls (TSH, 0.36–6.7 mIU/liter); there were no
differences in LDL or HDL levels (192). However, when
adjusted for age, race, sex, and the use of lipid-lowering
drugs, SHypo was not related to increased cholesterol levels
(192). In another study, there was no apparent relationship
in subjects with SHypo between serum concentrations of
TSH ranging from 4.0 to 49.0 mIU/ml and concentrations of
LDL-C (186). In the Rotterdam Study, TC was lower in
women with SHypo than in euthyroid women (193). Similar
data were reported in the Nagasaki study (194). In the New
Mexico Elder Health survey, there were no differences in TC,
HDL-C, or triglycerides between patients with a serum TSH
level below 4.6 mIU/liter and those with a serum TSH level
between 4.7 and 10 mIU/liter (77). The levels of LDL-C and
HDL-C were higher among women with serum TSH greater
than 10 mIU/liter than in euthyroid women, although the
difference was not significant (77). In the Busselton study,
serum TC was significantly higher in subjects with SHypo
than in euthyroid subjects, but the difference was barely
significant after adjustment for age and sex (195). Moreover,
LDL-C was significantly increased in subjects with mild
SHypo and TSH levels of at least 10 mIU/liter. In a Danish
study, SHypo (TSH, 3.70 mIU/liter) was associated with a
higher concentration of triglycerides and CRP (196).
In a large population-based study (2799 adults aged
70–79 yr), TSH levels were stratified to establish a cutoff
for the relationship between TSH and serum lipids (197).
A serum TSH level above 5.5 mIU/liter was associated
with a cholesterol increase of 0.23 mmol/liter (10 mg/dl).
In a cross-sectional study of middle-aged patients, Bindels
et al. (198) estimated that, after correction for age, an in-
crease of 1 mIU/liter in serum TSH was associated with a
rise in serum TC of 0.09 mmol/liter (3.5 mg/dl) in women
and 0.16 mmol/liter (6.2 mg/dl) in men. They estimated
that approximately 0.5 mmol/liter (20 mg/dl) of serum
TC could be attributed to SHypo. Bauer et al. (172) eval-
uated the association of TSH with serum lipids in an un-
selected population of older women. After multiple ad-
justment, LDL-C was 13% higher and HDL-C was 12%
higher in womenwith elevated TSH (TSH 5.5 mIU/liter)
vs. women with normal TSH. The LDL-C to HDL-C ratio
was 29% greater among women with elevated TSH.
Women with multiple lipid abnormalities were twice as
likely to have increased TSH levels.
In conclusion, there are conflicting results about lipid pat-
tern and SHypo. This might reflect differences in the pop-
ulation studied (e.g., cause of SHypo, duration of thyroid
dysfunction, TSH levels), as well as differences in age, gen-
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der, and ethnicity of the subjects tested (199). In addition,
smoking and insulin resistance may play a role in mediating
the effects of mild hypothyroidism on serum lipids (183, 191,
199).
4. Emerging cardiovascular risk factors for atherosclerosis. “Non-
traditional” blood markers for atherosclerosis risk, such as
homocysteine CRP, fibrinogen, factor VIII, von Willebrand
factor (vWF), and lipoprotein (a), may be associated with an
increased risk of coronary heart disease (200–205). Serum
lipoprotein (a) levels are mainly under genetic control and
are associatedwith increased risk of both atherosclerosis and
thrombogenesis. This lipoprotein is similar to LDL in its lipid
composition, but it contains an additional glycoprotein, des-
ignatedApoA,which is linked toApoB by disulfide bridges.
Lipoprotein (a) has a striking homology to plasminogen.
Studies on the association between lipoprotein (a) and
SHypo have generally yielded consistently negative results
(172, 177, 182, 184, 188, 189). Lipoprotein (a) was found to be
increased only in patients with SHypo with a TSH value
above 12 mIU/liter (182, 206), and in postmenopausal
women with SHypo regardless of their serum TSH value
(185). The finding that a family history of chronic heart dis-
ease (CHD) and/or diabetes was significantly associated
with an elevated level of lipoprotein (a) suggested that the
increase was due to a genetic effect rather than to a reduced
thyroid hormone concentration (189). Similarly, homocys-
teine levels have not been shown to differ between individ-
ualswith SHypo and euthyroid controls in some case-control
studies (155, 168, 190). Hence, total homocysteine does not
appear to contribute to the potential increased risk of ath-
erosclerotic disease and myocardial infarction in subclinical
hypothyroid patients. In a cross-sectional study (New Mex-
ico Elder Health Survey) of a randomly selected sample of
Medicare recipients (age  65 yr), there was no significant
difference in serum homocysteine concentrations between
the 112 participants with SHypo (groups 2 and 3) and the 643
participants with TSH values no greater than 4.6 mIU/liter
(group 1) after adjusting for differences in gender, ethnicity,
age, and serum concentrations of folate, vitamin B12, and
creatinine (207). Only participants with the highest TSH lev-
els (10 mIU/ml) (group 3) had a significantly higher prev-
alence of coronary heart disease when compared with group
1 participants (P  0.007). No consistent significant differ-
ences in the prevalence of CHD or in the CHD risk factors
examined were observed when all participants with SHypo
(groups 2 and 3) were compared with group 1 participants.
Patients with thyroid diseases have abnormalities of blood
coagulation that may contribute to the high risk for cardio-
vascular disease (208). Both increased and decreased platelet
adhesiveness have been reported in hypothyroidism (209,
210). Alterations in coagulation parameters have been re-
ported in patients with SHypo (Table 5). The degree of hy-
pothyroidism may influence coagulation parameters. In a
study that compared moderate (TSH, 10–50 mIU/liter) and
severe hypothyroidism (TSH, 50 mIU/liter) with the eu-
thyroid state, women with moderate hypothyroidism had
decreased fibrinolytic activity with lower D dimer levels,
higher  2 antiplasmin activities, and higher levels of tissue
plasminogen activator inhibitor antigen (209).Moreover, fac-
tor VII activity and the factor VII activity:factor VII antigen
ratio were significantly increased in women with SHypo
(TSH, 6 mIU/liter) vs. euthyroid controls, whereas there
were no differences in vWF or in the other hemostatic and
lipid variables tested (211). This reflects activated factor VII
and might indicate a hypercoagulable state in SHypo. Can-
turk et al. (212) found increased levels of fibrinogen, plas-
minogen activator inhibitor antigen, and factor VII and de-
creased antithrombin III activity in SHypo patients (TSH
level, 8.9 mIU/liter) compared with controls. In another
study, factor VIII and vWF activities were lower (P  0.01)
in patients with SHypo than in controls (213). The global
fibrinolytic capacity was significantly lower in patients with
SHypo than in controls (P 0.002) in the study by Guldiken
et al. (214). Finally, in the recent fifth Tromsø study, an ep-
idemiological health survey, 83 subjects fulfilled the criteria
for SHypo (TSH level, 3.5–10.0 mIU/liter), and their blood
samples were analyzed for the hemostatic factors and com-
pared with 249 age- and sex-matched control subjects with
serum TSH in the range 0.50–3.49 mIU/liter. There were no
statistically significant differences between the SHypo group
and the controls regarding the hemostatic factors. However,
the factor VIIa levels were 10% lower in the SHypo group
than in the controls (P  0.055 after correction for multiple
comparison).Moreover, in the linear regressionmodel serum
TSH was a significant and negative predictor of the factor
VIIa level (215). On the whole, the above data support the
hypothesis that alterations in coagulation parameters might
play a role in the potential development of atherosclerosis in
patients with SHypo. The clinical importance of this finding
needs further study.
CRP is a strong predictor of cardiovascular risk. There is
disagreement about whether or not abnormalities of CRP
occur in patients with SHypo. CRP levels were significantly
higher in subclinical hypothyroid patients than in controls in
three studies (190, 196, 216). SHypo was associated with
higher concentrations of triglycerides and CRP in the study
by Kvetny et al. (196) and was a predictor of cardiovascular
disease in males below 50 yr of age, with an OR of 3.4 for
developing cardiovascular disease comparedwith euthyroid
age-matched males. Moreover, in the study by Tuzcu et al.
TABLE 5. Hemostatic profile in patients with SHypo in comparison with euthyroid control individuals
First author, year (Ref.) TSH (mIU/liter) SHypo
Chadarevian, 2001 (209) 10–50 2 D Dimer, 1 2 antiplasmin activities, 1 tissue plasminogen activator inhibitor antigen
Muller, 2001 (211) 6 1 Factor VII:C, 7 vWF, 1 Factor VII:C/Factor VII:Ag
Canturk, 2003 (212) 8.9 1 Fibrinogen, 1 Plasminogen activator inhibitor antigen, 1 Factor VII, 2 antithrombin III
Gullu, 2005 (213) 5–10 2 Factor VIII, 2 vWF
Guldiken, 2005 (214) 7.3  2.2 2 Global fibrinolytic capacity
Jorde, 2006 (215) 3.5–10.0 2 FVIIa
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(216), patients with SHypo had increased levels of both high
sensitive CRP (hsCRP) and fasting insulin vs. the control
group, and there was a positive correlation between hsCRP
levels and insulin levels in patients with SHypo (216). How-
ever, homeostasis model of assessment-insulin resistance
[fasting insulin (IU/ml)  fasting glucose (mmol/liter)/
22.5] values were not significantly different vs. controls. This
finding prompted the suggestion that the elevated hsCRP
level, and hence lowgrade inflammation, could be associated
with fasting hyperinsulinemia before insulin resistance be-
comes evident in patients with SHypo (216).
In contrast, CRP did not appear to contribute to the in-
creased risk for coronary heart disease in subclinical hypo-
thyroid patients reported in other studies (217, 218). In a large
population-based sample taken from the NHANES, hsCRP
levels were similar in patients with SHypo and euthyroid
individuals (219).
Ozcan et al. (220) recently evaluated all these “new” car-
diovascular risk factors in 84womenwith SHypo and amean
serum TSH of 9.3 mIU/liter. TC, LDL-C, hsCRP, asymmetric
dimethylarginine, and L-arginine levels were significantly
higher in patients than in controls, whereas nitric oxide levels
were lower.
In conclusion, data on a potential association of SHypo
with such “nontraditional” cardiovascular risk factors are
not consistent. Some studies support an increase in CRP and
alterations in coagulation parameters (190, 196, 209, 211–214,
215, 216, 220) in SHypo patients compared with euthyroid
age-matched subjects. Although homocysteine is an impor-
tant cardiovascular risk factor in patients with overt hypo-
thyroidism, it does not seem to have a role in SHypo patients
(155, 168, 190, 207).
5. Epidemiological studies. The data from case-control and
cross-sectional studies are controversial with respect to the
association between SHypo and cardiovascular disease (221–
224). In an early study of 945 consecutive hospitalized pa-
tients, women with a TSH level greater than 4 mIU/liter had
a significantly increased prevalence of coronary heart disease
(222). In a cross-sectional study (New Mexico Elder Health
Survey) of a randomly selected sample of Medicare recipi-
ents (age  65 yr), only subjects with the highest TSH levels
(10 mIU/liter) had a significantly higher prevalence of
coronary heart disease (77). SHypo has also been associated
with a high prevalence of dyslipidemia and a high preva-
lence of coronary heart disease in elderly men and women
(mean age, 75 9 yr) (224). However, a Finnish group found
no association between SHypo and coronary heart disease in
men and women (225). Peripheral arterial disease was as-
sociated with SHypo in a case-control study of elderly
women (226).
In the Whickham survey of 2779 randomly selected men
and women 18 yr old and above, there was no association
between autoimmune thyroid disease at study entry and
subsequent death from ischemic heart disease (227). The
assessment of ischemic heart disease was based on a verbally
administered standardized World Health Organization
pain-on-effort questionnaire, a personal history of angina or
myocardial infarction, and standard 12-lead electrocardio-
gram (ECG) evaluation. In this 20-yr cohort study, autoim-
mune thyroid disease was not associated with coronary dis-
ease. Autoimmune thyroid disease was defined as treated
hypothyroidism, positive antibodies, or elevated serumTSH,
without a separate analysis of individuals with elevated se-
rum TSH levels (228).
In the large cross-sectional Rotterdam study of 1149
women 55 yr or older, SHypo (defined as TSH  4.0 mIU/
liter) was present in 10.8% of participants (124 women), and
its associationwith atherosclerosis andmyocardial infarction
was investigated (193). Aortic atherosclerosis was assessed
from calcified deposits in the abdominal aorta on a radio-
graphic film of the lumbar spine (193). Myocardial infarction
was assessed by self-report and by analysis of standard 12-
lead ECGs. Women with SHypo were found to have an
increased risk of atherosclerosis (OR 1.7, 95% CI 1.1–2.6) and
a history of myocardial infarction (OR 2.3, 95% CI 1.3–4.0).
There was no association between TA itself and cardiovas-
cular disease, but patients with both mild TSH elevation and
positive antibodies had an increased relative risk. The risk of
myocardial infarction was not significantly increased during
an average follow-up of 4.6 yr (193).
Parle et al. (229) carried out a 10-yr cohort study of 1191
men and women 60 yr or older. The causes of death were
compared with age-specific, sex-specific, and year-specific
data for England and Wales. In this study, SHypo (defined
as TSH  5.0 mIU/liter with a prevalence of 10.8%) (94
subjects) was not associated with death from circulatory
disease during the 10-yr follow-up. However, 40% of indi-
viduals with SHypo developed overt hypothyroidism dur-
ing follow-up and began T4 replacement therapy.
In a cohort of atomic bomb survivors fromNakasaki (2550
men and women 40 yr or older; mean age, 58.5 yr), SHypo
(defined as TSH 5.0 mIU/liter with a prevalence of 10.2%)
(257 subjects) was associatedwith ischemic heart disease and
increased all-cause mortality in the cross-sectional analysis,
but only in men (194). The prevalence of ischemic heart
disease was independent of such coronary risk factors as
blood pressure, BMI, TC level, smoking status, and presence
of diabetes mellitus. There was no association between
SHypo and cerebrovascular disease, and the presence of
thyroid antibodies did not affect the association between
SHypo and ischemic heart disease. In the longitudinal fol-
low-up study, all-cause mortality was increased at 6 yr only
in men, although the specific causes of death were not de-
termined. However, mortality was not increased at the 10-yr
mark.
In the Leiden prospective cohort study of subjects aged 85
yr, SHypo was present in 30 patients, and in the 21 individ-
uals reassessed at age 88 yr it was associated with greater
longevity and a decreased risk of death from cardiovascular
disease during the 4-yr follow-up, and this was attributed to
a lower metabolic rate (92). Individuals with overt hypothy-
roidism and SHypo had lower all-cause and cardiovascular
mortality than clinically euthyroid individuals, although se-
rum cholesterol levels were higher.
The community-based study carried out in Busselton,
Western Australia, evaluated SHypo as a risk factor for car-
diovascular disease and found that this condition was an
independent predictor of coronary heart disease in the cross-
sectional and longitudinal analysis (38). The study included
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1063men and 1045women (mean age, 50 yr; range, 17–89 yr),
and the prevalence of SHypo was 5.6% (119 subjects). Eu-
thyroid subjects were those with a serum TSH of 0.4 to 2.0
mIU/liter, and patients with SHypo were divided into those
with a serum TSH level of 4–10.0 mIU/liter and those with
a serumTSH greater than 10mIU/liter. In the cross-sectional
analysis, the prevalence of coronary heart disease was sig-
nificantly higher in patients with SHypo and serum TSH
greater than 10 mIU/liter vs. euthyroid subjects (OR 1.8; 95%
CI, 1.0–3.1; P  0.04), after adjustment for age, gender, car-
diovascular risk factors, and self-reported thyroid disease or
goiter. The association with coronary heart disease was sig-
nificant in subjects with a TSH level greater than 10 mIU/
liter, but not in patients with mild to moderate SHypo (TSH
4–10 mIU/liter). In the longitudinal analysis (20 yr of fol-
low-up of 101 subjects with SHypo), the risk for coronary
heart disease was significantly increased in subjects with
SHypo after adjustment for age and gender (21 cardiovas-
cular deaths compared with 9.5 expected, and 33 coronary
heart disease events compared with 14.7 expected). The in-
creased risk for coronary events associated with SHypo was
found in subjects with a serum TSH level of 10 mIU/liter or
less as well as in those with a serum TSH greater than 10
mIU/liter. The risk remained significant after adjustment for
standard cardiovascular risk factors. There was no increased
risk of death from cardiovascular disease in patients with
SHypo of any degree (38). In a cross-sectional study of 1212
men and women aged 20–69 yr carried out in Denmark,
SHypo defined by TSH greater than 2.8 mIU/liter, TSH was
a predictor of cardiovascular disease, but only in subjects
younger than 50 yr (196).
In 1989–1990, 3233 U.S. community-dwelling individuals
aged 65 yr or older were enrolled in the Cardiovascular
Health Study, a population-based longitudinal study of risk
factors for the development of CVD in 5888 adults (230).
Eighty-two percent of participants (n  2639) had normal
thyroid function, 15% (n  496) had SHypo, 1.6% (n  51)
had overt hypothyroidism, and 1.5% (n  47) had SHyper.
SHypowas defined as a TSH concentration above 4.50 mIU/
liter and below 20mIU/liter and a normal FT4 concentration.
l-T4 replacement therapy was started during the follow-up
in 142 subjects with SHypo and in 31 with overt hypothy-
roidism. Data were adjusted for the use of thyroid hormone
medication. There were no differences in the incidence of
coronary heart disease, cerebrovascular disease, cardiovas-
cular disease, or all-cause death between the euthyroid and
subclinical or overt hypothyroid groups either in the cross-
sectional survey or in the longitudinal component of this
study. Moreover, there were no differences in serum cho-
lesterol concentrations, lipoprotein (a), CRP, or fasting in-
sulin and glucose concentration between individuals with
SHypo and those with normal thyroid function.
Congestive heart failure has also been linked to SHypo in
several studies. Rodondi et al. (231) assessed the risk of
SHypo (defined as a TSH level of 4.5 mIU/liter or greater) on
heart failure, coronary heart disease, stroke, peripheral ar-
terial disease, and cardiovascular-related and totalmortality.
A total of 2730 men and women, aged 70–79 yr, were eval-
uated and classified according to TSH levels (4.5–6.9, 7.0–9.9,
and 10 mIU/liter). SHypowas present in 12.4% of subjects
(338 subjects), and about 68% of all participants had mild
disease (TSH, 4.5–6.9 mIU/liter). At study entry, no associ-
ation was found between SHypo of any degree and the
prevalence of cardiovascular disease, heart failure, and cor-
onary heart disease. During the 4-yr follow-up, 178 subjects
had heart failure. Congestive heart failure was evaluated by
a panel of clinicians based on symptoms, signs, chest x-ray,
and echocardiographic findings. SHypo was associated with
an increased risk of congestive heart failure (CHF) among
older adults with a TSH level of 7.0 mIU/liter or greater.
Congestive heart failure events occurred more frequently
among subjects with a moderate or severe TSH increase
(TSH, 7.0–9.9 and 10 mIU/liter, respectively; 35.0 vs. 16.5
per 1000 person-years; P  0.06), but rates were similar to
controls among thosewith serumTSH levels between 4.5 and
6.9mIU/liter (P 0.71).WhenTSHwas used as a continuous
variable, each sd increase of 4.0 mIU/liter was associated
with a 30% increase in CHF events (95%CI, 8–55%; P 0.04).
SHypo was not associated with coronary heart disease
events, stroke, peripheral arterial disease, cardiovascular
mortality, or total mortality, despite significant higher cho-
lesterol levels. Because no other prospective study has as-
sessed the risk of CHF events in subjects with SHypo, other
large prospective studies are required to determine whether
SHypo causes or worsens preexisting heart failure.
An increased risk of CHF in patients with SHypo was also
identified in two small cross-sectional studies (232, 233). In
one study, 8 of 31 (26%) patients with CHF had a serum TSH
level greater than 3.6 mIU/liter with normal T4, suggesting
the possibility of a significant prevalence of SHypo in pa-
tients withmoderate-to-severe CHF (232). In the other study,
97% of patients with CHF had both SHypo and morpholog-
ical thyroid abnormalities (233). These studies were not pro-
spective, nor did they include a control group without CHF.
Although SHypo has been associated with signs of aortic
and coronary atherosclerosis, only a few studies evaluated
SHypo as a risk factor for atherothrombotic stroke (194, 230,
231, 234). Although the Classification of Cerebrovascular
Disease III study found that hypothyroidismwas a risk factor
for stroke (235), other studies have not found an association
between SHypo and stroke (194, 230, 231). In a recent report,
SHypo (TSH  10 mIU/liter) was associated with a signif-
icantly better outcome in patientswith acute stroke (236). The
protective effect might be attributable to the reduced adren-
ergic tone (237) or other unknown factors.
The potential cardiovascular risk in SHypo patients is an
important factor that affects decisions about the screening
and treatment of these patients. A recent meta-analysis eval-
uated the association of SHypowith all-cause and circulatory
mortality (238). Not all possible relevant confounders for the
association between SHypo and mortality were considered
in each of the prospective cohort studies. In fact, associated
atherosclerotic risk factors were evaluated only in few stud-
ies (38, 227, 230, 231), and baseline coronary artery disease
was assessed in only two studies (38, 230). Moreover, two
other studies (92, 194) involved selected populations (atomic
bomb survivors and 85-yr-old individuals), thereby limiting
the generalizability of the findings. Consequently, the au-
thors of the meta-analysis concluded that the current evi-
dence for a causal relation of SHypo with mortality is weak
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and should not be used to decide whether or not to treat
SHypo patients (238).
In conclusion, there are major discrepancies in epidemi-
ological data about cardiovascular risk in SHypo (Table 6).
This may be due to differences in the populations studied in
terms of age, sex, race/ethnicity, life style, the TSH range that
defines SHypo, methods of evaluation of cardiovascular dis-
ease, differences in adjustments for known risk factors for
cardiovascular disease, and duration of follow-up. Few stud-
ies stratified the analysis by TSH levels. Only one cross-
sectional study included a subgroup analysis by age and
found that the risk of CHD associated with SHypo was
higher and statistically significant only in subjects younger
than 50 yr (196). Furthermore, not all epidemiological studies
included follow-up data on thyroid function, and in other
studies some patients were treated with thyroid hormone
during follow-up. Only one study (194) reported increased
all-cause mortality in a male subpopulation of SHypo pa-
tients, whereas one study reported decreased all-cause mor-
tality in very elderly SHypo subjects (92). The risk of coro-
nary disease was increased in SHypo in the cross-sectional
analysis in the Rotterdam study (193) and in the cross-sec-
tional and longitudinal analysis in the Busselton study (38).
An increased risk of CHF was found in the only study in
which it was evaluated (231). If there is an excess risk of
coronary artery disease in SHypo, the causes remain un-
known because the risk was not explained by an excess of
traditional risk factors (174, 193–195, 230, 231). However, the
possibility of an increased prevalence of nontraditional risk
factors (endothelial dysfunction, CRP, and alterations in co-
agulation parameters) in SHypo remains to be clarified.
H. Subclinical hypothyroidism and neuromuscular
dysfunction
Hypothyroidism may induce a wide spectrum of alter-
ations in neuromuscular function, andmuscle-related symp-
toms are frequent in patients with hypothyroidism. The
mechanism underlying abnormalmuscle dysfunction is only
partly known. Impaired glycogenolysis (239, 240), alterations
in myosin heavy chain expression (241), and reduced mito-
chondrial activity have been implicated in this process (242,
243). The amplitude of the stapedial reflex, a biological pa-
rameter that reflects neuromuscular status, was abnormal in
patientswith subclinical and overt hypothyroidism (244). On
the other hand, distal motor latencies, motor and sensory
amplitudes, and nerve conduction velocities were not ab-
normal in patients with mild thyroid hormone deficiency
(245). Similarly, no abnormalities of peripheral nerves or
brainstem auditory evoked potentials were identified in pa-
tients with SHypo of short duration (246). Conflicting data
have been reported about the increase of serum creatine
kinase and serum myoglobin levels in patients with SHypo
(145, 247–249). Apositive correlation between creatine kinase
and TSH and a negative correlation between creatine kinase
and FT3 and FT4 have been reported in overt and subclinical
hypothyroid patients, (248). Monzani et al. (250) determined
skeletal muscle lactate and pyruvate production in the rest-
ing state andduring dynamic arm exercise in 12 patientswith
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Blood lactate and pyruvate levels did not differ between
patients and controls at rest. However, the mean lactate level
and the mean lactate increment were significantly higher in
patients with SHypo than in controls during exercise. This
finding is consistent with impaired mitochondrial oxidative
function. Moreover, the mean increment in blood lactate
during exercise was positively related to the duration of
SHypo, but not to the serum levels of TSH, FT3, and FT4.
There was no difference in blood pyruvate concentration
during exercise. This study suggests that muscle energy me-
tabolismmay be impaired in SHypo in proportion to disease
duration.
Finally, in a recent study by the same authors, muscle
metabolism and the response to exercise were significantly
impaired in SHypo. Exercise tolerance and both maximal
power output and maximum oxygen uptake (VO2) were
lower in SHypo, and respiratory quotient increments were
significantly higher in patients than in controls (251). Blood
lactate and pyruvate and their ratio increased with a steeper
slope in patients vs. controls. Resting plasma free fatty acid
and blood glycerol levels were significantly higher in pa-
tients at baseline and during exercise and recovery (251).
I. Effects of replacement therapy
1. Effects of treatment on disease progression. Treatment of goiter
in patients with Hashimoto’s thyroiditis with l-T4 is usually
recommendedwith the aim of decreasing thyroid size. How-
ever, thus far only three uncontrolled studies have evaluated
the effect of this treatment on thyroid volume in goitrous
subjects with overt hypothyroidism and SHypo induced by
Hashimoto thyroiditis (252, 253, 254). In one study, treatment
with l-T4 for 3 yr induced a 32% reduction in thyroid volume
in adults after l-T4 replacement evaluated by ultrasound,
although TPOAb remained unchanged (252). Similarly, in
another study a significant decrease in the thyroid volume
(decreased 80.9% % of initial volume; P  0.01) was found
in 77% (10 of 13) of SHypo adult patients with Hashimoto’s
thyroiditis after replacement therapy with l-T4 (253). In the
third study, l-T4 treatment, for a median 2.8 yr, was effective
in reducing thyroid volume in 90 pediatric patients with
Hashimoto’s thyroiditis, especially in those with hypothy-
roidism (254). In the latter study,median thyroid volumewas
reduced in euthyroid patients (	0.4 sd score; P  0.001),
subclinically hypothyroid (	1.4 sd score; P  0.001), and
overtly hypothyroid (	1.8 sd score; P 0.002) children with
autoimmune thyroiditis (254).
Serum TPO and other thyroid antibodies may decrease
during treatment with l-T4 in patients with Hashimoto thy-
roiditis or idiopathic myxedema (255). In hypothyroid pa-
tients with TSH receptor antibodies, treatment with l-T4 for
4 to 8 yr was associated with disappearance of these anti-
bodies in 71% of patients and euthyroidism in 50% after l-T4
discontinuation (256). In an unselected group of patients, the
degree of hypothyroidismworsened in 20 patients, remained
unchanged in 40, and improved in 19 at least 1 yr after l-T4
withdrawal. A large goiter and high TSH levels at the time
of diagnosis, associated with a familial incidence of thyroid
disease, were related to an increased likelihood of recovery
of normal thyroid function (257). In a group of children with
Hashimoto’s thyroiditis, euthyroidism was obtained after
l-T4 withdrawal in some patients with goiter, whereas hy-
pothyroidism was irreversible in children with atrophic thy-
roiditis (258).
2. Effects of replacement therapy on symptoms and signs. Eight
placebo-controlled studies have assessed the effects of l-T4
replacement therapy on symptoms and signs, quality of life,
and psychometric tests in subclinical hypothyroid patients
(97, 109, 110, 115, 249, 259–261). The double-blind placebo-
controlled study carried out by Cooper et al. (109) reported
a higher prevalence of specific symptoms and signs assessed
with the Billewicz clinical hypothyroidism scale in 33 sub-
clinical hypothyroid patients aged 32–78 yr, with a mean
baseline TSH of 10.8 mIU/liter (TSH range, 3.6–55.3 mIU/
liter) than in euthyroid controls. The study population was
selected from a large cohort of women enrolled in a fol-
low-up study of patients treated for hyperthyroidism. The
SHypopatients hadmore hypothyroid symptoms than the 20
euthyroid controls. One year after the study onset, the symp-
tom score improved significantly (by 2.1 points; individual
scores ranged from 	5 to 
9) in patients treated with re-
placement doses of l-T4 (between 0.05 and 0.125 mg); their
TSH level was 2.6  0.5 mIU/liter. In contrast, the mean
symptom score decreased by 1.2 points in the placebo group
(TSH 14.7 3.3 mIU/liter). The symptom score improved in
50% of the l-T4-treated group vs. about 25% of the placebo
group. Similarly, in another double-blind crossover 12-
month study of 20 women aged 51–73 yr with SHypo (TSH
concentration between 4 and 15 mIU/liter with TSH above
30 mIU/liter after TRH), neuropsychometric parameters im-
proved after 6 months of replacement l-T4 therapy in pa-
tients with serum TSH levels between 4.8 and 9.9 mIU/liter
(249). However, a fixed l-T4 dosage was used in this study,
with a final l-T4 daily dose of 0.15 mg. In a double-blind
placebo-controlled study of 37 patients older than 55 yr,
Jaeschke et al. (259) reported a significant improvement in
memory scores but not in overall health-related quality of
life.
Meier et al. (260) evaluated 66 women, aged 18–75 yr, with
SHypo (TSH 11.7  0.8 mIU/liter) due to thyroiditis or a
history of Graves’ disease. An improvement in two symptom
scores (the Billewicz andZulewski scores)was observed after
48 wk of replacement therapy vs. baseline values. However,
the comparison of the mean treatment effects between the
two treatment groups (placebo group and the T4 group) did
not reach the level of significance (Billewicz score, P  0.31;
Zulewski scores, P  0.53). An improvement in symptom
scorewas seen only in patientswith pretreatment TSHvalues
higher than 12 mIU/liter and was not significant in patients
with pretreatment TSH values lower than 12 mIU/liter.
Kong et al. (110) evaluated 40 women (mean age, 49 yr)
with SHypo and serum TSH between 5 and 10 mIU/liter
randomly assigned to receive l-T4 or placebo for 6 months.
TheHospital Anxiety andDepression scores and the General
Health Questionnaire score did not change significantly after
placebo or l-T4, which suggests that replacement therapy
had no benefit in women with SHypo. As absolute scores,
anxiety scores in the l-T4-treated group improved in 50%,
were unchanged in 10%, andworsened in 40%. In the placebo
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group, therewas improvement, no change, andworsening in
50, 43, and 7%, respectively. Depression scores in the T4
group improved in 65%, were unchanged in 25%, and were
worse in 10% compared with 64, 7, and 29%, respectively, in
the placebo group. The General Health Questionnaire scores
in the T4 group improved in 60%, were unchanged in 10%,
and were worse in 6%, compared with 92, 0, and 8%, re-
spectively, in the placebo group. However, serum TSH was
measured only once, so it is possible that some patients had
a mild transient TSH increase and not persistent SHypo. In
fact, after 6months of treatment,women in the placebo group
showed a trend toward spontaneous normalization of thy-
roid function (mean baseline  sd, TSH 7.3  1.6 mIU/liter;
mean change from baseline, 	1.7  2.0 mIU/liter). More-
over, a fixed l-T4 dose was given (50 or 100 g/d), and TSH
did not normalize in all l-T4 treated patients but remained
at the upper limit of normal range with some patients ben-
efitingmore from treatment than others (baseline TSH value,
8.9  1.5 mIU/liter; change from baseline, 	4.6  2.3
mIU/liter).
In the Tromso study of 89 subjects (TSH 5.57  1.68 mIU/
liter), the relation between neuropsychological function and
SHypowas investigated by using 14 tests of cognitive function,
the Beck Depression Inventory, General Health Questionnaire,
and a questionnaire on hypothyroid symptoms (115). In this
double-blind placebo-controlled study with T4 given for 1 yr,
there was no significant difference between T4 therapy and
placebo as regards cognitive function or depression (115).
In a recent randomized double-blind placebo crossover
study, quality of life was assessed in the largest number of
patients to date (100 patients; mean age, 53  12 yr; range,
18–80 yr) with SHypo defined by TSH greater than 4 mIU/
liter (261). In this study, all subscales of the SF35-version 2
(apart from the emotional item) tended toward improvement
after replacement therapy with l-T4, although none reached
statistical significance after correction for multiple compar-
isons. Interestingly, in this study there was a trend toward
improvement of sex life, which was attributed to the im-
provement in tiredness. However, in this study, l-T4 was
administered for a short period (3 months) and at a fixed
dosage (100 g/d), and 10% of l-T4 subjects had subnormal
serum TSH values at the end of the treatment period. In
another study, l-T4 was no more effective than placebo in
improving cognitive function and psychological well-being
in patientswith symptoms of hypothyroidismwhose thyroid
function tests were within reference range (97).
In summary, conflicting results emerge from these double-
blind placebo-controlled studies on the improvement of
symptoms after l-T4 therapy in SHypo patients. This is prob-
ably due to differences in the selection of patients in terms
of etiology of the disease, age of patients evaluated, and TSH
level at the baseline evaluation. Moreover, there are impor-
tant differences in the study design in terms of duration of
therapy, l-T4 dosage, and differences in the scores used to
assess the symptoms. In addition, in some studies, SHypo
may not have been persistent in the placebo group, and in
other studies either euthyroidism was not reached with re-
placement therapy or somepatientswere inadvertently over-
treated (this is particularly true for studies in which a fixed
dose of l-T4 was used).
3. Effects of replacement therapy on cardiac function. Diastolic
function improved in all studies in which it was evaluated
after replacement therapy (129, 130, 133, 134); two studies
were double-blind placebo-controlled investigations (133,
134) (Table 7). In the first double-blind placebo-controlled
study, there was a decrease in isovolumic relaxation time
and late transmitral flow velocity and a significantly im-
proved early-to-late transmitral peak flow velocity ratio
(E/A) after 1 yr of l-T4 replacement therapy (133). These
results were confirmed in the second double-blind place-
bo-controlled study, which also reported no significant
change in left ventricular morphology (134). In one study,
diastolic function improved significantly after 6 months of
l-T4 therapy in 10 of 26 randomly selected patients with
SHypo (129).
A positive effect on systolic function was observed after
replacement therapy in one uncontrolled clinical trial (262) and
in fourdouble-blindplacebo-controlled trials (109, 133, 134, 249)
in which the initially prolonged PEP/LVET ratio significantly
decreased after l-T4 therapy (Table 8). In the study by Cooper
et al. (109), a significant improvement was seen with l-T4 only
in patients with the highest PEP/LVET ratio (0.39); changes
vs. placebo were not statistically significant. Unfortunately, the
other three controlled studies did not include a statistical anal-
ysis of the results obtained in SHypo patients treated with l-T4
vs. the placebo group (133, 134, 249)
The end-diastolic volume, stroke volume, ejection fraction,
and cardiac index increased, and SVR decreased after l-T4
therapy in a study conductedwithMRI (149). Unfortunately,
this trial was not placebo-controlled.
Systolic and diastolic function on effort improved after
TABLE 7. Summary of studies examining diastolic function after replacement therapy with L-T4 in patients with SHypo
First author, year (Ref.)






(mIU/liter) Cardiac findings Cardiac methods
Biondi, 1999 (129) 10 9.2  4.2 1.7  1 2 A, 1 E/A, 2 IRT Doppler echo
Monzani, 2001 (133)a 10 5.4  2.4 1.17  0.6 2 A, 1 E/A, 2 IRT Doppler echo
Brenta, 2003 (130) 10 11.  4.2 1.9  1.1 2 TFR Radionuclide ventriculography
Yazici, 2004 (134)a 23 8.4  1.9 2.4  1.3 1 E/A, 2 IRT Doppler echo
TSH values represent mean  SD. IRT, Isovolumic relaxation time; TPFR, time-to-peak filling rate; E/A, early-to-late transmitral peak flow
velocity ratio.
P values for SHypo pretreatment vs. posttreatment: IRT, Biondi andMonzani, P 0.05; Yazici, P 0.0001. E/A, Biondi, P 0.001; Monzani,
P  0.05; Yazici, P  0.0001. A, Biondi, P  0.01; Monzani, P  0.05. TPFR, Brenta, P  0.001.
a Double-blind placebo-controlled.
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l-T4 replacement therapy in patients with SHypo in five
studies performed with radionuclide ventriculography,
Doppler echocardiography, and cardiopulmonary exercise
testing (130, 147, 263–265) (Table 9). However, two studies
were not placebo-controlled (130, 147), and three studies
(263–265) did not compare pre- and posttreatment values of
cardiac performance during exercise in subclinically hypo-
thyroid patients vs. the control group. Responses to treat-
ment in all these studies consisted of improvement or cor-
rection of the abnormalities of contractile function of the left
ventricle with exercise and normalization of diastolic func-
tion with exercise.
The impaired muscle energy metabolism could contribute
to the reduced exercise tolerance in SHypo. The energy and
metabolic response to physical exercise in patients with
SHypo was examined at baseline and after 6 months of re-
placement therapy with l-T4 in a double-blind randomized
placebo-controlled study (251). The pattern of substrate uti-
lization was altered in SHypo patients. However, while im-
proving neuromuscular symptoms, l-T4 replacement did not
cause significant changes in the energy or substrate response
to exercise and did not correct this alteration after 1 yr of
stable euthyroidism. It remains to be established whether
these effects on muscle metabolism are irreversible or
whether more time is needed for normalization.
In an uncontrolled study, evaluation with tissue Doppler
imaging showed that precontraction times and precontrac-
tion-contraction ratios decreased, albeit not significantly, af-
ter replacement therapy with T4 in 22 subclinical hypothy-
roid patients (TSH 13.3  9.1 mIU/liter). Septal lateral
annulus and lateral myocardial relaxation times were sig-
nificantly decreased after l-T4 (266).
In summary, all these studies, performed with correct
methods to evaluate cardiac function, support the hypothesis
that l-T4 replacement therapy can normalize the hemody-
namic alterations induced by SHypo. However, only four
studieswere double-blind placebo-controlled trials (109, 133,
134, 249).
4. Effects of replacement therapy on the vascular system. In un-
controlled clinical trials, appropriate replacement therapy
with l-T4 induced a significant decrease in SVR (149, 157),
mean arterial pressure (157), and central arterial stiffness
(162) in normotensive subclinically hypothyroid patients.
After l-T4 therapy, there was a significant decrease of the
augmentation gradient, augmentation index, corrected aug-
mentation index, and the diastolic brachial and aortic blood
pressure (162). However, SVR was unchanged after replace-
ment therapy in two double-blind placebo studies in which
SVRwas not increased at baseline evaluation (133, 134). After
6 months of stable euthyroidism, endothelial function im-
proved in patients with SHypo in an uncontrolled clinical
trial (166). Indeed, there was a significant improvement in
acetylcholine-induced vasodilatation and restoration of the
inhibitory effect of L-NMMA, indicating that l-T4 treatment
improves endothelium-dependent vasodilatation by restor-
ing nitric oxide availability (166). These results were recently
confirmed in a randomized double-blind crossover study of
l-T4 vs. placebo (261). Brachial artery flow-mediated dilata-
tion improved significantly after replacement therapy; this
effect was independent of other cardiovascular risk factors
(261). Finally, Monzani et al., in a double-blind placebo-con-
trolled study of individuals less than age 55, reported that
replacement therapywith l-T4 significantly decreasedCIMT.
The reduction was directly related to the decrease of both TC
and TSH (168).
On the basis of the data available, treatment of SHypo
could, in theory, improve the well-being of the vascular
system by decreasing SVR, endothelial function, and carotid
intimal thickness, and might thereby prevent or reverse ath-
erosclerosis and coronary artery disease. However, only a
TABLE 8. Left ventricular systolic function in patients with SHypo before and after replacement therapy





Ridgway, 1981 (262) 20 44  16 28  29 2 PEP/ET Weissler’s method 1.9  1.4 Uncontrolled study
Cooper, 1984 (109)a,b 33 32–71 3.6–39.4 7 PEP/ETa Weissler’s method 2.6  0.5 Randomized double-blind
placebo-controlled (1 yr)
Nystrom, 1988 (249)a 17 51–73 7.7  3.7 2 PEP/ET Weissler’s method 1.9  1.8 Double-blind placebo crossover
design (2  6 months)
Monzani, 2001 (133)a 10 32  12 5.4  2.4 2 PEP/ET Doppler echo 1.17  0.6 Randomized double-blind
placebo-controlled (1 yr)
Yazici, 2004 (134)a 23 40  7.9 8.4  1.9 2 PEP/ET Doppler echo 2.41  1.3 Randomized double-blind
placebo-controlled (1 yr)
Data are expressed as mean  SD. ET, Ejection time; PEP, preejection period.
P values for SHypo vs. control subjects: PEP/ET, Ridgway, P  0.001; Nystrom, P  0.01; Monzani and Yazici, P  0.05.
a Double-blind placebo controlled.
b2 PEP/ET in five patients with highest values (PEP/ET  0.39).
TABLE 9. Summary of studies examining systolic and diastolic
function during exercise after replacement therapy with L-T4 in
patients with SHypo
First author, year (Ref.) n TSH (mIU/liter) Exercise
Bell, 1985 (263)a,b 18 17.9  10 1SF
Forfar, 1985 (264)a,b 10 18.2  9 1SF
Arem, 1996 (265)a,c 8 14.8  9.5 1SF
Kahaly, 2000 (147)a,d 20 11.2 (6.3–19.5) 1SF
Brenta, 2003 (130)a,b 10 110  1.4 1DF
TSH values are mean  SD. SF, Systolic function; DF, diastolic
function.
a Clinical trial uncontrolled.
b Radionuclide ventriculography.
c Echocardiography during exercise.
d Cardiopulmonary exercise test.
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few of these studies were randomized placebo-controlled
trials, and the resultswere not concordant (133, 134, 168, 261).
5. Effects of replacement therapy on lipid profile and cardiovascular
risk factors. It remains to be established whether or not re-
placement therapy with l-T4 lowers serum lipid levels in
patients with SHypo. Two meta-analyses have been carried
out regarding the effects of l-T4 therapy on serum cholesterol
levels in patients with mild thyroid failure (267, 268). In the
first meta-analysis of 13 studies from 1976 to 1995, thyroid
hormone replacement therapy decreased TC in patients with
SHypo by 0.4 mmol/liter (15 mg/dl) independently of the
initial plasma level; however, plasma levels remained ele-
vated in most patients (267). In the other meta-analysis per-
formed in 2000 on 247 patients from 13 selected studies,
serum TC was reduced by about 0.2 mmol/liter (8 mg/dl or
5%) and serum LDL-C by about 0.3 mmol/liter (10 mg/dl)
after l-T4 treatment, whereas triglyceride and HDL-C levels
did not change (268). Thedecrease in serumTCconcentration
was about 0.04 mmol/liter greater (1.6 mg/dl) for each 0.23
mmol/liter (10mg/dl) increase in the baseline concentration.
When the studies were divided according to a mean baseline
serum TC cutoff of 6.2 mmol/liter (240 mg/dl), l-T4 reduced
serum TC by 0.4 mmol/liter (16 mg/dl) in cases above the
cutoff value, and by 0.02 mmol/liter (0.8 mg/dl) in cases
equal to or less than the cutoff point (268). Furthermore,
greater changes were seen in those patients with SHypo due
to inadequately treated overt hypothyroidism compared
with patients with only SHypo at the outset.
It must be emphasized that some of the studies included
in these two meta-analyses had important limitations. Only
a few studies were randomized with placebo controls,
namely, three studies in the meta-analysis by Danese et al.
(268). Moreover, in many studies the results were obtained
in a small number of patients, sometimes using poor selec-
tion criteria in terms of etiology and persistence of thyroid
disease, the TSH value after replacement therapy was com-
pletely different in the various studies, and the period of
replacement therapy was different. Thus, in the meta-anal-
ysis by Danese et al. (268) the changes in cholesterol were
much greater in those studies that were judged to be of
poorer quality.
More recently eight placebo-controlled randomized clin-
ical trials have been carried out to examine the effects of l-T4
on serum lipids in SHypo (Table 10). In four of these studies,
T4 did not reduce TC (109, 110, 249, 259), whereas a beneficial
effect was found in the remaining four studies (168, 189, 260,
261). The first two randomized trials published found only
minimal, nonsignificant reductions of TC levels during l-T4
therapy and provided no data for LDL-C (109, 249). In an-
other placebo-controlled study, LDL-C was reduced by 3.6%
(0.13 nmol/liter) after T4 replacement therapy, which was
not significant (259). Kong et al. (110) found no clinically
relevant benefit of replacement therapy on LDL-C levels in
womenwith SHypo after 6months of T4 therapy vs. a placebo
group.
In a double-blind placebo-controlled study, Meier et al.
(260) reported a decrease in TC and LDL-C levels in patients
with SHypo after T4 replacement therapy. The LDL-C de-
crease was more pronounced in patients with TSH levels
greater than 12 mIU/liter or elevated LDL-C at baseline. No
significant changes were seen in patients with baseline TC
and LDL-C values that were below 12 mmol/liter (260 mg/
dl) and 4 mmol/liter (154 mg/dl), respectively. When the
results were analyzed as a randomized trial, the mean treat-
ment effects for TC and LDL-C at the end of the study were
no different from the intervention group (l-T4) and the pla-
cebo group. Pretreatment LDL-C level was 4.0 mmol/liter in
the treatment group vs. 3.8 mmol/liter in the placebo group,
and the posttreatment LDL-C level was the same in both
groups (3.7 
 0.2 mmol/liter; P  0.11).
The effect of l-T4 therapy on TC and LDL-Cwas evaluated
in another double-blind placebo-controlled study of 49 pa-
tients with SHypo (189). Both TC and LDL-C concentrations
decreased significantly after l-T4 therapy in direct propor-
tion to the respective baseline values, whereas lipoprotein (a)
levels were unchanged (189). Furthermore, the subgroup of
patients with lower TSH value had a lesser reduction in lipid
concentrations. However, no changes occurred in the pla-
cebo group, and the comparison of the mean treatment ef-
TABLE 10. Summary of double-blind placebo-controlled studies examining lipid abnormalities and responses to replacement therapy with
L-T4 in patients with SHypo
First author, year (Ref.) n M/F Age (yr) TSH (mIU/liter)









Cooper, 1984 (109) 17 0/17 58  9 10.8  8.8 7 12
Nystrom, 1988 (249) 17 0/17 58  5 7.7  3.7 7 6
Jaeshke, 1996 (259) 18 55 12.3 7 7 7 10
Meier, 2000 (260)a 31 0/33 57  11 12.8.  7.7 2 2 7 7 12
12.0 2 2
12.0 7/2 7/2
Kong, 2002 (110) 23 0/23 53  3 8.0  1.5 7 7 7 6
Caraccio, 2002 (189)a 49 7/42 35  9 5.4 (3.7–15.0) 2 2 7 7 6
6.0 2 2
6.0 7/2 7/2
Monzani, 2004 (168)a 45 8/37 37  11 6.31 (3.65–15.0) 2 2 7 7 6
Razvi, 2007 (261) 100 19/81 53.8 
12 5.3 (3.7–15.8) 2 2 7 3
Values are mean  SD. Lp(a), Lipoprotein (a); M, males; F, females.
a Studies in which a greater improvement of lipid profile by L-T4 occurred in subgroups of SHypo patients with a more elevated serum total
or LDL cholesterol.
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fects between placebo and l-T4 treated patients did not reach
statistical significance in any of the lipid patterns examined
(189).
Increased CIMT represents a marker of underlying ath-
erosclerosis (269). The double-blind placebo-controlled
study by Monzani et al. (168) showed that l-T4 replacement
therapy significantly reduced both TC and LDL-C vs. pla-
cebo. The CIMT was found to be significantly higher in
young (mean age, 37 yr) SHypo patients than in euthyroid
controls (168) and correlated with serum lipids (TC, LDL-C,
Apo B, and triglycerides). After 6 months of restored euthy-
roidism, themeanCIMTwas reduced by almost 10%, and the
absolute mean CIMT reduction was directly related to the
absolute decrements of both serum TC and TSH concentra-
tions. No significant change in biochemical parameters or
CIMTwas observed in the placebo group. Replacement ther-
apy also reduced the mean CIMT in the subgroup of patients
with serumTSH levels lower than 10mIU/liter. The decrease
of mean CIMT was significant in both younger and older
patients, and the mean CIMT became equivalent to that of
euthyroid controls. The improvement of both the atherogenic
lipoprotein profile and CIMT suggests that lipid infiltration
of the arterial wall might be a mechanism underlying the
increase of CIMT in SHypo.
In the most recent randomized controlled study, a double-
blind crossover design was used to evaluate the effects of
replacement therapy in 100 patients. l-T4 therapy signifi-
cantly reduced TC and LDL-C (5.5% decrease in TC and 7.3%
decrease of LDL-C, respectively, from baseline values) (261)
with a significant inverse relationship between reduction in
TC levels and the increase in FT4 levels. It is noteworthy that
in the Helsinki Heart Study, a decrease of only 7% in serum
LDL-C levels in men was associated with a 15% reduction in
the incidence of coronary heart disease (270).
Recently, the effect of l-T4 replacement on non-HDL-C
levels (a measure of TC minus HDL-C) was evaluated in
patients with SHypo. The serum concentrations of TC, non-
HDL-C, remnant-like particle cholesterol, and Apo B were
significantly decreased in SHypo patients, whereas no sig-
nificant changes in the serum concentrations of LDL-C,
HDL-C, triglycerides, Apo A-I, and lipoprotein (a) were ob-
served (271).
In various studies, lipoprotein (a) (168, 185, 188, 189, 260,
271, 272) and plasma-oxidized LDL-C (177) remained sub-
stantially unchanged after replacement therapy in patients
with SHypo. However, only a few of these studies were
controlled with a placebo group (168, 189, 260). Milionis et al.
(273) reported a beneficial effect of l-T4 therapy in patients
with increased baseline lipoprotein (a) levels and low mo-
lecular weight ApoA isoforms, and Tzotzas et al. (185) found
a significant decrease in lipoprotein (a) in postmenopausal
women. Homocysteine levels were unaffected by treatment
of SHypo in three double-blind placebo-controlled studies
(168, 190, 274). In a recent study, replacement therapy with
l-T4 to normalize TSH did not modify homocysteine levels
in the fasting or postmethionine states in 24 patients with
mild hypothyroidism (TSH levels between 5 and 10 mIU/
liter) (274).
l-T4 replacement therapy resulted in a significant decrease
in plasminogen activator inhibitor-1 and factor VII, and
hence had a beneficial effect on coagulation parameters in
patients affected by SHypo in an uncontrolled study (212).
Moreover, SHypo was associated with minor changes in
factor VIII activity and vWFwhen compared with euthyroid
subjects. These effects were reversed by l-T4 (213). l-T4 re-
placement did not affect CRP levels in a double-blind pla-
cebo-controlled study in patients with SHypo (190). In a
recent study, both the overt and subclinical hypothyroid
groups had higher thrombin activatable fibrinolysis inhibitor
(TAFI), an inhibitor of fibrinolysis, than the control group
(P 0.05). High levels of TAFI antigen were correlated with
the degree of thyroid failure. After achieving a euthyroid
state with l-T4 replacement, TAFI antigen levels decreased
significantly in patients with overt and subclinical hypothy-
roidism (P  0.05) (275).
In summary, four double-blind placebo randomized con-
trolled trials found that replacement therapy may have had
a beneficial effect on lipid profile (168, 189, 260, 261). Re-
placement therapy does not appear to affect lipoprotein (a),
homocysteine, or CRP. Controlled studies are necessary to
evaluate the effect of l-T4 on coagulation parameters. It is not
easy to draw conclusions about the effects of l-T4 replace-
ment therapy on cardiovascular risk factors associated with
SHypo. The studies carried out on this topic have some
limitations, and there are differences in terms of cause and
duration of SHypo, sex, age of patients evaluated, TSH level
at the baseline evaluation and after replacement therapy, and
the period of replacement therapy. TSH values were strati-
fied in only a few studies, whichmakes it difficult to evaluate
the effects of l-T4 in patients with mild SHypo, i.e., serum
TSH levels between 4.5 and 10 mIU/liter.
J. Thyroid hormone deficiency before and during pregnancy
1. Epidemiology. Thyroid function was evaluated in blood
specimens in two prospective studies of 12,000 women in
Mainewhowere 17wk pregnant (276, 277). TSH values were
above 6.0 mIU/liter in 2.3% of the women and above 12
mIU/liter in 0.3%. Seventy percent of womenwith abnormal
TSH values had TPO antibodies vs. 11% of controls. FT4
concentrations were 2 sd below the control mean in 0.3% of
the women with the highest TSH concentrations. Similar
results were reported in two other studies (278, 279). In a
prospective study of 1900 consecutive pregnant women car-
ried out to evaluate the occurrence of undiagnosed SHypo,
the overall prevalence of SHypo was 2.3% (278). Moreover,
in 40% of women the cause of hypothyroidism was related
to TA (278). In a recent study of 25,756 pregnantwomen, 0.2%
were found to have overt hypothyroidism, and 2.3% had
SHypo (279).Moreover, 88%of the subclinically hypothyroid
women had a serum TSH concentration below 10 mIU/liter.
In a reviewof 14 articles for a total of 14,148 pregnantwomen,
the prevalence of anti-TPO antibodies and/or TgAb in preg-
nancy was found to be 10.8%, and there was a strong asso-
ciation with hypothyroidism (280). Therefore, it appears that
untreated or inadequately treated chronic autoimmune thy-
roiditis is the most common cause of thyroid hormone de-
ficiency in pregnancy. Other risk factors for SHypo in preg-
nancy are diabetes mellitus, iodine deficiency, thyroid
ablation or surgery, a family or personal history of thyroid
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disease, goiter, history of spontaneous abortion, or any
symptom suggesting hypothyroidism (280).
There is a complex relationship between TA and female
andmale infertility (281–285). Although themechanisms that
link thyroid hormone deficiency or TA to fertility remain to
be clarified, TA is clearly associatedwith infertility inwomen
andmiscarriage risk irrespective of thyroid function. Despite
this observation, treatment with l-T4 of TA associated with
these conditions remains controversial.
2. Maternal and fetal risk. Recent studies suggest that TA may
entail an increased risk of recurrent miscarriage (282–284). It
is not known whether the risk is related to TA itself or to a
subtle thyroid dysfunction characteristic of SHypo. In a
meta-analysis of studies carried out on papers published
since 1990, TSH levels in antibody-positive but euthyroid
womenwere higher than in antibody-negative women (283).
The adverse effects of overt maternal hypothyroidism in-
clude a higher risk of perinatal mortality, increased risk of
fetal death, increased frequency of low birth weight, fetal
distress, preterm birth, and impaired mental and somatic
development (286, 287). The evaluation of adverse preg-
nancy outcome in seven recent uncontrolled studies showed
a frequency of preterm births in 6% of women with SHypo
and in 20% of women with overt disease, whereas the fre-
quency of gestational hypertension was 11% in SHypo and
23% in overt hypothyroidism. The frequency of perinatal
mortality was 2.9 and 7% in cases of SHypo and overt hy-
pothyroidism, respectively (287). However, in a study that
included a control population, only fetal deaths were in-
creased in women with thyroid hormone deficiency; the fre-
quency was 8.1% in women with a TSH of 6–9.9 mIU/liter
and 0.9% in women with TSH less than 6 mIU/liter (280). In
another controlled study, only an increased risk of gesta-
tional hypertension and low birth weight was reported in
women with SHypo (288). Glinoer et al. (289) reported that
the number of preterm deliveries in womenwith antithyroid
antibodies was double that in a control population. This is
also the conclusion of a recent paper byNegro et al. (290)who
observed a markedly decreased miscarriage and premature
delivery rate in women with autoimmune thyroid disease
and normal serum TSH values who received thyroid hor-
mone therapy.
Abalovich et al. (291) studied 114 women with primary
hypothyroidism receiving inadequate l-T4 treatment. The
outcome of pregnancy in overtly hypothyroid and SHypo
patients was abortion in 60 and 71.4%, premature delivery in
20 and 7.2%, and term delivery in 20 and 21.4%, respectively.
When treatment was adequate, 100% of overtly hypothyroid
patients and 90.5% of SHypo patients carried pregnancies to
term, and there were no abortions in the group. Although
these data are consistent with the importance of adequate
treatment of overt hypothyroidism and SHypo during preg-
nancy to maintain normal serum TSH values, it must be
acknowledged in the absence of controlled trials that poorly
treated hypothyroidism might be a surrogate for poor med-
ical care. In women with treated hypothyroidism, the l-T4
dose requirement increases early in pregnancy and may rise
by 30–50% of prepregnancy values (292, 293).
3. Intellectual outcome in the offspring of pregnant women with
SCTD. Maternal FT4 is critical for fetal brain development
and maturation. Fetal thyroid ontogeny begins at 10–12 wk
gestation and is not complete until delivery, and T4 is not
secreted until 18–20 wk gestation. Before this time, the fetal
brain is dependent on circulating maternal T4. It has yet to
be established whether or not SHypo impairs fetal brain
development. Thyroid hormone of maternal origin plays a
significant role in fetal neurodevelopment up to 20 wk ges-
tation, and experimental results obtained in the rat strongly
support the conclusion that thyroid hormone is already re-
quired for normal corticogenesis very early in pregnancy
(294–296). For example, T4 crosses the placenta in a sufficient
amount to normalize T3 concentration in the brain of hypo-
thyroid fetal rats (295). Moreover, T4 is found in human
coelomic fluid as early as 4 wk gestation (297) and in cord
blood of newborns with athyreosis or thyroid dysgenesis.
This demonstrates the importance of thematernal-fetal trans-
fer of T4 in hypothyroid newborns who are incapable of
synthesizing T4 (298).
The potential adverse effects of maternal hypothyroidism
on fetal development before the start of normal thyroid func-
tion are well documented. In 1969, Man and Jones (299)
reported that children of hypothyroid mothers inadequately
treated had lower IQs than those of adequately treated pa-
tients and normal controls. They used measurements of se-
rum butanol extractable iodine to distinguish between eu-
thyroidism and hypothyroidism. These findings were
confirmed 30 yr later in an unselected population of 25,000
pregnant women inMaine (300). Womenwere considered to
be hypothyroid if their TSH concentration (measured in sera
collected at 17 wk gestation) was equal to or above the 97.7th
percentile. Sixty-two women with hypothyroidism were ret-
rospectively identified. Of these, 14 were identified and
treated before and during pregnancy with a dose of T4 that
remained constant during pregnancy. The children under-
went 15 tests that evaluated intelligence, reading, language,
attention, school performance, and visual-motor impairment
at approximately 8 yr of age. The full-scale IQs did not differ
between the children of the 62 hypothyroidwomen and those
of the 124 controls. However, further examination showed
that 33% of the children of the 48 untreated mothers had IQs
1 sd below the control mean vs. 15% of the control children
and only 7% of the children from hypothyroid mothers
treated with l-T4. However, it must be emphasized that in
this study themeanTSH in the T4-treated patientswas higher
than in the untreated patients. A subsequent study showed
that IQ was inversely correlated with maternal TSH (301).
Suboptimal concentrations of maternal T4, as occurs in the
case of iodine deficiency, might also have a deleterious effect
on the intellectual development of offspring.Women in areas
of borderline iodine insufficiency (60–100 g/d) have rela-
tive hypothyroxinemia, increased serum T3/T4 ratios, and
high-normal TSH levels as pregnancy progresses (286). Pop
et al. (302) evaluated mental and psychomotor development
in 220 healthy children at 10 months of age. They were born
after uncomplicated pregnancies and deliveries, by mothers
with serum TSH within the reference range (0.15–2.0 mIU/
liter) during early pregnancy and living in the Netherlands,
which is an iodine-sufficient country. Children of women
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with FT4 levels below the 5th and 10th percentiles at 12 wk
gestation and normal serumTSH levels had an increased risk
of delayed psychomotor development at 10 months of age
compared with children of mothers with higher FT4 values
(relative risk 5.8). These mothers were three times as likely
to be TPO antibody-positive (25 vs. 8%). Subsequently, Pop
et al. (303) showed that low maternal plasma FT4 concen-
tration during early pregnancy was an important risk factor
for impaired infant development. Mental and psychomotor
scores were lower in infants in the low-serum FT4 group at
both 1 and 2 yr. Neurodevelopment was delayed in infants
whose mothers had low serum FT4 concentrations at 10 wk
gestation; neurodevelopment delay was especially pro-
nounced in infants whose mothers had persistently low con-
centrations. The conclusion of this study supports the hy-
pothesis that maternal FT4 values in the low normal range
during early pregnancy are associated with impaired child
development. This observation has important clinical impli-
cations for pregnant women from iodine-deficient areas.
There is still much to learn about the adverse effects of
thyroid hormone deficiency in pregnancy. In the study noted
above by Casey et al. (279), women with SHypo had a 2-fold
higher incidence of preterm delivery, a 3-fold increase in
placental abruption, and a significant increase in the pro-
portion of neonates admitted to the intensive-care unit vs.
euthyroid controlwomen. This study suggests the possibility
that the intellectual consequences of SHypo in the long-term
outcome of offspring may be related to the effects of pre-
maturity rather than to the thyroid hormone abnormality per
se. Therefore, the consequences of undiagnosed or untreated
SHypo on developing brain might be due in part to insuf-
ficient maternal transfer of thyroid hormone to the children
and in part to the obstetrical consequences of untreated
SHypo.
In conclusion, the data available suggest that l-T4 therapy
for pregnant women with SHypo can reduce pregnancy loss
and preterm delivery and improve the outcome of offspring.
The thyroid status of women with TA should be monitored
during pregnancy. l-T4 therapy is the preferred method for
thyroid hormone replacement in pregnant women and in
women contemplating pregnancy. Women with overt and
SHypo should be treated, and the l-T4 dose should be in-
creased during pregnancy if necessary.
4. Screening for thyroid insufficiency during pregnancy. The
American Thyroid Association (ATA) and the American As-
sociation of Clinical Endocrinologists concluded that there is
not enough evidence to determine whether screening for
SHypo before or during pregnancy in asymptomatic women
is warranted or necessary (5, 527). However, other societies
recommend the “case finding” of pregnantwomen if they are
at high risk, and of women with a history of thyroid disease,
TA or diabetesmellitus, or a family history of thyroid disease
(6, 304). Ideally these women should have their thyroid
health evaluated before planning pregnancy and again
shortly after becoming pregnant (304). However, a recent
prospective study on 1560 consecutive pregnant women,
evaluated by TSH, FT4, and FT3 during their first prenatal
visit, showed that at least one third of pregnant women with
thyroid disease can be missed by a high-risk case finding
approach (305).
More research is required to establish normal ranges for
serum thyroid hormone and TSH levels during each trimes-
ter of gestation. Before deciding whether screening is of
value, it is important to establish which thyroid tests are
optimal and when they should be performed. Other issues
that remain to be determined are: the TSH threshold for
treatment in mild thyroid deficiency, the role of thyroid
hormone deficiency or autoimmunity during gestation, and
the effects of replacement therapy in mild thyroid hormone
deficiency. A prospective randomized controlled study is
currently being conducted by J. H. Lazarus and colleagues
(University ofWales College of Medicine) to test the value of
screening for thyroid disease and the effect of treatment in
women with increased serum TSH.
K. Subclinical hypothyroidism in the elderly
The thyroid gland undergoes several anatomical changes
with age. There is a reduction in weight of the gland, in the
size of follicles, and in the content of colloid, and increased
fibrosis often with marked lymphocytic infiltration. How-
ever, these changes do not correlate with thyroid function.
The half-life of T4 increases to 9.3 d in the seventh decade of
life (306). Serum T4 concentration is not affected by this
change because its production decreases with age. Although
studies of heterogeneous populations suggested that T3 lev-
els decline with age, studies of selected healthy people in-
dicated that T3 levels are unaffected by aging (307). TSHmay
increase or decrease with age in relation to the iodine intake
(16, 308); however, the very elderly (octogenarians and be-
yond), may have a mild TSH decrease (309), suggesting the
presence of an “altered set point” of the hypothalamic-pi-
tuitary-thyroid axis in some elderly individuals (310).
There is an age-dependent increase in the prevalence of
antithyroid antibodies in the ambulatory population. From
40 to 70% of older subjects with elevated TSH concentrations
have thyroid autoantibodies, however only a minority of
older patients with thyroid autoantibodies have elevated
TSH. The increase in thyroid autoantibodies with age seems
to be due to the effect of age-associated disease rather than
aging per se (16, 308, 309). The percentage of people with
positive TPO antibodies decreased in subjects older than 80
yr, suggesting either that antithyroid antibodies decline after
age 80 or that TPOAb-positive patients die (306).
SHypo is prevalent in the elderly population, especially in
women, andmayprogress to overt disease (16, 24, 40, 65, 75–78,
89). The causes of SHypo in the elderly are similar to the causes
of SHypo in young and middle-aged patients, previously de-
scribed. Autoimmune thyroiditis and treatment of hyperthy-
roidismare themain causes of thyroid hypofunction in patients
older than 55 yr (92). SHypo may remain unrecognized in the
elderly especially if the decline in thyroid function is gradual.
In some cases, the manifestations of thyroid hormone defi-
ciency in the elderlymaybe erroneously attributed to the effects
of aging (311, 312). Among the drugs that may induce thyroid
hormone deficiency, amiodarone, lithium, and interferon- are
frequently administered in the elderly (311). The risks associ-
ated with SHypo in the elderly, like those in younger patients,
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are hypertension, atherogenic dyslipidemia, atherosclerosis,
decreased cardiac function, and muscle dysfunction. The car-
diovascular risk may be further increased in older subjects
because they are more likely to have an underlying heart
disease.
It remains to be establishedwhether or not elderly patients
with SHypo should be treated (5, 6). Most professional or-
ganizations and an evidence-based guideline advocate start-
ing replacement therapy in elderly patients who have TSH
concentrations greater than 10 mIU/liter and in those with
antithyroid antibodies (6), and in symptomatic elderly pa-
tientswith TSH levels between 4.5 and 10mIU/liter (5). From
a cardiovascular viewpoint, it seems reasonable to be con-
cerned about treating SHypo in the elderly for fear of in-
creasing the oxygen demand of the heart. On the other hand,
replacement therapy could improve cardiac function thereby
reducing SVR, which in turn would reduce the risk of dia-
stolic heart failure and of atherosclerosis. However, there are
no data on the effects of replacement therapy on the cardio-
vascular system in elderly patients.
Evidence suggests that the effect of replacement therapy
on health outcome could bemore complex in elderly patients
than in other age groups (92). In a recent study, SHypo was
a risk factor for depression in 323 elderly individuals over 60
yr old (313). In an observational, population-based prospec-
tive follow-up study carried out in Leiden, The Netherlands,
559 individualswere followedup from the ages of 85 through
89 yr (92). Thyroid statuswas assessed at baseline and during
follow-up. No patients were treated regardless of thyroid
status. At annual visits, investigators evaluated daily life
activities and cognitive and affective function. At baseline
and during follow-up, there was no association between
SHypo or overt hypothyroidism and lessened physical func-
tion, depressive symptoms, and cognitive function. At the
end of follow-up, no patient with SHypo at baseline had
progressed to overt hypothyroidism (92). Both overt hypo-
thyroidismand SHypowere associatedwith lowermortality,
and higher levels of T4 were associated with increased mor-
tality after adjusting for sex, disability, and health status. In
support of these data, low serumFT4was recently associated
with a better 4-yr survival in a population of independently
living elderly men (314). There was an inverse relationship
between T3 and physical performance and lean body mass,
and between FT4 and mortality, which suggests that a lower
activity of the thyroid hormone axis is beneficial during
aging and could be an adaptive mechanism to prevent ex-
cessive catabolism (314).
Thyroid hormone deficiency may exert protective effects in
the elderly, namely a lower metabolic rate, reduced adrenergic
tone, and the protective effects of hypothyroidism in case of
acute events. Moreover, in theory, very elderly patients (e.g.,
above 85 yr of age) may be biologically different from moder-
ately old patients (e.g., 60–70 yr). In fact, octogenarians with
higher bloodpressure values tend to live longer than thosewith
lower values (315). Moreover, several risk factors associated
with thyroid hormone deficiency (TC and LDL-C levels) are
powerful, independent cardiovascular risk factors in the mid-
dle-aged, but not in the very elderly (316).
In conclusion,more information is needed as to the normal
reference range for TSH in the elderly. The benefits of treat-
ing very elderly subjects with SHypo are uncertain. More-
over, other chronic diseases are often associated with a het-
erogeneous health status in subjects older than 65 yr.
Although large randomized trials are needed, limited evi-
dence suggests that treatment of SHypo should probably be
avoided in patients older than 85 yr whose TSH level is
between 4.5 and 10 mIU/liter (92). After the identification of
elderly patients who would benefit from replacement ther-
apy, treatment should be individualized in those with a
serum TSH concentration above 10 mIU/liter. In such cases,
l-T4 therapy can be initiated with the aim of reaching a TSH
serum level of 4–6 mIU/liter in individuals older than 70 yr
(317). It must be noted that overtreatmentwith excessive l-T4
doses can have negative consequences in the elderly (317).
Prospective therapeutic trials are necessary to clarify the
necessity of replacement therapy in the elderly.
L. Subclinical hypothyroidism in children
Congenital hypothyroidism occurs in approximately one
in 3000–3500 babies in the United States. This condition may
lead to severe, irreversible mental retardation. Infants with
congenital hypothyroidism often appear normal at birth.
Therefore, it is recommended that all newborns undergo
thyroid testswhen they are between 3 and 5d old. Congenital
hypothyroidism is diagnosed in approximately 30% of all
newborns with elevated TSH, and the infants are immedi-
ately given l-T4 replacement therapy. However, most new-
borns with elevated TSH levels (60–70%) have normal or
nearly normal TSH and FT4 at recall examination.
A prospective study was carried out in 56 false-positive
newborns with elevated serum TSH and normal FT4 at birth
and normal or borderline high/normal TSH at recall exam-
ination (318). Evaluation of thyroid function at birth, in the
neonatal period, and at 2–3 yr of age showed that persistent
SHypo in early childhood was very frequent (70%) among
false-positive children who had slightly elevated serum TSH
concentrations (5–12 mIU/liter) at recall examination. These
results suggest that all infants with elevated serum TSH at
neonatal screening are at risk of SHypo in early childhood
and require follow-up (318).
Hashimoto’s thyroiditis is the most common cause of thy-
roid disease in children and adolescents, and it is often found
in patients with type I diabetes and other autoimmune dis-
orders such as celiac disease, polyglandular autoimmune
disorders, and juvenile idiopathic arthritis (319, 320). An
increase in the prevalence of autoimmune thyroiditis among
schoolchildren was reported after iodine prophylaxis in
Greece (321). An increased serum TSH concentration was
also seen (0.96%) in children with autoimmune thyroiditis
(2.92%) in Sardinia, which is an area of moderate iodine
deficiency (322). A significant increase of autoimmune thy-
roid disease was observed in girls older than 11 yr, which
suggests that puberty can be a factor in determining the
prevalence of TA (322). The clinical course of autoimmune
SHypo in children is variable, and spontaneous remission
may occur in adolescence (94, 323). Thyroid hormone defi-
ciency is frequent in patients with Down syndrome (324).
Patients with Turner’s syndrome are also at a higher than
average risk of developing autoimmune thyroid disease not
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only in adolescence and adult age but also in childhood.
SHypo is the most frequent thyroid dysfunction (325).
Among hematological conditions, patients with -thalasse-
mia major and patients who received bone marrow trans-
plantation during childhood or adolescence were found to
have an increased risk of SHypo in two studies without a
control population (326, 327).
The clinical features of SHypo in children are goiter, men-
strual disorders, and possibly short stature (319). SHypowas
associated with an increased risk of symptomatic hypogly-
cemia in children and adolescents with type 1 diabetes mel-
litus (328). Interestingly, a recent study showed a better per-
formance and cognitive function in adolescents with SHypo
than in the euthyroid group, even after adjustment for sex,
age, and family income level (329). SHypo does not increase
the risk of myocardial structural or functional abnormalities
in children with Down syndrome and SHypo (330). Among
parameters of cardiovascular risk, plasmahomocysteine con-
centrations were not increased in adolescents with SHypo
(331). HDL-C levels were significantly lower in 46 children
with TSH greater than 4.65 mIU/liter (332). These findings
could indicate that an atherogenic lipid profile can occur in
adolescents.
Very few studies have examined the effects of l-T4 re-
placement therapy in young people with SHypo. In an un-
controlled study, SHypo was detected in 39 (1.9%) of 2067
young patients with short stature in a study performed in
1989, in which the disease was identified by the TRH test
(333). After 1 yr of l-T4 replacement therapy, growth velocity
and the growth velocity sd score improved in prepubertal
andpubertal patients; the improvementwasmore significant
in the pubertal group. A longitudinal study on long-term
l-T4 therapy in 13 adolescent girls with SHypo caused by
chronic lymphocytic thyroiditis did not adversely affect bone
mineral density (BMD) or bone turnover, which indicates
that attainment of peak bone mass is not impaired by l-T4
(334). A double-blind crossover placebo-controlled trial in-
volving children and adults with Down syndrome and
SHypo failed to document any cognitive, social, or physical
changes attributable to 8–14 wk of T4 treatment (335). How-
ever, treatment duration was probably too short to identify
effects of replacement therapy.
In conclusion, controlled studies are needed to assess the
effect of replacement therapy in children with SHypo. For
those not taking thyroid hormone, thyroid function should
be periodically evaluated because SHypomay regress ormay
progress. Obviously, replacement therapy with l-T4 is not
necessary in children who spontaneously normalize serum
TSH.
M. Screening for hypothyroidism
SHypo is easily diagnosed with a TSH test. The ATA
recommends that adults be screened for thyroid dysfunction
at the age of 35 yr and every 5 yr thereafter (336). More
frequent TSH tests are suggested for individuals with signs
and symptoms potentially attributable to thyroid dysfunc-
tion and those with risk factors (336). Indeed, screening for
mild thyroid failure was considered cost-effective when
compared with other widely used preventive medical inter-
ventions (breast cancer and hypertension), particularly in
elderly women (337). Nevertheless, neither the American
College of Physicians nor the Institute of Medicine of the
National Academy of Sciences recommends general popu-
lation screening for mild thyroid failure on the basis that the
potential benefits of early detection and treatment might be
outweighed by the associated cost of therapy and follow-up
testing (338, 339). Similar conclusions were drawn by a panel
of 13 experts (7), The Royal College of Physicians (340), and
the U.S. Preventive Service Task Force (341). In contrast, a
non-evidence-based consensus statement from theAmerican
Association of Clinical Endocrinologists, The Endocrine So-
ciety, and the ATA recommended routine screening for
SCTD in the general population (5).
Screening for mild thyroid failure is recommended by
some scientific/medical societies in specific high-risk sub-
jects such as the elderly (5, 6, 338, 342) and pregnant women
(5, 343). The American Academy of Pediatrics recommends
that children with Down syndrome have a thyroid function
test at 4–6 and 12 months of age and annually thereafter
(344). Screening is defined as testing for a disease in the
absence of symptoms, with the goal of improving not only
quality of life but also the outcome. Currently, there are not
sufficiently robust data about the potential beneficial effect
of replacement therapy on the outcome of SHypo. On the
other hand, SHypo may progress to overt hypothyroidism,
and it has been argued (336) that treatment of SHypo diag-
nosed through screeningwouldprevent the subsequentmor-
bidity from overt hypothyroidism in such cases.Whether the
costs of screening are outweighed by the potential benefits
remains to be seen, although one analysis suggested that it
was cost-effective (337).
N. Treatment of subclinical hypothyroidism
Whether to treat SHypo remains a dilemma (345, 346).
Most clinicians treat SHypo patients who have a serum TSH
concentration above 10 mIU/liter, whereas opinions differ
about the management of mild disease in which TSH ranges
between 4.5 and 10 mIU/liter, especially in elderly asymp-
tomatic patients. Some endocrinologists support the idea that
treatment is indicated in patients with SHypo, even those
with a mild TSH increase, in the presence of risk factors (1,
8, 347), whereas others believe that treatment is seldom nec-
essary (6, 9, 348).
A panel of 13 experts (eight had expertise in thyroid dis-
ease, and eight had expertise in cardiology, epidemiology,
biostatistics, evidence-based medicine, health service re-
search, general internal medicine, and clinical nutrition) was
convened to propose evidence-based guidelines for the di-
agnosis, treatment, and screening of SCTD (6). The panel
concluded that there was not sufficient evidence to recom-
mend routine treatment for patients with TSH between 4.5
and 10 mIU/liter and suggested that patients be monitored
at 6- to 12-month intervals. Although dyslipidemia was con-
sidered proven only in patients with TSH above 10 mIU/
liter, treatment was recommended in patients with TSH
above 10 mIU/liter because of their high rate of progression
to overt hypothyroidism (6). The three societies that spon-
sored the consensus panel (theAmericanAssociation of Clin-
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ical Endocrinologist, The Endocrine Society, and the ATA)
considered the recommendations against treatment and
screening inappropriate because they were based on a lack
of evidence for benefit rather than evidence for a lack of
benefit (5). The three societies recommended routine treat-
ment of patients with SHypo who had serum TSH levels of
4.5–10 mIU/liter. Moreover, measurement of anti-TPO an-
tibodies was deemed useful in predicting the risk of devel-
oping overt hypothyroidism or associated autoimmune
disease.
The factors that influence a clinician’s decision to treat
SHypowere evaluated in 539 patientswhose serumTSHwas
between 5.1 and 10.0 mIU/liter (349) T4 therapy was pre-
scribed in 39% of patients with TSH levels between 5.1 and
10 mIU/liter. Among these, patients with thyroid-positive
autoantibodies, those with higher TSH values, and those
with lower FT4 were more likely to receive T4 replacement
therapy. Younger patients (31–50 yr) were more likely to be
treated than older patients (61–80 yr) (349).
It seems reasonable to treat symptomatic patients, those
with cardiovascular risk factors, pregnant women, patients
with goiter and a positive thyroid antibody test, and subjects
with ovulatory dysfunction and infertility because there is
evidence of the potential reversibility of these dysfunctions
associated with mild thyroid failure (1, 123, 346, 347) (Fig. 3).
Treatment of persistent mild SHypo with appropriate doses
of l-T4 to normalize serum TSH may be of benefit from a
cardiovascular perspective, although data showing this to be
clinically relevant are lacking. Replacement therapy with
l-T4 may reverse the systolic and diastolic dysfunction, ar-
terial hypertension, increased central arterial stiffness, en-
dothelial dysfunction, and other cardiovascular risk factors
associated with this condition (123, 347). However, although
cardiovascular risk factors have been associated with SHypo
in some studies, epidemiological studies in which cardio-
vascular morbidity and mortality have been evaluated had
yielded conflicting results, and there are no data showing
that therapy with T4 improves outcomes such as cardiac
morbidity or mortality. More randomized controlled trials
and longitudinal studies are necessary to evaluate whether
replacement therapy with T4 reduces the risk of CHD in
subjects with SHypo. In the meantime, it could be useful to
identify and consider l-T4 replacement in higher-risk pa-
tients with SHypo with the aim of reducing cardiovascular
risk. In high-risk individuals, it is reasonable to ascertain
whether hyperlipidemia, diastolic hypertension, diastolic
dysfunction, or other possible associated cardiovascular risk
factors may be improved with replacement therapy. Current
data suggest that middle-aged individuals may benefit more
from treatment than the elderly (38, 92, 230). T4 therapy is
able to lower the chance of miscarriage and premature de-
livery in pregnant women with SHypo (350).
l-T4 is the drug of choice for the treatment of SHypo. It is
inexpensive and it stabilizes thyroid hormone levels. There
is no reason to use T3, and there is no evidence of benefit from
combinedT3 andT4 therapy (351, 352). Small doses, i.e., 25–75
g/d, are often adequate to normalize serum TSH levels in
SHypo. The l-T4 replacement dose should be carefully ad-
justed to avoid iatrogenic hyperthyroidism. The goal of l-T4
therapy in patients with persistent mild thyroid failure could
Subclinical hypothyroidism serum TSH <10 mIU/L 
Clinical stratification
High background cardiovascular risk
Documented diastolic dysfunction 
Diastolic hypertension




Low background cardiovascular risk
Normal cardiac function 
Normal arterial pressure 
No atherosclerotic risk factors 
Normal lipid profile




No positive antithyroid peroxidase antibodies




No evidence of benefit for L-T4 replacement.
Regular monitoring of thyroid function and








should  be considered,
with regular monitoring
of thyroid function and
cardiovascular risk
OR AND
FIG. 3. Algorithm for the diagnosis and treatment of SHypo. This algorithm is based on data showing an increased all-cause mortality (194),
increased risk of atherosclerosis (193), coronary events (38, 193, 194, 196), and CHF (231), infertility and maternal and fetal risk (281–291,
299–301), and progression to overt hypothyroidism in autoimmune thyroiditis (24, 90, 93) and on double-blind placebo-controlled studies
showing an improvement after replacement therapy of goiter (252–254), symptoms (109, 249, 259, 260), cardiac function (109, 133, 134, 249),
vascular system (168, 261), and lipid profile (168, 189, 260, 261).
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be a TSH level between 1 and 2–3 mIU/liter in young and
middle-aged patients. Once optimal therapy has been
achieved, periodic evaluations of serum TSH levels are re-
quired to ensure that replacement therapy is not under- or
overprescribed. A TSH test should be performed every 6 to
12 months. It is often necessary to increase the l-T4 dosage
progressivelywith time because of further impairment of the
thyroid gland and progression to overt hypothyroidism. In
case of suppressed TSH, the l-T4 dose should be lowered. If
a low TSH persists, or if very low doses of l-T4 normalize
thyroid function, thyroid tests should be carried out after
l-T4 withdrawal to evaluate whether SHypo is permanent.
The risks associated with l-T4 replacement therapy in sub-
clinical hypothyroid patients are: 1) risk of starting l-T4 ther-
apy in subclinical hypothyroid patients who have clinically
established coronary disease; 2) risk of treating elderly sub-
clinical hypothyroid patients especially in the presence of
underlying heart disease; and 3) risk of iatrogenic SHyper
due to overzealous hormonal dosing with insufficient bio-
chemical monitoring.
In epidemiological studies, the risk of CHDwas increased
in young andmiddle-aged patients (38, 193, 194, 196) but not
in elderly patients (229–231) with SHypo (353) (Fig. 4). In-
deed, SHypo appeared to exert a protective cardiovascular
effect in patients older than 85 yr (92).On this basis, treatment
of SHypo is not indicated in very elderly patients if serum
TSH is lower than 10 mIU/liter (317), especially in the pres-
ence of documented cardiac disease. Moreover, when con-
templating replacement therapy in very elderly patientswith
TSH above 10 mIU/liter, it should be started at very low
doses (12.5–25 g/d) and gradually increased because of
possible underlying heart disease. The dose can be gradually
increased every 4–8 wk in relation to the serum TSH and
cardiac symptoms. If angina develops or worsens and is
resistant to medical therapy, l-T4 therapy should be discon-
tinued, and surgery or angioplasty for coronary artery dis-
ease should be considered when the patient is still hypothy-
roid. Low doses of l-T4 are often adequate in elderly patients
because of decreased T4 metabolism. A reasonable target
TSH level should be 3–4mIU/liter in individuals between 60
and 75 yr old and 4–6 mIU/liter in individuals older than
that.
Approximately 20% of l-T4-treated patients have de-
creased serum TSH, which usually indicates overtreatment.
Physician education can improve this situation, and inad-
vertent overtreatment should not be used as an argument
against l-T4 replacement therapy in subjects with SHypo. All
drugs have adverse effects if given without appropriate safe-
guards, but if properly monitored to maintain a normal se-
rum TSH concentration, l-T4 therapy is certainly safe. Ter-
tiary prevention, i.e., care of an existing disease to detect
progression and treatment monitoring to assess compliance
and to prevent complications, has been advocated for SCTD.
Tertiary prevention seems to be underused in the United
States, considering that only 60% of patients receiving thy-
roid hormone had normal thyroid function (354).
Treatment of patients with SHypo during pregnancy is a
special issue (355). Serum TSH levels should preferably be
checked before pregnancy, and in our opinion l-T4 therapy
should be started if serum TSH is greater than 2.5–3 mIU/
liter in the presence of thyroid autoantibodies (290). The
mean replacement dose of l-T4 during pregnancy is about 2.0
g/kgd. The magnitude of l-T4 dosage increment depends
on the etiology of hypothyroidism and increases as the de-
gree of underlying thyroid deficiency increases, with an av-
erage of 30–50% (355). In patients withmild SHypo, the dose
may not increase at all. Women of childbearing age should
have an average iodine intake of 150 g/d. During preg-
nancy and breast-feeding, women should increase their daily
iodine intake to 250 g/d (355). TSH should be monitored
every 6–8 wk during pregnancy and sooner (after 4–6 wk)
if l-T4 dosage adjustment was required because of increased
serum TSH levels. Iron and calcium supplementation should
not be given together with l-T4 in order not to affect l-T4
absorption.
VI. Subclinical Hyperthyroidism
SHyper is defined by low or undetectable serum TSH and
normal FT4 and FT3 concentrations (3, 4). This entity
emerged as a distinct entity as the sensitivity of TSH assays
increased. SHyper was first identified from a reduced noc-
turnal TSH surge or a blunted TSH response to TRH (356).
With the second-generation immunometric TSH assays, it
became possible to discriminate between patients with sub-
normal TSH values and normal subjects (357). Third-gener-
ation assays, which have a functional sensitivity of 0.01–0.02
mIU/liter, discriminate complete suppression from incom-
plete suppression of TSH in patients with SHyper and other
clinical conditions (358, 359). Although thyroid hormones are
defined as being within normal range in patients with SHy-
per, they are often at the upper limit of the reference range,
and thus sufficiently increased to suppress TSH and poten-
tially produce abnormal tissue effects.
A. Subclinical hyperthyroidism and minimally suppressed
TSH
A recent panel of experts classified patients with SHyper
into two categories: patients with low but detectable serum
TSH (0.1–0.4 mIU/liter), and patients in whom serum TSH
was undetectable (0.1 mIU/liter) (6). We shall examine the
causes, epidemiology, likelihood of progression to overt hy-
perthyroidism, the clinical implications, and treatment sug-
gestions using these two definitions of SHyper.
FIG. 4. Hypothetical relationship between age and effect of SHypo on
cardiovascular disease. Published data suggest that the possible ef-
fects are age related.
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B. Etiology of subclinical hyperthyroidism
The most common cause of SHyper is exogenous SHyper
due to unintentional excessive replacement therapy in hy-
pothyroid patients or to intentional TSH suppressive therapy
for benign or malignant thyroid disease (4, 360–365) (Table
11). Endogenous SHyper is commonly associated with au-
tonomous thyroid function as occurs in Graves’ disease,
multinodular goiter, and solitary autonomously functioning
thyroid nodules (AFTN) (3, 4, 360, 361, 364, 365). In Graves’
disease, SHyper may resolve spontaneously without treat-
ment. Alternatively, it may be transitory during treatment
with antithyroid drugs or after radioiodine therapy (because
of delayed recovery of the suppressed pituitary thyrotrophic
cells) (364), or it may be persistent because of the continued
thyroidal autonomy. Long-standing SHyper with a progres-
sive increase in thyroid hormone levels, sometimes preced-
ing the onset of overt hyperthyroidism, is frequent in patients
with multinodular goiter and autonomously functioning
thyroid adenoma (3, 4).
It remains to be established whether or not exogenous and
endogenous SHyper are similar conditions that exert the
same effects. Serum FT4 concentrations are at the upper
limits of normal range or frankly elevated in many patients
undergoing l-T4 suppressive therapy. In these patients, se-
rum T3 and FT3 are usually in the middle of their reference
ranges, and the T4/T3 ratio is greater than in patients with
endogenous SHyper (366, 367). Indeed, in the natural history
of thyroid autonomy, serum T3 levels start to rise before T4
levels rise. Moreover, exogenous SHyper is characterized by
constant TSH suppression during intentional suppressive
treatmentwith l-T4 andmaydiffer fromendogenous SHyper
in terms of the rate and the duration of the rise in thyroid
hormone level.
C. Differential diagnosis in subclinical hyperthyroidism
It is important to differentiate SHyper from other causes
of transient TSH suppression (Table 12). Transient TSH sup-
pression usually occurs during subacute, silent, or postpar-
tum thyroiditis. The differential diagnosis of a low serum
TSH level includes diseases other than SHyper, namely non-
thyroidal illness, psychiatric illness, drug administration
(high-dose steroids, dopamine, or dobutamine) and pituitary
dysfunction (3, 4, 360, 368). Thyroid hormone levels are usu-
ally low in nonthyroidal illness. However, although low,
serum TSH can usually be detected with a third-generation
TSH assay. Pituitary dysfunction is suggested by a persis-
tently decreased serum TSH concentration associated with
low or low normal serum thyroid hormone levels. In addi-
tion, TSH concentration may be below the normal range in
some elderly patients as a result of an age-related decrease
in thyroid hormone clearance (369) or an altered set point of
the hypothalamic-pituitary-thyroid axis.
Candidates for treatment can be identified by persistent
SHyper documented by repeatedly subnormal or undetect-
able serum TSH levels and normal free thyroid hormone
levels, together with a detailed medical history and detailed
clinical evaluation. For example, in the presence of sup-
pressed TSH, it is important to exclude the recent adminis-
tration of an iodinated contrast agent or excessive iodine
exposure. If necessary, 24-h thyroidal radioactive iodine up-
take and scanwill differentiate between the increased uptake
in patients with Graves’ disease, the presence of warm or hot
nodule(s) in multinodular goiter and autonomously func-
tioning thyroid adenoma, and the absence of uptake in pa-
tients in the hyperthyroid phase of thyroiditis and in patients
who are taking exogenous thyroid hormone or iodine-con-
taining preparations. Lastly, SHyper may be present in
women affected by hyperemesis gravidarum or by tropho-
blastic disease with high serum human chorionic gonado-
tropin concentrations (4, 360).
D. Prevalence of subclinical hyperthyroidism
The prevalence of exogenous and endogenous SHyper in
the general population is between 0.7 and 12.4% (368). SHy-
per is common during l-T4 therapy, being present in about
10–30% of patients (16, 40, 370). Endogenous SHyper is more
prevalent in women than in men and in the elderly. Graves’
disease is prevalent in areas of high iodine intake, whereas
toxic nodular goiter is more prevalent in areas where iodine
intake is low (371).
In the Whickham survey, which was carried out between
1972 and 1974, before ultrasensitive TSH assays became
available, the prevalence of SHyper defined as a serum TSH
concentration less than 0.5 mIU/liter was 10% in women but
0% in men (75). The prevalence of SHyper (TSH 0.1 mIU/
liter) was 2.5% in 968U.S. subjects over the age of 55 yr, about
two thirds of whom were taking thyroid hormone prepara-
tions (372). In a study carried out in England, the prevalence
of SHyper (TSH  0.5 mIU/liter) was 6% (373). In the Col-
orado cross-sectional study of 25,862 subjects, SHyper
(TSH  0.3 mIU/liter) was found in 0.9% of 24,337 individ-
uals, but was present in 20.7% of the 1,525 individuals who
were taking thyroid hormone preparations (40).
In the NHANES III study, the prevalence of SHyper
(TSH  0.1 mIU/liter) was 0.7% in people over 12 yr of age
(16). However, with a TSH cutoff of 0.4 mIU/liter, the prev-
alence of SHyper reached 3.2%. The percentage of people
with TSH less than 0.4 was significantly higher in females
than males in the three population groupings (P 0.05). The
TABLE 11. Causes of persistent SHyper
Endogenous causes
Graves’ disease
Autonomously functioning thyroid adenoma
Multinodular goiter
Exogenous causes
Excessive thyroid hormone replacement therapy
Intentional thyroid hormone suppressive therapy




Administration of drugs (dopamine, glucocorticoids)
Pituitary or hypothalamic insufficiency
Decreased age-related thyroid hormone clearance or pituitary set
point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percentage with TSH no greater than 0.4 mIU/liter was sig-
nificantly higher in blacks than in whites (P  0.01) .
In another U.S. study of 3242 pre- and early perimeno-
pausal women, the prevalence of SHyper (TSH  0.5 mIU/
liter) was 3.2% (374). With a serum TSH cutoff below 0.1
mIU/liter, the prevalence of SHyper was 3.9% in the Fra-
mingham Heart Study of 2575 ambulatory persons older
than 60 yr; also in this study about half of them were taking
thyroid hormones (375). In the recent Cardiovascular Health
Study of 3233 U.S. community-dwelling individuals aged 65
yr or older, the prevalence of SHyper (TSH 0.10–0.44 mIU/
liter) was 1.5% (230). In Sweden, 1.8% of 886 subjects 85 yr
of age or older had SHyper (376).
The prevalence of thyroid autonomy is inversely cor-
related with the population’s iodine intake (377). In a
cross-sectional survey carried out in Germany, which is an
iodine-deficient area, the prevalence of SHyper, defined as
serum TSH less than 0.3 mIU/liter, was 11.3% in the 20-
to 79-yr-old group (378). However, with a TSH cutoff
below 0.1 mIU/liter, the SHyper prevalence was 1.8%. The
prevalence of the disease was similar among women and
men, but it increased in the elderly (378). The prevalence
of endogenous SHyper due to AFTN and multinodular
goiter has been evaluated in two iodine-deficient areas of
Italy (23, 379). The prevalence of AFTN was 4.4% and the
prevalence of toxic nodules was 1.3% in the study from
northeastern Sicily performed in 1983 on 31,373 subjects
who were referred to a center of thyroid disease between
1965 and 1980 (379). Methods for the measurement of
thyroid hormones in this study were protein-bound iodine
until 1970 and then RIA (379). The prevalence of functional
autonomy was 6.4% in the Pescopagano survey in which
SHyper was defined by TSH less than 0.4 mIU/liter. It
progressively increased with age, reaching 15.4% in sub-
jects above the age of 75 yr (23).
In conclusion, the prevalence of endogenous SHyper de-
pends on the cause of the disease, sex, age, iodine intake, the
sensitivity of the methods used to measure serum TSH con-
centrations, and the investigator’s definition of the lower
limit of the normal range. This variability can explain the
differences in the prevalence of endogenous SHyper re-
ported in various studies.
E. Natural history of subclinical hyperthyroidism
The frequency with which SHyper progresses to clinically
overt disease is uncertain and depends on the initial serum
TSH concentration and on the cause of endogenous SHyper.
Some studies of subjects with SHyper monitored for 1–4 yr
suggested that SHyper may develop into overt disease at a
rate of 1–5% per year (76, 369, 375, 376, 380). In the study by
Sawin et al. (369), of 33 patients older than 60 yr with SHyper
(TSH less than 0.1 mIU/liter) there was a 4.1% rate of pro-
gression over 4 yr. Tenerz et al. (381) reported that 33 elderly
patients with SHyper (TSH  0.1 mIU/liter) had a higher
prevalence of multinodular goiter than matched controls (68
vs. 29%). These subjects were more likely to develop overt
thyrotoxicosis (30% hyperthyroid, 23% remained with sup-
pressed TSH, and 10% normalized TSH) during 2 yr of fol-
low-up (381). In a 12-month follow-up study of 66 patients
older than 60 yr with SHyper, serum TSH evaluated with a
sensitive assay reverted to normal in 38 of 50 patients with
subnormal but detectable TSH and remained subnormal in
14 of 16 patients with undetectable TSH; only one patient
developed hyperthyroidism (76). This study suggests that
progression of subclinical to overt hyperthyroidism is less
frequent in patientswith low serumTSH (1.2%per year) than
in patients with undetectable TSH (76). In a study of 15
patients older than 60 yr with SHyper and serum TSH con-
centration less than 0.1 mIU/liter monitored for 4–12
months, TSH reverted to normal in seven and remained
suppressed in eight, and there was progression to overt hy-
perthyroidism in two patients (382). Similarly, in 33 patients
older than 60 yr with a serum TSH less than 0.1 mIU/liter
monitored for 4 yr, TSH reverted to normal in 24 patients and
remained low (0.1–0.4 mIU/liter) in nine, and there was
progression to overt hyperthyroidism in two (369). More-
over, in the study by Parle et al. (229), during 10 yr of fol-
low-up of 70 patients older than 60 yr, three (4.3%) developed
overt hyperthyroidism.
Few data are available about the natural history of au-
tonomously functioning thyroid adenoma. In a retrospec-
tive analysis of AFTN by Hamburger (383), 14 of 159
untreated patients with SHyper became overtly thyrotoxic
over a 6-yr follow-up period. Most patients who devel-
oped overt hyperthyroidism had nodules more than 3 cm
in diameter. Woeber (384) retrospectively examined the
natural history of 16 ambulatory patients with SHyper
monitored for a cumulative follow-up of 11–36 months.
Serum TSH reverted to normal in five of the seven patients
with subclinical Graves’ disease and remained subnormal
in all nine patients with multinodular goiter. Only one of
the seven patients with subclinical Graves’ disease devel-
oped overt hyperthyroidism, whereas none of the nine
patients with multinodular goiter progressed to overt dis-
ease. This study suggests that the natural history of SHy-
per depends on the cause of the disease: it is often revers-
ible and occasionally progressive in subclinical Graves’
disease, whereas it may be more likely to persist un-
changed in cases of multinodular goiter. Moreover, in the
study by Brownlie and Legge (385), of 93 euthyroid pa-
tients with a history of hyperthyroidism, persistent SHy-
per with subnormal TSH values occurred in 24% of pa-
tients previously treated with antithyroid drugs and was
predictive of relapse to overt hyperthyroidism. Finally, it
has been reported that SHyper is frequent in elderly pa-
tients with multinodular goiter in areas of iodine defi-
ciency, and that overt hyperthyroidism can develop after
an acute increase in the supply of iodine (386, 387).
The results of all these studies suggest that serum TSH
concentration should be regularlymonitored in patientswith
endogenous SHyper to evaluate whether the disease is per-
sistent or progressive. This is particularly true before decid-
ing whether to treat young and middle-aged patients. In
elderly patients, atrial fibrillation (AF) could be the first
manifestation of SHyper (381); consequently, treating these
patients earlier rather than later should be seriously
considered.
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F. Symptoms and quality of life in subclinical
hyperthyroidism
As in patients with SHypo, the decision to treat patients
with SHyper is often based on the assessment of the clin-
ical symptoms and signs, which can be mild. As in overt
disease, this evaluation can be performed by assessing
specific symptoms and signs, or more generally by testing
the quality of life. It is particularly important to consider
the age of patients with SHyper, because the presence of
symptoms and signs of hyperthyroidism are often masked
in the elderly even in patients with severe overt disease
(388, 389). Furthermore, the clinical consequences of SHy-
per are potentially far more significant in the elderly,
compared with younger individuals.
1. Symptoms and quality of life in exogenous SHyper. Three
studies assessed the presence of symptoms and signs of
hyperthyroidism in patients with SHyper compared with
normal subjects (390–392). Evaluatedwith a symptom rating
score (SRS), patients with exogenous SHyper were found to
have more specific symptoms and signs of overt hyperthy-
roidism, with a higher prevalence of palpitations, tremor,
heat intolerance, sweating, nervousness, anxiety, reduced
feeling of well-being compared with normal subjects (390–
392). Seventeen athyreotic patients, aged 45  10 yr, who
were receiving TSH suppressive doses of l-T4 for thyroid
cancer, were evaluated by Shapiro et al. (390). In this study
TSH was suppressed to near the limits of assay detection
(0.01), and the mean serum T4 and FT4 levels were signif-
icantly increased comparedwith the control group, although
the mean serum level of FT3 was similar in the two groups.
These patients had minimal symptoms but a significantly
greater symptom score than controls (SRS, 4  3 vs. 2  1 in
controls; P  0.05). However, symptomatic patients, who
were already under treatment with beta-blocking drugs,
were excluded from the evaluation. Two other studies re-
ported significantly higher mean symptom scores in patients
with exogenous SHyper than in controls (11.1 0.2 vs. 4.2
2.3, P 0.001; and 9.6 3.7 vs. 5.3 2.6, P 0.01) (391, 392).
In one of these studies, the patients receiving TSH suppres-
sive therapy were selected for the presence of palpitations,
increased heart rate, as well as other symptoms mimicking
exaggerated -adrenergic activity (391). In both studies, the
scores were higher mainly for symptoms mimicking exag-
gerated -adrenergic activity. In these two studies, TSH was
below the detection sensitivity of themethod,whichwas 0.05
mIU/liter in the study by Biondi et al. (391) and 0.1mIU/liter
in the study by Mercuro et al. (392). FT4, but not FT3, was
significantly higher in patients than in controls (0.001) in
both the studies, although only two patients in the study by
Biondi et al. and five patients in the study by Mercuro et al.
had total T4 and FT4 levels that exceeded the upper limit of
reference range. Although it could be argued that some of
these subjects actually had “overt” exogenous hyperthyroid-
ism, patients with differentiated thyroid cancer (DTC) who
are receiving TSH suppressive therapy may sometimes have
serum FT4 levels that are at the upper limit of normal range
or frankly elevated (362). In fact, FT4 levels can be 10–25%
higher when measured in specimens drawn within 3–4 h
after the morning l-T4 dose.
Schlote et al. (393) investigated subclinically hyperthyroid
individuals selected from a working population. They eval-
uated signs and symptoms of hyperthyroidism, sleep qual-
ity, depression, ability to concentrate, anxiety, and other
dimensions of well-being in 15 subjects with SHyper taking
l-T4 and in 27 euthyroid controls. Patients with exogenous
SHyper had significantly higher total T4 levels and more
palpitations than controls, and they slept less. However,
psychometric results revealed only a few differences be-
tween patients with SHyper and normal subjects with no
significant difference in mood.
Psychological performance and quality of life were re-
cently studied in 18 patients with DTC, aged 44 13 yr, with
TSH less than 0.1 mIU/liter during chronic TSH suppressive
therapy (394). At baseline evaluation, most patients had el-
evated serum FT4 concentrations. Compared with healthy
controls, patients with DTC had impairment of several in-
dices: the total score, and the emotional, sleep, energy, and
social items of the Nottingham Health Profile; the mental
health, general health, and social function of the SF-36; and
the total score on the Wais Digit Span (P  0.05 for all
comparisons). Quality of life and cognitive performance
were comparablewith those of euthyroid controls 4–7 d after
l-T4 withdrawal (whenmost patients had normal serum FT4
and free T3 levels). Finally, in a very recentmulticenter study,
the SF-36 scores of 228 patients with DTC were found to be
above those of normal U.S. adults in six of eight categories
during l-T4 therapy, with the exception of modestly lower
scores on the general heath andmental health domains (395).
In conclusion, patients receiving TSH suppressive doses of
l-T4 may have symptoms and signs of thyroid hormone
excess. The presence of these symptoms should be consid-
ered when deciding on the appropriate target TSH levels in
patients with DTC. This is particularly important in patients
with low risk DTC who require long-term l-T4 therapy but
may not require aggressive TSH suppression (362, 363).
2. Symptoms and quality of life in endogenous SHyper. The
Wayne score (a clinical index of hyperthyroidism), has been
used for the clinical evaluation of patients with endogenous
SHyper. Stott et al. (382) reported that the meanWayne score
of 15 elderly patients (aged 61–90 yr) with endogenous SHy-
per and undetectable TSHwas similar to that of patientswith
overt thyrotoxicosis and worse vs. normal subjects. Similar
findings were obtained by Sgarbi et al. (396) in 10 patients
with endogenous SHyper aged 16–72 yr: the Wayne clinical
index was significantly greater in patients with endogenous
SHyper than in controls and was significantly correlated
with serum TSH.
The SRS and SF-36 were used to evaluate 23 patients with
endogenous SHyper aged 43  9 yr with undetectable TSH
in comparison with euthyroid subjects (397). The mean SRS
for thyrotoxic symptoms was significantly higher in patients
than in controls. Moreover, quality of life was reduced ac-
cording to the SF-36 mental and physical component scores,
and the SRS were inversely correlated with the cumulative
score of the mental and physical components. Similarly,
Gulseren et al. (398) reported reduced mental and physical
component scores in patients with SHyper vs. a control
group.
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In conclusion, in patients with endogenous SHyper, the
symptoms and signs, when present, are usually much less
severe and not as specific as they are in overt thyrotoxicosis.
There is an increased prevalence of symptoms and signs of
adrenergic overactivity, and palpitations are frequent in
young and middle-aged patients. Similar to SHypo, the ex-
tent of symptoms of SHyper is likely related to age, the
duration of hyperthyroidism, and the patient’s individual
sensitivity to thyroid hormone excess.
G. Subclinical hyperthyroidism, mood, and cognitive
function
There is no general consensus about the prevalence of
anxiety and depression in patients with SHyper. A study
conducted with the Beck Anxiety Inventory showed that
patients with SHyper had significantly higher anxiety scores
than a euthyroid group (116). However, in another study,
anxiety scores did not differ between patients with SHyper
and controls (399).
A reduced feeling of well-being and feelings of fear, hos-
tility, and inability to concentrate were reported in patients
with SHyper or previously treated hyperthyroidism (400).
The study included patients with “remitted” hyperthyroid-
ism, and it was observed that even after a long period of
euthyroidism, neither the psychopathological nor the neu-
ropsychological state became completely normal. Oomen et
al. (401) evaluated thyroid function in all patients admitted
to three psychiatric hospital in The Netherlands and found
that 4.1% had a serum level of TSH less than 0.4 mIU/liter.
Affective disorders (particularly depression in females and
mania in males) were more prevalent in patients who had a
suppressed serum TSH (401). However, causal relations
cannot be determined from this cross-sectional study be-
cause suppressed TSH concentrations could be the conse-
quence rather than a cause of the psychiatric illness and
hospitalization.
In the population-based prospective Rotterdam study of
1846 persons over 55 yr of age, subjects with endogenous
SHyper, defined by a serum TSH less than 0.4 mIU/liter at
baseline, had a 3-fold increased risk of dementia and Alz-
heimer’s disease (relative risk, 3.5) during 2–4 yr of fol-
low-up (402). The risk of dementiawas particularly increased
in patientswith positive antiperoxidase antibodies, hence the
role of autoimmunity itself remains to be clarified. Similarly,
in a case-control study there was a strong association be-
tween vascular dementia and low serumTSHdefined as TSH
of 0.5mIU/liter or less (403). A low serumTSH concentration
was associated with a 2-fold increased risk for Alzheimer’s
disease in another case-control study (404). However, in a
cross-sectional investigation of 829 consecutive geriatric pa-
tients, no association was found between serum TSH levels
and Alzheimer’s disease (405). In a population-based cohort
study of 1077 subjects aged 60–90 yr and dementia-free at
baseline, with a follow-up of 5.5 yr, subjects with higher FT4
levels had more pronounced hippocampal and amygdalar
atrophy on MRI (406). The functional significance of the
association between higher FT4 levels with brain atrophy on
MRI remains to be elucidated. Finally, in a recent commu-
nity-based cross-sectional study of 127 persons aged 65 yr or
older, SHyper was not associated with depression, anxiety,
or cognition when compared with euthyroid subjects (117).
In summary, it is difficult to draw conclusions about the
effects of SHyper on mood and cognitive function. Some
confounding factors may interfere with this evaluation, i.e.,
the presence of autoimmunity and depression itself. It is
difficult to establish whether TSH suppression, which is fre-
quently associated with dementia, represents the cause or is
a consequence of the disease. Moreover, patients identified
by population screening may be less symptomatic than pa-
tients evaluated in clinical studies carried out to assess the
effects of subclinical disease on symptoms.
H. Cardiovascular risk in subclinical hyperthyroidism
1. Cardiovascular effects of exogenous SHyper. It is noteworthy
that the l-T4 doses used to treat benign or malignant thyroid
disease have progressively decreased over the years. In the
decade 1970–1980, the daily dose of l-T4 tended to be be-
tween 200 and 300 g/d (407). In the 1970s, with the widely
used l-T4 dose of 150g/d, about 30%of treated subjects had
raised serumT4 levels (408, 409). At that time, a lack of serum
TSH response to TRH was a common finding in patients
taking T4 replacement therapy (410). Decreased systolic time
intervals, typical of hyperthyroidism, increased levels of glu-
tathione-S-transferase, sex hormone binding protein and an-
giotensin-converting enzyme, alanine aminotransferase, and
-glutamine transferase were reported in hypothyroid pa-
tients overtreated during T4 replacement therapy, which in-
dicated “tissue thyrotoxicosis” (411, 412). The adverse effects
of this high l-T4 dosage were attributed, in these early stud-
ies, to increased FT4 levels. In subsequent years, highly sen-
sitive TSH assays allowed amore accurate adjustment of l-T4
replacement therapy (413). However, adverse cardiac effects
(shortened interventricular conduction time and PEP) were
reported also in patients with normal free thyroid hormones
but fully suppressed serum TSH (144). This was the first
evidence that TSH suppression was indicative of thyroid
hormone excess in peripheral target tissues (144), and it
prompted studies of the effects of TSH suppressive therapy
on the cardiovascular system.
The cardiovascular risk in patients with exogenous SHy-
per is related to the effects that can occur after brief exposure
to thyroid hormone excess due to the electrophysiological
action of the hormone (4, 414). T3 increases the systolic de-
polarization and diastolic repolarization rate and decreases
the action potential duration and the refractory period of the
atrial myocardium as well as the atrial/ventricular nodal
refractory period (415). Atrial arrhythmias (sinus tachycar-
dia, atrial premature beats, and AF) are frequent complica-
tions of overt hyperthyroidism (121, 122, 136). In an attempt
to evaluate the cardiac effects of SHyper, heart rate was
monitored by 24-h ECG in four studies performed in patients
receiving long-termTSH suppressive doses of l-T4 (390, 416–
418) (Table 13). A significant increase in the average heart
rate, compared with controls, was identified in three studies
of patientswith exogenous SHyper (416–418). In two of these
studies by Biondi et al. (417, 418) serum TSH was undetect-
able (TSH  0.05 mIU/liter) in patients receiving long-term
therapy for benign or malignant disease, whereas TSH was
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suppressed after TRH in the study by Bell et al. (416) of
normal subjects after 24 d of l-T4 administration. TSH was
fully suppressed, and FT4 was at the upper limit of normal
range and was significantly increased vs. the control group
in two of these studies (417, 418). However, in another study
of patients with the same hormonal pattern, the mean heart
rate in exogenous SHyper patients was similar to that re-
corded in euthyroid subjects (390). Moreover, TSH suppres-
sive doses of l-T4 had no effect on 11 patients evaluated by
Ching et al. (419) using ambulatory monitoring of pulse and
blood pressure.
Atrial premature beats were notmore frequent vs. controls
in the patients in the study by Shapiro (390), but symptomatic
patients receiving -adrenergic receptors blockers were ex-
cluded from the cardiac evaluation. In contrast, in two stud-
ies, the prevalence of atrial premature beats was higher in
young and middle-aged patients with exogenous SHyper
than in a control group, and one young patient had a spon-
taneous run of AF (417, 418). Unfortunately, there have been
no other studies of the prevalence of atrial arrhythmias in
young and middle-aged patients with exogenous SHyper.
However, four epidemiological studies showed an increased
prevalence of AF in elderly patients with exogenous and
endogenous SHyper (230, 375, 381, 420). The threshold forAF
decreases with age, and the later diagnosis and coexistence
of ischemic and degenerative heart disease likely predis-
poses elderly individuals to the development of AF in the
presence of mild thyroid hormone excess.
Data on the electrophysiological action induced by l-T4
suppressive therapy suggest that a standard ECG could be
used to identify high-risk patients: those with a short P-R
interval who are predisposed to reentrant atrioventricular
nodal tachycardia (421) and those with higher maximum P
wave duration and P wave dispersion who are predisposed
to AF (422). In predisposed patients (those with two func-
tionally distinct AV nodal conduction patterns), l-T4 therapy
may increase the occurrence of reentrant-atrioventricular
nodal tachycardia because of the enhanced atrial excitability,
which increases the number of atrial premature beats, and
the shortening of the refractory period of the conducting
tissue (421). Moreover, by measuring P maximum and P
wave dispersion values, one could theoretically identify the
patients with SHyper that are at high risk of AF (422). Holter
ECG could be performed before starting l-T4 treatment in
doses that suppress TSH to potentially identify patients who
may be less tolerant to l-T4 treatment.
Long-term SHyper consequent to l-T4 treatment can in-
duce changes in cardiacmorphology and function because of
the increased cardiac workload (417, 418). Chronic hyper-
thyroidism induces cardiac hypertrophy in animal models
(423). The mechanism of this hypertrophy is multifactorial
and involves a direct effect exerted by thyroid hormone on
the heart, indirect effects related to stimulation of the ad-
renergic nervous system or altered left ventricular loading
conditions (increase in cardiac work), and local renin-angio-
tensin system activation (423–425). A significant increase in
the left ventricular mass index (LVMI) has been documented
in almost all studies of patients with exogenous SHyper
compared with controls by Doppler echocardiography (390,
392, 417- 419, 426–428) (Table 14). The LVMI was not sig-
nificantly higher in SHyper patients than in euthyroid con-
trols in the study by Botella-Carretero et al. (429). However,
the absence of significant cardiac structural changes in this
study might be related to the shorter duration (a mean of
approximately 4 yr) of TSH suppressive therapy compared
with previous studies. Importantly, this study was the first
to show that TSH suppressive T4 therapy results in an in-
crease in nighttime systolic and mean blood pressure (429).
Interestingly, the increase in both interventricular septum
and left ventricular posterior wall thickness, and conse-
quently LVMI, was significantly greater in patients with
symptoms and signs of adrenergic overactivity (SRS ex-
ceeded the mean value of the control group by more than 2
TABLE 13. Heart rate in patients with exogenous SHyper
Author No. of patients Method SHyper Heart rate
Bell, 1983 (416)a 7 Holter ECG Suppressed TSH after TRH 1
Biondi, 1993 (417)b 20 Holter ECG 0.05 mIU/liter 1
Biondi, 1999 (418)b 60 Holter ECG 0.05 mIU/liter 1
Shapiro, 1997 (390)b 17 Holter ECG 0.01 mIU/liter 7
Ching, 1996 (419)b 11 Ambulatory monitoring of pulse and blood pressure 0.05 mIU/liter 7
a Results before vs. after L-T4 therapy.
b Results compared to euthyroid controls.
TABLE 14. LVMI in patients with exogenous SHyper in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients LVMI P value TSH (mIU/liter) Duration of L-T4 treatment
Biondi, 1993 (417) 19 1 0.02 0.05 5  2.6 (1–9 yr)
Ching, 1996 (419) 11 1 0.01 0.05 9.6 (3–21 yr)
Shapiro, 1997 (390) 17 1 0.05 0.01 9.2  5.4 (2.9–23 yr)
Biondi, 1999 (418) 60 1 0.001 0.05 1–11 yr
Mercuro, 2000 (392) 23 1 0.01 0.05  0.03 5.7  3.5 (2–20 yr)
Botella-Carretero, 2004 (429) 21 7 0.03  0.03 4 yr (47  54 months)
Gullu, 2004 (426) 12 1 0.01 0.05 2 yr
12 0.1–04 2 yr
Smit, 2005 (427) 25 1 0.1 0.05–0.3 10 yr
Shargorodsky, 2006 (428) 25 1 0.05 0.05–0.3 3–21 yr
TSH values are mean  SD.
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sd) than in less symptomatic patients and normal subjects
(391).
The clinical consequences of increased left ventricular mass
in patients with SHyper remain to be established, although this
increase is a negative prognostic factor for cardiovascular mor-
tality and morbidity in the general population (430). In six
studies, the increase in left ventricularmasswas responsible for
diastolic dysfunction, documented by Doppler echocardiogra-
phy and radionuclide ventriculography (392, 418, 426, 427, 431,
432) (Table 15). Thyroid hormone excess exerts a beneficial
effect on diastolic function. It affects the calcium-regulating
proteins sarcoplasmic reticulum calcium-ATPase and phos-
pholamban, thereby improving myocardial relaxation (120,
121). This beneficial effect of thyroid hormone excess is poten-
tiated in hyperthyroid subjects by the enhanced ventricular
suction effect (the atrial ventricular pressure gradient across the
mitral valve) and the increased -adrenergic stimulation (433).
However, in long-term SHyper, the beneficial effects of thyroid
hormone excess on diastolic function are counteracted by the
concomitant ventricular hypertrophy induced by the chroni-
cally increased cardiac workload (Fig. 2). Indeed, the increase
in the left ventricular mass was found to be significantly cor-
related with late diastolic filling (431).
Three studies investigated physical exercise capacity in
SHyper patients (392, 432, 434). Impaired exercise tolerance
was documented bymeans of cardiopulmonary exercise test-
ing in symptomatic SHyper patients (392). Exercise tolerance,
maximal VO2 achieved at peak exercise, and anaerobic
threshold were significantly reduced in patients receiving
TSH suppressive doses of l-T4. Plasma noradrenaline con-
centrations in patients who underwent the ergometabolic
test were significantly lower in TSH suppressed patients in
both the supine and standing position vs. euthyroid controls
(392). In another study, maximal exercise capacity was
greatly impaired in symptomatic patients with exogenous
SHyper as documented by a significant reduction in peak
workload and exercise durationduring the bicycle ergometer
test (432). Finally, radionuclide ventriculography has shown
that the ejection fraction did not increase during exercise, but
rather fell markedly below baseline in patients undergoing
long-term TSH suppressive therapy (432). In both studies,
there was a pronounced impairment of cardiac functional
reserve and a reduction in physical exercise capacity in pa-
tients receiving TSH suppressive doses of l-T4, which could
impair quality of life (392, 432). In contrast, a recent study
showed that exercise capacity evaluated by treadmill car-
diopulmonary exercise test was not impaired in young and
middle-aged female patients with exogenous SHyper (434).
In conclusion, the cardiovascular effects of exogenous
SHyper are well documented in subjects with undetectable
serum TSH. The major risk is represented by AF in elderly
subjects. However, even in young andmiddle-aged patients,
TSH suppressive doses of l-T4 could impair quality of life by
increasing heart rate and by reducing exercise capacity. Fur-
thermore, long-term TSH suppression may increase the left
ventricular mass. Although the consequences of this increase
remain to be clarified, increased LVMI is a negative prog-
nostic cardiovascular factor in the general population.
2. Cardiovascular effects of mild TSH suppression in exogenous SHy-
per. The serum TSH cutoff point that determines the adverse
cardiac effects of SHyper remains to be established. Mercuro et
al. (392) adjusted the l-T4 dose in SHyper patients so that serum
TSH rose from approximately 0.03 to 0.1 mIU/liter. All echo-
cardiographic and ergometabolic parameters were improved
after 6months of “individual tailoring” of the TSH suppressive
l-T4 dose. Systolic indices were significantly decreased, and
LVMI significantly improved in terms of interventricular sep-
tumand left ventricular posteriorwall thickness.Diastolic func-
tion remained largely unchanged, although isovolumic relax-
ation time decreased. Moreover, l-T4 dose adjustment induced
a significant increase inmaximalworkload andmaximumVO2
at anaerobic threshold. Circulating noradrenaline, measured
when the patient was supine or standing, was not significantly
increased by customized l-T4 doses (392).
Using Doppler echocardiography and the bicycle ergome-
ter test, Gullu et al. (426) recently evaluated the effects of
long-term TSH suppressive therapy (at least 2 yr) on cardiac
function in patients with mild TSH suppression (serum TSH
between 0.1 and 0.4mIU/liter) and in patients with complete
TSH suppression (serum TSH  0.05 mIU/liter). LVMI and
isovolumic relaxation time were higher in patients with un-
detectable serum TSH than in patients with mild TSH sup-
pression. Moreover, basal heart rate and the mean basal
systolic blood pressure were higher in patients with unde-
tectable serum TSH, and the baseline meanmaximal exercise
TABLE 15. Diastolic function in patients with exogenous and endogenous SHyper in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients Causes Method LV diastolic function
Fazio, 1995 (431) 25 Exo Doppler echocardiography 1 IRT, 2 E/A
Biondi, 1996 (432) 10 Exo Radionuclide ventriculography 2 PFR
Shapiro, 1997 (390) 17 Exo Doppler echocardiography 7 E/A
Biondi, 1999 (418) 45 Exo Doppler echocardiography 1 IRT, 2 E/A
Mercuro, 2000 (392) 19 Exo Doppler echocardiography 1 IRT, 7 E/A
Biondi, 2003 (397) 23 Endo Doppler echocardiography 1 IRT, 2 E/A
Petretta, 2001 (435) 30 Endo Doppler echocardiography 7 IRT, 7 E/A
Gullu, 2004 (426) 12 Exo Doppler echocardiography 1 IRT 2 E/A
Sgarbi, 2003 (396) 10 Endo Doppler echocardiography 1 IRT
Smit, 2005 (427) 25 Exo Doppler echo, tissue Doppler 1 IRT, 2 E/A
IRT, Isovolumic relaxation time; PFR, peak filling rate; Exo, exogenous; Endo, endogenous; E/A, early-to-late transmitral peak flow velocity
ratio.
P values for SHyper vs. control subjects: IRT, Mercuro, P  0.05; Fazio and Smit, P  0.001; Biondi 1999, P  0.01; Biondi 2003, P  0.06;
Sgarbi, P  0.08; Gullu, P  0.01. E/A, Fazio and Smit, P  0.001; Biondi 1999, P  0.01; Biondi 2003, P  0.001; Gullu, P 0.01. PFR, Biondi
1996, P  0.005.
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time and the baseline peak workload were also higher in
these patients than in patients with mild TSH suppression.
However, even in patients with mild TSH suppression, the
basal heart rate was higher and LVMI and isovolumic re-
laxation timewere increased vs. an untreated healthy control
group. LVMI was positively correlated with late diastolic
flow velocity and negatively correlated with early diastolic
flow velocity. Moreover, the baselinemeanmaximal exercise
and the baseline peak workload were lower in patients with
mild TSH suppression vs. controls. These results indicate that
adverse cardiac effects may occur even when serum TSH is
mildly suppressed (0.1–0.4 mIU/liter).
A prospective, randomized placebo-controlled study was
carried out in athyreotic subjects with DTC receiving long-
term TSH suppressive therapy (10 yr) to assess the revers-
ibility of the effects of exogenous SHyper on systolic and
diastolic function (427). These low-risk patients were ran-
domized to continue TSH suppressive therapy (target serum
TSH level  0.4 mIU/liter) or to a decreased l-T4 dose to
restore euthyroidism (target serum TSH within the normal
range, 0.4–4.8 mIU/liter). At baseline, LVMI, interventric-
ular septum, and left ventricular posterior wall thickness
were higher in DTC patients than in controls, and four pa-
tients had left ventricular hypertrophy. Left ventricular ejec-
tion fraction and fractional shorteningwere lower in patients
than in controls, and, diastolic dysfunction was documented
in DTC patients by Doppler echocardiography and tissue
Doppler imaging. After 6 months, in the euthyroid group,
LVMI had not improved, whereas left ventricular ejection
fraction, fractional shortening, left ventricular end diastolic
dimensions, and diastolic function had. No change was ob-
served in the low TSH group. The results of this study in-
dicate that diastolic dysfunction due to long-term exogenous
SHyper is reversible when euthyroidism is restored.
In conclusion, prospective studies are needed to clarify
further the cardiovascular effects of mild TSH suppression
induced by l-T4. However, the available data support the
hypothesis that the negative effects of complete TSH sup-
pression are partly reversible by reducing the l-T4 dosage.
Studies with a longer follow-up can clarify whether these
negative effects are fully reversible. The target serum TSH
that will minimize negative cardiovascular effects remains to
be established.
3. Cardiovascular effects of endogenous SHyper. The cardiovas-
cular effects of endogenous SHyper are similar to those re-
ported in exogenous SHyper. Five studies have evaluated the
cardiovascular effects of stable endogenous SHyper using
ECG and Doppler echocardiography (396, 397, 435–437). An
increase in the average heart rate was found in three studies
in which serum TSH was undetectable (396, 397, 435) (Table
16). Biondi et al. (397) reported a higher prevalence of atrial
premature beats in patientswith endogenous SHyper than in
controls, although the difference was not significant. On the
other hand, Sgarbi et al. (396) reported a significant increase
in atrial and ventricular premature beats in patients with
endogenous SHyper. They also found that TSH and FT4
levels correlated significantly with atrial and ventricular pre-
mature beats (396). However, in a study of patients with
SHyper and detectable serumTSH,Holter ECGdid not dem-
onstrate differences in mean, minimal, and maximal heart
rate between patientswith endogenous SHyper due tomulti-
nodular goiter with serumTSHbelow 0.4mIU/liter or above
0.4 mIU/liter and controls (436). Moreover, the frequency of
atrial or ventricular premature beats did not differ among the
groups studied. In another study, heart rate variability was
analyzed to characterize autonomic control in patients with
subclinical and overt hyperthyroidism (435). “Heart rate
variability” has become the conventionally accepted term to
describe variations of both instantaneous heart rate and RR
intervals. In this study, the variations in heart rate were
evaluated by the time domainmeasures (435). The procedure
entails measurement of either the heart rate at any point in
time or the intervals between successive normal complexes.
In a continuous ECG record, each QRS complex is detected,
and the so-called normal-to-normal (NN) interval (that is, all
intervals between adjacent QRS complexes resulting from
sinus node depolarizations) or the instantaneous heart rate
is determined. This study showed that average NN intervals
and all time and frequency domain measures decreased pro-
gressively from normal individuals to patients with endog-
enous SHyper and to patients with overt disease (P 0.001).
These data demonstrate a reduction in cardiac vagal control
in SHyper—a finding that may have important clinical im-
plications, because reduced heart rate variabilitymay predict
an increased risk for subsequent cardiac events in the general
population (437).
Four studies have evaluated Doppler echocardiography
findings in patients with endogenous SHyper (396, 397, 435,
438), and an increase in left ventricular mass was found in
three studies (396, 397, 438) (Table 17). In the study by Tamer
et al. (438), mild or moderately hypertensive patients with
endogenous SHyper had a greater increase in left ventricular
mass compared with mild or moderately hypertensive sub-
jects without SHyper, which suggests that persistent SHyper
may further increase the cardiovascular risk associated with
hypertension. An increase in left ventricular mass was not
found in one study (435), and altered diastolic function was
found in two studies (396, 397) (Table 15).
In a recent population-based study involving 1510 indi-
viduals aged 45–79 yr in Pomerania (439), SHyper was not
TABLE 16. Heart rate (HR) in patients with endogenous SHyper in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients Methods HR TSH(mIU/liter)
Biondi, 2003 (397) 23 Holter ECG 1 0.16  0.11
Petretta, 2001 (435) 30 HRV HRV2 0.05  0.07
Sgarbi, 2003 (396) 10 Holter ECG 1 0.05  0.03
Berghout, 2003 (436) 26 Holter ECG 7 0.6  0.4
TSH values are mean  SD. HRV, Heart rate variability.
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associated with left ventricular hypertrophy, whereas a pos-
itive association was found between overt hyperthyroidism
and left ventricular hypertrophy. Logistic regression analysis
showed that hyperthyroidism was an independent risk fac-
tor for left ventricular hypertrophy. However, this popula-
tion-based study did not examine patients with known thy-
roid disorders, who were excluded from the evaluation. On
this basis, the subjects with decreased TSH levels that were
identified may correspond to individuals with an earlier
stage of SHyper (439).
In the population-based health study carried out in Po-
merania, the analysis of data from 2086 individuals at least
45 yr oldwith carotid ultrasound andwithout known thyroid
disorders revealed a linear relationship between thyroid
function and CIMT (440). Subjects with decreased serum
TSH levels and overt hyperthyroid individuals had higher
IMT values than subjects with elevated serum TSH levels.
This relationship remained statistically significant after ap-
propriate adjustment for known IMT risk factors. Moreover,
subjects with low serum TSH levels had higher IMT values
than subjects with serum TSH levels within the second and
the third quartile of TSH distribution. It was suggested that
the increase in IMT in the common carotid artery was related
to medial hypertrophy rather than to true intimal athero-
sclerosis. In another study, no difference was found in flow-
mediated dilatation in SHyper vs. euthyroid subjects (441).
Finally, in the population-based study of health in Pome-
rania that included 4310 subjects aged 20–79 yr, thyroid
function status was found to be associated with plasma fi-
brinogen concentration (442), and decreased serum TSHwas
an independent risk factor for elevated plasma fibrinogen
levels. Increased factor X activity was recently found in pa-
tients with SHyper, but it is unknown whether the increased
factor X levels in the range reported could induce a hyper-
coagulable state (443). This situation might be particularly
dangerous in subjects with SHyper who are more prone to
develop AF because of the increased risk of embolic events.
In conclusion, some important cardiovascular risk factors
could be associated with endogenous SHyper: increased
heart rate, increased risk for atrial arrhythmias, reduced
heart rate variability, and increased left ventricular mass. It
remains to be established whether these cardiovascular risks
could be responsible for the increased cardiovascular mor-
tality reported in some studies. Additional studies are re-
quired to determine whether these cardiovascular risk fac-
tors can be reversed by appropriate treatment.
4. Epidemiological cardiovascular studies. Cardiovascular mor-
bidity and mortality in patients with exogenous and endog-
enous SHyper have been investigated in several epidemio-
logical studies (Table 18). The first study was carried out in
1990. Twenty-nine women treated with l-T4 from one to 28
yr were identified from among a Swedish population of 1462
middle-aged women and were investigated for the risk of
myocardial infarction, diabetes mellitus, stroke, cancer, and
death (444). The 12-yr follow-up of this small number of
patients treated with l-T4 in 1968 and 1969 did not indicate
any increase in morbidity or mortality. However, the results
of this study should be viewed in the light of the heteroge-
neity of the patients receiving l-T4 (seven patients for spon-
taneous hypothyroidism, five for euthyroid nodular goiter
after surgery, five after surgery for thyrotoxicosis, five for
euthyroid goiter, and two for other indications). Moreover,
although FT3 was defined as being in the normal range, data
about FT4 values and the degree of TSH suppression were
not reported.
In 1992, Leese et al. (445) examined 1180 patients aged 38
to 60 yr on l-T4 replacement therapy who were recalled for
clinical and biochemical assessment. Ninety percent were
female, 75% of these were over 50 yr of age, and 40% were
over 65 yr of age; 51% were originally thyrotoxic, and 49%
had primary hypothyroidism. Patients on l-T4 with sup-
pressed TSH (0.05 mIU/liter; 59%) were compared with
those in whom TSH was detectable (0.05–4.0 mIU/liter;
38%). Overall hospital admission rates of l-T4-treated pa-
tients were identical in those with normal serum TSH (48%)
and those with suppressed serum TSH (47%). Although pa-
tients under the age of 55 yr on l-T4 had an increased risk of
ischemic heart disease compared with the general popula-
tion, this risk did not differ between women with fully
suppressed TSH and those with TSH between 0.05 and
4.0 mIU/liter.
Various studies have identified an increased risk of AF in
older patients with SHyper (230, 375, 381, 420). Tenerz et al.
(381) reported the results of a 2-yr follow-up investigation
that included 40 patients with subclinical thyrotoxicosis and
40 euthyroid control subjects. Twelve (30%) of the patients
but none of the individuals in the control group were treated
during the follow-up period for clinical thyroid disease. AF
was found in 11 (28%) patients compared with four (10%) of
the controls. Patients with endogenous SHyper, defined by
a TSH serum level below 0.1mIU/liter (mean age, 65 yr), had
a 2.8-fold increased risk of AF over 2 yr compared with
aged-matched euthyroid controls.
In a prospective study, 2007 people 60 yr or older who did
not have AF at the start of the study were examined to
determine the frequency of this arrhythmia during a 10-yr
follow-up period (375). Subjects were classified according to
their serum TSH concentration: low values (0.1 mIU/liter;
TABLE 17. LVMI in patients with endogenous SHyper in comparison with euthyroid control individuals
First author, year (Ref.) No. of patients Methods LVMI P vs. controls TSH (mIU/liter)
Biondi, 2003 (397) 23 Doppler echo 1 0.001 0.16  0.11
Petretta, 2001 (435)a 30 Doppler echo 7 0.05  0.07
Sgarbi, 2003 (396) 10 Doppler echo 1 0.02 0.05  0.03
Tamer, 2005 (438)b 16 Doppler echo 1 0.01 0.15  0.1
TSH values are mean  SD.
a 6 Grave’s disease, 14 thyroid autonomy, 10 multimodular goiter.
b Hypertensive patients with endogenous SHyper.
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61 subjects), slightly low values ( 0.1 to 0.4 mIU/liter; 187
subjects), normal values (0.4 to 5.0 mIU/liter; 1576 sub-
jects), and high values (5 mIU/liter; 183 subjects). During
the 10-yr follow-up, 192 subjects (10%) developed AF. The
cumulative incidence of AF at 10 yr among subjects with a
low TSH was 28% vs. 11% among those with normal TSH
(P  0.005). The incidence of AF did not differ between
subjects with a slightly low TSH and the normal TSH group
(16 vs. 15%). After adjustment for other known risk factors,
the relative risk forAFwas 3.1 for subjectswith lowTSH (P
0.001) and 1.6 for those with slightly low TSH (P  0.05) vs.
those with normal TSH. There was no increased mortality
associated with SHyper over the course of 10 yr.
Auer et al. (420) carried out a retrospective study of 23,638
subjects to evaluate the risk of AF in overt and subclinical
hyperthyroidism. The evaluation was performed on 1338
consecutive patients with low TSH (85% with functional
thyroid autonomy, 15% with Graves’ disease), of whom 725
patients had overt hyperthyroidism and 613 had SHyper
(TSH  0.4 mIU/liter). The pool of patients comprised all
consecutive patients referred for thyroid function testing for
different reasons (screening, suspected thyroid disease, con-
comitant disease). The control group consisted of 22,300 eu-
thyroid people at least 45 yr old who were admitted to the
institution between 1989 and 1994. AF was present in 2.3%
of people with normal thyroid function, in 13.8% of patients
with overt hyperthyroidism, and in 12.7% of patients with
SHyper. A low serumTSHwas associatedwith a greater than
5-fold higher likelihood of AF, with no significant difference
between overt and SHyper patients. Although the patients in
this study had a high prevalence of underlying heart disease
(coronary artery disease, dilated cardiomyopathy, valvular
heart disease, or a combination of these), when the results
were adjusted for age and for the presence of other known
risk factors for AF (hypertension, left ventricular hypertro-
phy, and underlying heart disease), the relative risk of AF in
subjects with SHyper remained significantly different (P 
0.01) from those with normal serum TSH (relative risk, 2.8).
A recent study by Cappola et al. (230) confirmed these data
on the risk of AF in SHyper patients. They evaluated 496
patients with a mean age of 73 yr (15% of the study popu-
lation) with SHyper (mean age, 72.7 yr) and 2639 subjects
(82%) with normal thyroid function to determine the rela-
tionship between baseline thyroid status and incident AF,
cardiovascular disease, and mortality. SHyper was defined
as a serumTSHconcentration of 0.10–0.44mIU/liter (n 40)
or less than 0.10 mIU/liter with a normal FT4 concentration
(n  7). During a 13-yr follow-up, the incidence of AF was
greater in individuals with SHyper than in the euthyroid
group, with 67 vs. 31 events per 1000 person-years (P 
0.001). After adjustment for age, sex, clinical cardiovascular
disease at baseline, subsequent medication use, and other
known risk factors for AF, subjects with SHyper had nearly
twice the risk of developing AF. The incidence rate of AF in
the subgroup of patients with a serum TSH concentration
between 0.1 and 0.44mIU/liter was 59 per 1000 person-years
(P  0.007 vs. the euthyroid group). Mortality was signifi-
cantly higher in patientswith SHyper (58.1 vs. 34.2 events per
1000 person-years; P  0.02), which disappeared after ad-
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clinical cardiovascular conditions were observed in this
study.
Parle et al. (229) carried out a community-based review of
subjects with SHyper monitored for 10 yr to define the car-
diovascular risk associated with endogenous subclinical dis-
ease. A total of 1191 subjects age 60 and older who were not
receiving T4 therapy or antithyroid medication were evalu-
ated. Serum TSH was measured at baseline in 1988–89. At
the time of blood sampling, 70 individuals had SHyper, of
whom 69 were in sinus rhythm and one had AF. Causes of
death were identified for subjects who died after the fol-
low-up and were compared with age, gender, and specific
data for England and Wales. All-cause mortality was found
to be significantly increased 2, 3, 4, and 5 yr after initial
measurement in subjectswith low serumTSHconcentrations
(0.5 mIU/liter; n  71) compared with the expected mor-
tality for the control population. The increase in all-cause
mortality was due to a significant increase in mortality be-
cause of circulatory diseases and, specifically, cardiovascular
diseases. There was no significant difference in survival be-
tween subjects with serum TSH 0.1–0.4 mIU/liter vs. serum
TSH less than 0.1 mIU/liter. Although the underlying cause
of the reduced TSH value was not investigated in this cohort,
certain findings support the hypothesis that the low TSH
concentration was due to true endogenous mild SHyper
rather than to such other causes as drug treatment or non-
thyroidal illnesses (446). For example, the mean serum con-
centration of free thyroid hormone was inversely related to
serum TSH in this cohort. Moreover, many patients had
clinical features of thyroid disease, e.g., goiter. Furthermore,
common causes of death, other than vascular causes, were
not associated with low serum TSH, which would be ex-
pected if serum TSH were a nonspecific reflection of other
illnesses (446).
In the study by Gussekloo et al. (92) of a cohort of subjects
over age 85 yr, increased cardiovascular mortality was ob-
served during 4 yr of follow-up in 17 subjects with low levels
of TSH at baseline evaluation.Moreover, higher levels of FT4
were associated with an increased risk of cardiovascular and
noncardiovascular mortality (92). van den Beld et al. (314)
also reported that higher FT4 levels within the normal range
(independent of TSH levels) were associated with a higher
risk of 4-yr mortality in subjects aged 73 to 94 yr. However,
in this study, 444 subclinically hyperthyroid subjects did not
have a higher 4-yr mortality than euthyroid subjects. Finally,
Walsh et al. (38) recently assessed the risk for cardiovascular
disease in SCTD in 2108 subjects during a 20-yr follow-up.
SHyperwas defined as a serumTSH serum level of 0.02–0.40
mIU/liter and was found in 39 patients (prevalence, 1.8%),
whose mean age was 51.3  14.9 yr. Subjects with SHyper
had no adverse outcomes and no evidence of increased car-
diovascular risk. There was no significant increase of coro-
nary heart disease events in the group of subjects with SHy-
per or in the subgroups with TSH less than 0.1 mIU/liter and
between 0.1 and 0.4 mIU/liter. These results are in contrast
to those reported in older patients by Parle et al. (229). Un-
fortunately, AF was not evaluated in this study.
In conclusion, conflicting results emerge from epidemio-
logical studies on cardiovascular mortality in SHyper. Sim-
ilar to the studies performed in SHypo patients, subjects in
studies of SHyper differ with respect to the etiology of con-
dition (exogenous or endogenous), age and sex, disease du-
ration, and duration of follow-up. Very few analyses were
adjusted for age, sex, and race. Some patients may have
progressed to overt disease during the follow-up, and this is
particularly true for studies in which only one serum TSH
evaluation was performed at baseline evaluation. Moreover,
some studies evaluated TSH alone without concomitant thy-
roid hormone assessment, so that overt hyperthyroidism
cannot be ruled out. Nevertheless, the evidence strongly
indicates that there is a higher risk of AF in elderly persons
with SHyper, and it supports the concept that treatment
should be considered in this group.
I. Subclinical hyperthyroidism and bone and mineral
metabolism
Thyroid hormone excess is associated with accelerated
bone remodeling, thereby leading to a negative calcium bal-
ance and a net bone loss (447, 448). Overt hyperthyroidism
is an important risk factor for osteoporosis and fractures (449,
450). It is still a matter of debate whether persistent SHyper
can affect bone metabolism and increase the risk of fractures.
In experimental animals, T4 excess caused osteopenia, which
is more pronounced in cortical bone than in trabecular bone
(451). Conflicting results have been reported concerning the
serum concentration of osteocalcin, a marker of bone for-
mation, in both endogenous and exogenous SHyper (452-
458). A weak negative correlation was seen between serum
TSHand serum levels of osteocalcin in three studies (452, 456,
458). Elevated urinary excretion of bone collagen, urinary
pyridinoline cross-links, and hydroxyproline was reported
in postmenopausal women with SHyper (459), and telopep-
tide type I, a marker of bone resorption, was slightly but
significantly increased in patients with SHyper (460).
Thyroid hormones affect bone remodeling in patients with
thyroid disease by acting directly or indirectly on osteoclast
activity. TSH may also affect skeletal remodeling by inter-
acting with the specific receptors expressed on bone cells
(461). In experimental animals, the reduced expression of the
TSH receptor leads to the development of osteoporosis,
which raises the possibility that the effect of TSH suppression
on bone turnover could be mediated by TSH deficiency
rather than by thyroid hormone excess (461). Although the
osteoporosis associated with hyperthyroidism is tradition-
ally viewed as a secondary consequence of altered thyroid
function, these data provide experimental evidence that TSH
directly affects both osteoblastic bone formation and oste-
oclastic bone resorption.
The effects of exogenous and endogenous SHyper on BMD
and the risk of fractures in pre- and postmenopausal women
have been widely studied. However, it should be stressed
that the criteria used to select patients and controls were not
very stringent in the early studies. Similarly, techniques
that accurately measure BMD have only recently become
available.
1. Effects of exogenous SHyper on BMD. Studies of the effects
of thyroid hormone suppressive therapy in premenopausal
women have yielded conflicting results. Early cross-sectional
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studies of bone resorption in premenopausalwomen showed
reduced bone density in the femoral neck and forearm but
not of the lumbar spine as measured by single-photon ab-
sorptiometry and dual-photon absorptiometry (462–465).
However, at that time, high doses of l-T4 or T3 were used to
suppress TSH, leading to iatrogenic hyperthyroidism and
not SHyper in many instances. In addition, patients with a
history of hyperthyroidism were included in the evaluation
of BMD. In subsequent cross-sectional studies, l-T4 did not
have significant adverse effects on bone in men (466–468) or
in premenopausal women (467–477). Over the last 15–20 yr,
lower l-T4 doses have been used to obtain mild TSH sup-
pression, especially in patients with benign thyroid disease.
This could explain the differences in BMD data between
earlier and more recent studies and suggest that a lesser
degree of TSH suppression can minimize the risk of
osteoporosis.
Longitudinal studies of premenopausal women receiving
suppressive doses of l-T4 report a decrease in BMD of the
spine or forearm (478–480) or no significant adverse effects
on bone (481, 482). The different durations of follow-up in
these longitudinal studies could account for the conflicting
findings. Similarly, conflicting data have been reported for
postmenopausal women with SHyper. BMD was decreased
in postmenopausal women with exogenous SHyper in sev-
eral cross-sectional (483–488) and longitudinal studies (481,
489). However, exogenous SHyper had no significant ad-
verse effects on BMD in postmenopausal women in other
cross-sectional (467, 468, 470–472) and longitudinal (456, 481,
490, 491) studies.
Two meta-analyses of patients with exogenous SHyper
(combining 13 and 41 cross-sectional studies, respectively),
assessed the effects of l-T4 suppressive therapy in pre- and
postmenopausal women (492, 493). In neither studywas l-T4
therapy shown to adversely affect BMD in premenopausal
women. However, in postmenopausal women, there was a
loss of 0.77–1.39% in bone mineral per year, which was a
significant reduction compared with controls (492). More-
over, there was an excess annual loss of 0.91% per year after
9.9 yr in postmenopausal women compared with normal
controls (493). Cortical bone was more affected than trabec-
ular bone.
The effects of TSH suppression on BMD are controversial
in patients with DTC (494–495). The effects of TSH suppres-
sion may be more pronounced in patients with DTC because
they undergo constant and long-term TSH suppression. In a
recent overview (494), it was found that there was no change
or only a small decrease in BMD as a result of long-term TSH
suppressive therapy (mean, 7.1 yr in eight trials) in pre-
menopausal women with DTC. However, the findings for
postmenopausalwomen remain unclear, with two of the best
controlled studies reporting opposing results (467, 489).
However, dietary calcium intake differed in the two studies,
being higher in the study by Franklyn et al. (467). In contrast,
a recent cross-sectional study of 66 DTC patients in pre- and
postmenopausal status showed that 28 postmenopausal pa-
tients had higher values of the C-telopeptide of type 1 col-
lagen and bone alkaline phosphatase and lower BMD values
than healthy subjects (496).
Heemstra et al. (495) recently examined 21 studies of pa-
tients with DTC receiving long-term TSH suppressive ther-
apy; the studies were stratified according to gender and
menopausal status. The results showed that TSH suppressive
therapy did not affect BMD in men or in premenopausal
women, whereas postmenopausal patients were at risk of
bone loss.
Conflicting data have also been reported in longitudinal
studies (480, 490–491). A bone loss of 6.7% in the hip after
2 yr of follow-up was also found in the study by Kung and
Yeung (497) of 15 postmenopausal women with DTC. How-
ever, in one study, long-term TSH suppressive therapy in 59
patients with DTC did not result in reduced BMD of the hip
in pre- and postmenopausal women, or in men (498). BMD,
expressed as Z score,was not correlatedwith duration of l-T4
therapy, and even in patients who had undergone suppres-
sive therapy for more 10 yr there was no significant decrease
in BMD.Moreover, long-term TSH suppressive therapywith
l-T4 (12 5 yr) did not affect skeletal integrity in 88 pre- and
postmenopausal women with DTC in another study by Re-
verter et al. (499).
In conclusion, TSH suppression induced by l-T4 therapy
probably does not affect BMD in premenopausal women or
men, although conflicting findingswere obtained concerning
patients with DTC. In postmenopausal patients, l-T4 may
accelerate bone turnover, depending on the degree of serum
TSH suppression and dietary calcium intake.
2. Effects of endogenous SHyper on BMD. Data about BMD in
patients with endogenous SHyper differ from study to study
(454, 455, 500–505). Three studies found that endogenous
SHyper did not affect BMD in premenopausal patients (454,
455, 500). In contrast, in two studies of postmenopausal
women, forearm bone density was decreased (501, 502). In a
case-control study of 37 pre- and postmenopausal women
with SHyper, the bone densities of the lumbar spine, femoral
neck, and the midshaft of the radius were not significantly
decreased in premenopausal patients with endogenous SHy-
per due to solitary AFTN. However, decreased BMD was
observed in postmenopausal women (503). Sites rich in cor-
tical bone were preferentially affected. Kumeda et al. (504)
assessed bone metabolism in 19 premenopausal patients
with SHyper due to Graves’ disease vs. 30 premenopausal
Graves’ disease patientswith normal serumTSH levels. Con-
centrations of serum and urine bone turnover markers were
significantly higher in patients with persistent TSH suppres-
sion than in women with normal serum TSH values, which
suggests that it may be important to achieve normalization
of TSH levels during antithyroid therapy so as to normalize
bone turnover. In a study in men, BMD was reduced, and
levels of osteocalcin and alkaline phosphatase were in-
creased in 49 patients, 32 with recent onset overt and SHyper
due to Graves’ disease, and 17 receiving TSH suppressive
therapy when compared with treated (but euthyroid)
Graves’ patients, confirming the data reported for women
(505).
In conclusion, the effects of endogenous SHyper are likely
influenced by the duration of the disease and associated risk
factors for bone loss (4). The major problem in assessing the
adverse skeletal effects of endogenous SHyper is the diffi-
culty in establishing disease duration. Thus, studies carried
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out to evaluate BMD may have compared patients who had
different disease durations. Although only a few studies
have been performed and the numbers of patients with en-
dogenous SHyper were small, the results support the hy-
pothesis that SHyper can cause reduced BMD, particularly in
cortical bone.
3. SHyper and risk of fractures. Few studies have evaluated
whether SHyper increases the risk of fractures. Solomon et al.
(506) interviewed 300 white postmenopausal women (160
with thyroid disease and 140 without thyroid disease) to
investigate whether having thyroid disease or taking thyroid
hormone increased the prevalence of having a hip, vertebral,
or forearm fracture. Thirty-seven (23%) women with thyroid
disease and 45 (32%) women without thyroid disease had a
fracture. There were no significant differences between these
groups in the number or type of fractures.Moreover, the dose
of thyroid hormone and duration of therapy or disease did
not affect fracture occurrence inwomenwith thyroid disease.
However, womenwith a history of hyperthyroidism (9 of 32)
or thyroid cancer (2 of 11) appeared to have their first fracture
earlier (P 0.01) than women without thyroid disease (506).
Three studies have evaluated the risk of fracture in pa-
tients with low serum TSH. In a study of 1180 patients re-
ceiving l-T4 (ofwhom59%had a lowTSH concentration), the
overall fracture rate after 5 yr was 2.5% in women over age
65 yr with a low TSH concentration and 0.9% in those with
normal TSH values; the difference was not significant (445).
Sheppard et al. (507) conducted a population-based, case-
control analysis of the risk of a femoral fracture in a large
cohort of patients from the United Kingdom who had been
prescribed l-T4. No association between fracture and l-T4
prescription was found. Femoral fracture was significantly
associated with l-T4 therapy in males, but not in women,
after correction for other confounding risk factors. However,
this study did not evaluate patientswith lowTSH vs. patients
with normal TSH (507). Bauer et al. (508), in a prospective
cohort studywith case-cohort sampling, evaluated the risk of
fractures in 686 women older than 65 yr with low serum TSH
from a cohort of 9704 women recruited between 1986 and
1988 from the population-based listings at four clinical cen-
ters. The study included women with exogenous and en-
dogenous SHyper. After adjustment for age, history of hy-
perthyroidism, and use of estrogen and thyroid hormone,
women with a serum TSH level of 0.1 mIU/liter or less had
a 3-fold increased risk of hip fracture and a 4-fold increased
risk of vertebral fracture compared with women who had
normal serum TSH levels. Women receiving l-T4 doses to
maintain TSH in the range of 0.1–0.5 mIU/liter did have an
increased risk of fracture. However, data on FT4 or FT3 levels
in the populationwere not reported. Therefore, it is unknown
whether the patients with low serum TSH levels had SHyper
or more severe hyperthyroidism.
In conclusion, confounding factors may have affected the
results of studies about fracture risk in SHyper. Moreover, in
some studies, patients with overt disease were included in
the evaluation. It remains to be clarified whether or not a risk
of fracture is associated with SHyper and, should this be the
case, to be determined at which serum TSH level this risk
occurs.
J. Effects of treatment
1. Effect of treatment on quality of life. Few studies have eval-
uated whether treatment of exogenous or endogenous SHy-
per improves quality of life and thyrotoxic symptoms. An
improvement in quality of life was identified bymeans of the
SRS after the addition of a beta-blocking drug to l-T4 treat-
ment in 11 patients with symptoms and signs of adrenergic
overactivity (391). The SRS significantly decreased from
11.1  5 to 5.4  3 after 6 months of bisoprolol treatment.
Individual titration of the l-T4 dose to the minimal amount
able to keep serumTSH concentration at 0.1mIU/liter or less
in seven symptomatic patients with exogenous SHyper was
associated with a significant improvement in the thyrotoxic
score 6 months after the initial evaluation (from 12. 8  2 to
9.9  3; P  0.005). However, although the symptom score
improved in treated patients, it still differed significantly vs.
controls (9.2  3 vs. 5.3  3) (392). Moreover, the Wayne
clinical index was significantly reduced in 10 patients with
endogenous SHyper who had reached the euthyroid state
after methimazole treatment (396).
Quality of life was recently evaluated in 24 subjects with
DTC receiving long-term TSH suppressive therapy to deter-
mine the effects of restoration of euthyroidism (509). The
study was a prospective, single-blinded randomized con-
trolled study of 6-month duration with two parallel groups.
After inclusion, patients were randomized to continue TSH
suppressive therapy (low-TSH groupwith target serum TSH
level  0.4 mIU/liter) or restoration of euthyroidism by
decreasing the l-T4 dose (euthyroid group target serum TSH
levels within the normal reference range, 0.4–4.8 mIU/liter).
At baseline, the somatic disorder questionnaire showed
greater somatic dysfunction in patients with DTC, whereas
depression was less than in the reference group. All other
quality of life parameters were normal. After 6 months, none
of the quality of life parameters in the low TSH group dif-
fered from baseline values. In the euthyroid group, motiva-
tion was significantly improved, and there was no improve-
ment in somatic disorder questionnaire score. This study
suggests that quality of life is preserved in patients with
DTC, with no further improvement after restoration of
euthyroidism.
In conclusion, a lesser degree of TSH suppression may
improve quality of life in exogenous SHyper (392), and beta-
blocking drugs can be useful in patients complaining of
symptoms and signs of adrenergic overactivity (391). Anti-
thyroid drugs have been reported to improve quality of life
in patients affected by endogenous SHyper (396); however,
this finding should be verified in other studies.
2. Is it possible to reduce the cardiovascular risk induced by ex-
ogenous SHyper? The addition of propranolol to T4 prevented
both the increased heart rate and the hypertrophic response
in hyperthyroid rats (510). In patients with exogenous
SHyper, the administration of a beta-blocking drug reduced
the increased heart rate and left ventricular mass, thereby
improving diastolic and systolic function during exercise
(391, 431, 432). In the first of these studies, bisopropol, a
cardioselective beta-blocking drug with a long half-life, was
added to l-T4 suppressive therapy (TSH 0.05 mIU/liter) in
11 patients affected by palpitations, increased heart rate, and
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other symptoms mimicking exaggerated -adrenergic activ-
ity (391). The addition of bisoprolol to l-T4 suppressive ther-
apy produced normalization of heart rate and disappearance
of atrial arrhythmias. After 6 months of l-T4 plus bisoprolol
therapy, the LVMI normalized, the indices of left ventricular
systolic function were reduced, and there was a tendency to
normalization. Also diastolic dysfunction, cardiac perfor-
mance, and exercise tolerance were significantly improved
by adrenergic beta-blockade (431, 432).
In a study by Gullu et al. (426), atenolol at a dosage of 50
mg/d for 3months was given to patients receivingmild TSH
suppressive therapy (TSH 0.1–04 mIU/liter). There was no
statistically significant improvement in LVMI and diastolic
function after atenolol therapy. However, both the mean
maximal exercise time and peak workload increased during
-adrenergic blockade. This study confirms that beta-block-
ade improves cardiac function in patients with mild TSH
suppression even after short-term administration of a beta-
blocker. Both of these studies support the idea that -adren-
ergic blocking drugs should reduce the cardiovascular risk,
and thus they might be considered for patients requiring
long-term TSH suppressive therapy, especially symptomatic
patients with high-risk thyroid cancer in which more ag-
gressive TSH suppression may be required.
3. Is it possible to reduce the cardiovascular risk induced by en-
dogenous SHyper? Two studies have assessed the cardiovas-
cular effects of normalization of serum TSH concentration in
patients with endogenous SHyper after antithyroid drugs
and radioiodine, respectively (396, 511). Ten patients, me-
dian age 59 yr, were reevaluated byHolter ECG andDoppler
echocardiography after 6 months of methimazole treatment
with a median dose of 20 mg/d to achieve stable euthyroid-
ism (396). Heart rate and the number of atrial and ventricular
premature beatswere significantly reducedwhen euthyroid-
ism was reached and were similar to those recorded in eu-
thyroid controls. The LVMI was significantly reduced after
methimazole treatment, and it became similar to that of the
control group. The thyrotoxic symptom score improved after
therapy, although it remained significantly higher in SHyper
patients than controls (396). In another study, radioiodine
treatment given to normalize serum TSH in six subclinical
hyperthyroidwomenwithmultinodular goiter resulted in an
11% reduction in heart rate, a 19% reduction in cardiac out-
put, and a concomitant 30% increase in SVR, although cat-
echolamine concentrations did not change (511). However,
the study lacked a control population. These two investiga-
tions show that treatment of endogenous SHyper improves
cardiovascular parameters, which could be responsible for
the increased cardiovascular risk that is present in older
SHyper patients. Moreover, treatment of SHyper induced
spontaneous reversion of AF to sinus rhythm in four patients
(512). This supports the hypothesis that prompt restoration
of euthyroidism might induce spontaneous reversion or fa-
cilitate cardioversion of AF to sinus rhythm (512). However,
no long-term prospective controlled trials have been con-
ducted to see whether chronic treatment to normalize serum
TSH levels or treatment with beta-blockers could reduce the
risk of AF and other adverse cardiovascular events.
4. Effects of treatment on BMD. Treatment of benign (469, 487)
andmalignant thyroid disease (468, 497) with l-T4 doses that
induce mild TSH suppression did not significantly affect
BMD and was not associated with a risk for osteoporosis in
pre- and postmenopausal patients. Moreover, in postmeno-
pausal women with exogenous SHyper, bone turnover was
related to the serum TSH level, and a reduction of l-T4 dose
reduced bone turnover, thereby increasing BMD (497).
Calcium supplementation was able to prevent bone loss
in postmenopausal patients with exogenous SHyper with
inadequate calcium intake (497). A similar effect was ob-
tained in a study of estrogen replacement therapy in which
196 women taking thyroid hormone for a mean of 20.4 yr
were compared with 795 women not using thyroid hor-
mone (485). Although TSH values were not reported in this
study, it showed that women taking both estrogen and
thyroid hormone at a dose of 1.6 g/kg or greater had a
significantly higher BMD than women taking the same
l-T4 dosage alone (485). Furthermore, the BMD of women
taking estrogen and T4 was comparable to the BMD ob-
served in women taking only estrogen. These results show
that estrogens can prevent the bone loss induced by sup-
pressive doses of l-T4 in postmenopausal women. This
would be beneficial for postmenopausal women with
high-risk DTC who have no contraindications to estrogen
replacement therapy. Finally, pamidronate, a bisphospho-
nate, was able to prevent the increased bone turnover
caused by thyroid hormone (490).
Successful treatment of overt hyperthyroidism produces a
significant increase in BMD (513, 514). Few studies have
evaluated BMD in endogenous SHyper after normalization
of serum TSH by radioiodine treatment or antithyroid drugs
(501, 502). In one study, 16 postmenopausal women with
SHyper due to multinodular goiter underwent radioiodine
treatment because of compressive symptoms, whereas 12
asymptomatic postmenopausal women with SHyper re-
mained untreated. After 2 yr of follow-up, BMD remained
stable in the spine in the treated group, whereas progressive
bone loss occurred in the untreated group. In another study,
BMD in the hip increased significantly after 2 yr in the treated
group but decreased in the untreated group (501). Similarly,
postmenopausal women with SHyper were prospectively
monitored for 2 yr. Eight patients were treated with me-
thimazole to achieve euthyroidism and eight remained un-
treated. At the end of follow-up, distal forearm BMD was
stable and significantly increased in the treated group com-
pared with the untreated group (502). However, in a small
randomized study of premenopausal women, BMD at base-
line was slightly but not significantly different from age-
matched controls and did not improve after 6 months of
euthyroidism (515).
In conclusion, randomized prospective trials of large
groups of patients are necessary to clarify the possible ben-
eficial effects of treatment with antithyroid drugs or radio-
iodine on BMD in young and middle-aged patients with
endogenous SHyper. The available data support the concept
that treatment of postmenopausal women with SHyper will
be of benefit in terms of improved skeletal health.
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K. Treatment guidelines
1. Optimal TSH target for benign andmalignant thyroid disorders.
Of course, there is no reason to suppress TSH in patientswith
hypothyroidism who need replacement therapy; the goal of
treatment is to maintain TSH in the normal range, and thy-
roid function should be periodically assessed to avoid under-
or overtreatment.
TSH suppressive therapy in the management of patients
with nontoxic solid thyroid nodules is a controversial issue
in terms of efficacy, the optimal level of TSH suppression, the
optimal duration of treatment, and potential side effects
(516). This treatment has been used for over half a century to
shrink nodules, to prevent growth of nodule (s), and to
prevent the appearance of newnodules. Complete regression
of thyroid nodules is unusual. In a prospective multicenter,
randomized, double-blind, placebo-controlled French trial,
l-T4 suppressive therapy reduced the growth of solitary thy-
roid nodules and prevented the development of newnodules
(517). In another study, l-T4 therapy (to suppress serum TSH
to below 0.1 mIU/liter) was able to prevent the development
of new lesions and an increase nodule and thyroid size (518).
These data might be relevant to populations living in areas
of relative iodine deficiency.
Recent guidelines do not recommend routine suppressive
therapywith l-T4 of benign thyroid nodules (363, 519). How-
ever, this treatment is still preferred by nearly half the mem-
bership of the ATA and the European Thyroid Association,
especially in areas of borderline-low iodine intake (520, 521).
l-T4 therapy is less frequently used by members of the Latin
American Thyroid Society than by ATA and European Thy-
roid Association members (522).
Long-term suppressive therapy with serum TSH concen-
trations below 0.1 mIU/liter is recommended for DTC pa-
tients with persistent disease and a high risk of recurrence
(362, 363). Beta-blockade might be considered in high-risk
thyroid cancer patients with adrenergic hyperresponsive-
ness to l-T4 (4, 362). In the case of long-term serum TSH
suppression, supplemental calcium and bone-sparing drugs
should be considered, especially in postmenopausal women
to reduce the risk of osteoporosis and possibly fractures. In
low-risk patients with no evidence of disease (patients with
undetectable suppressed and stimulated serum thyroglob-
ulin and negative ultrasound of the neck after thyroidectomy
and radioiodine ablation), the long-term risk of recurrence is
less than 1%, and the goal of l-T4 treatment should be to
maintain the TSH level in the lower limit of the normal range.
Clinicians should prescribe the lowest possible dose of l-T4
to achieve the desired TSH concentration in patients with
benign and malignant thyroid disease.
2. Treatment of endogenous SHyper. Opinions differ about the
treatment of endogenous SHyper (338, 523). According to the
American College of Physicians’ guidelines, the potential
benefits of treating patients with SHyper are only theoretical,
and the management of patients without clinical findings is
not clear (338). A recent panel of experts recommended
against routine treatment for those patients whose TSH is
mildly decreased; treatment was recommended for those
with serum TSH levels below 0.1 mIU/liter who were older
than 60 yr; for those with or at increased risk of heart disease,
osteopenia, or osteoporosis; or those with symptoms of hy-
perthyroidism (6). Individual assessment for treatment or
follow-up is recommended for younger individuals with
SHyper and serum TSH persistently below 0.1 mIU/liter.
The same opinion was expressed by the American Associ-
ation of Clinical Endocrinologists, the ATA, and The Endo-
crine Society (5). A case-based mail survey of ATAmembers
on the management of patients with SHyper showed that
most recommended observation alone for young patients
with a low but detectable serum TSH (84%) or an undetect-
able TSH (58%) (524). However, 66% favored treating older
patients who had an undetectable serum TSH. Radioactive
iodinewas considered the treatment of choice for toxicmulti-
nodular goiter.
Although it has not been demonstrated that early treat-
ment of symptomatic patients with SHyper improves clinical
outcome, treatment of SHyper might improve quality of life,
cardiovascular risk factors, and BMD, and would prevent a
possible progression to overt disease. Before treatment is
started, it should be established whether the subnormal se-
rum TSH is related to endogenous SHyper and whether it is
persistent (Fig. 5). In the presence of low or undetectable
serum TSH and normal free thyroid hormones, other causes
of transient TSH suppression (thyroiditis, nonthyroidal ill-
ness, pregnancy, or medications) should be excluded. A 24-h
radioiodine uptake and thyroid scan should be considered to
establish the correct etiology of the disease and the possible
therapeutic approach. Neck ultrasound is used, especially in
areas of iodine deficiency, to identify the nodules for fine-
needle biopsy before definitive treatment with radioiodine.
Thyroid function should be reevaluated after 2, 4, and 6
months in asymptomatic patients with suppressed serum
TSH to establish whether SHyper is a persistent or progres-
sive disease. If serum TSH remains suppressed, therapy will
depend on the results of clinical assessment of the possible
risk factors related to the disease (Fig. 5).
Young, asymptomatic patients with low but detectable
TSH should undergo periodic follow-up without treatment.
In young and middle-aged symptomatic patients, especially
thosewith undetectable serumTSH, palpitations, or a history
suggesting atrial arrhythmias, the cardiac effects should be
assessed to establish the cardiovascular risk. In this case,
ECG and ambulatoryHolter ECG can be used to evaluate the
presence of atrial arrhythmias, whereas Doppler echocardi-
ography can be used to assess the presence of left ventricular
hypertrophy, possible alterations of cardiac function, and
possible underlying structural heart disease. Symptomatic
young patients with undetectable serum TSH should be
treated with antithyroid drugs to normalize serum TSH.
Treatment with antithyroid drugs for 3–6 months can be
used to evaluate the possible beneficial effect of TSH nor-
malization on quality of life, heart rate, and atrial premature
beats before definitive treatment with radioiodine or sur-
gery. Low doses of antithyroid drugs (methimazole 5–15
mg/d, or propylthiouracil 50–150 mg/d) are usually able to
normalize serum TSH in SHyper. As an alternative, beta-
blocking drugs should be considered. However, definitive
treatment of SHyper should be considered in symptomatic
patients with endogenous SHyper in the presence of under-
lying heart disease, AF, or left ventricular hypertrophy.
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In elderly or postmenopausal patients, definitive treat-
ment of SHyper in the presence of low or undetectable serum
TSH should be considered because of the increased risk ofAF
and the risk of osteoporosis in this age group. In older pa-
tients with or without AF, ablative therapy with 131I is the
preferred option formost patients. However, in patientswith
AF or underlying heart disease, antithyroid drug therapy
should be considered to reverse AF and to improve cardiac
function. Furthermore, it is prudent to restore normal thyroid
function before radioiodine in such patients to avoid a pos-
sible worsening of thyroid function after therapy. Treatment
of thyrotoxicosis with antithyroid drugs can cause sponta-
neous reversion of AF to sinus rhythm in two thirds of
patients with overt hyperthyroidism within 8–10 wk (525).
-Adrenergic blockade may be useful to control ventricular
rate, and anticoagulation should be considered.
Only two studies, which both involved small numbers of
patients with SHyper, reported conversion of AF to stable
sinus rhythm after treatment with radioiodine or antithyroid
drugs (381, 512). There are no controlled studies comparing
the efficacy of different therapies (antithyroid drugs, radio-
iodine, or surgery) in patients with SHyper. The options for
definitive therapy are based on the considerations recom-
mended for overt disease (364, 526).
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Erratum
In the article “Uteroglobin: A Steroid-Inducible Immunomodulatory Protein That Founded the Secretoglobin
Superfamily” by Anil B. Mukherjee, Zhongjian Zhang, and Beverly S. Chilton (Endocrine Reviews 2007,
28:707–725), Fig. 3 was printed with missing text. The corrected figure and the legend appear below.
FIG. 3. Organization of the UG gene. The three exons are black boxes, and the intervening introns are open boxes.
PRE designates a cluster of progesterone response elements. The 404-bp BamH1 rabbit promoter (	394/
10) is
enlarged to show the locations of an ERE, two Sp1/3 binding sites, a SOX17 site, a RUSH (RUSH/SMARCA3) site,
and a YY1 site juxtaposed to the TACA box. The cis-binding sites that are most important in the rabbit promoter are
shown in bold relief against less important elements.
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